

Atar D (see Serebruany et al). 2005;150:882-6 (Curriculum cardiol.)
ATOMIX Study Group (see Cenarro et al). 2005;150:1154-62
Aufderheide TP (see Riegel et al). 2005;150:927-32
Aylward PE (see Frazier et al). 2005;150:1260-7
Aymong E (see Weisz et al). 2005;150:358-64

B

Bacher AC (see Lim et al). 2005;150:934-40, 941-6
Badia T (see Leoncini et al). 2005;150:401.e9-401.e14
Baim DS (see Kuntz et al). 2005;150:4-6 (Editorial)
Bair TL (see Muhlestein et al). 2005;150:182-7
Bair TL (see Whiting et al). 2005;150:243-50
Bairey Merz CN (see Kip et al). 2005;150:900-6
Bairey Merz CN (see Marroquin et al). 2005;150:109-15
Bakan A (see Sievers et al). 2005;150:737-42
Balbarini A (see Limbruno et al). 2005;150:102-8
Bandinelli S (see McDermott et al). 2005;150:276-81
Barbagelata A, Di Carli MF, Calif RM, Garg J, Birnbaum Y, Grinfeld L, Gibbons RJ, Granger CB, Goodman SG, Wagner GS, Mahaffey KW, AMISTAD Investigators. Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial. 2005;150:659-65
Barker D (see Williams et al). 2005;150:983.e1-983.e6
Barrington W (see Hreybe et al). 2005;150:1064.e1-1064.e5
Bashore TM (see Krasuski et al). 2005;150:725-8
Baskett RJF, O'Connor GT, Hirsch GM, Ghali WA, Sabadosa KA, Morton JR, Ross CS, Hernandez F, Nugent WC, Lahey SJ, Sisto D, Dacey IJ, Klempner JD, Helm RE, Maitland A. The preoperative intraaortic balloon pump in coronary bypass surgery: a lack of evidence of effectiveness. 2005;150:1122-7
Baskett RJF (see Hassan et al). 2005;150:1026-31
Al Basyk F (see Win et al). 2005;150:695-700
Bates ER (see Brener et al). 2005;150:89-93
Bauer F (see Sitges et al). 2005;150:852-8
Baughman KL (see Ardehali et al). 2005;150:459-63
Baum H (see Dibra et al). 2005;150:344-50
Baumann G (see Staudt et al). 2005;150:729-36
Bauters C (see Lamblin et al). 2005;150:137-43
Bax JJ (see Salm et al). 2005;150:775-81
Becker DM (see Michos et al). 2005;150:1276-81
Becker LC (see Michos et al). 2005;150:1276-81
Becker RC. The vulnerable endothelium—priming the vascular endothelium for thrombosis with unfractionated heparin: biological plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. 2005;150:189-92 (Editorial)
Bedi M (see Hreybe et al). 2005;150:1064.e1-1064.e5
Bell MR (see Hillis et al). 2005;150:1268-75
Bellandi F (see Leoncini et al). 2005;150:401.e9-401.e14
Beller G (see Michaels et al). 2005;150:1066-73
Benedetti G (see De Luca et al). 2005;150:563-8
Benner JS (see Klingman et al). 2005;150:595-601
Berenguer A, Mainar V, Bordes P, Valencia J, Gómez S, Lozano T. Incidence and predictors of restenosis after sirolimus-eluting stent implantation in high-risk patients. 2005;150:536-42
Berger PB (see Al Suwaidi and Berger). 2005;150:7-10 (Editorial)
Berger PB (see Bhatt et al). 2005;150:401.e1-401.e7
Berger PB (see Campbell et al). 2005;150:796-9
Berkoff F (see Arcand et al). 2005;150:716.e1-716.e5
Bernardi V (see Rodriguez et al). 2005;150:188.e1-188.e7
Berrocal DH (see Cohen et al). 2005;150:1204-11
Bertel O (see Straumann et al). 2005;150:1000-6
Bertoni AG (see Goff et al). 2005;150:717-24
Betocchi S (see Cecchi et al). 2005;150:947-54
Bhakta J (see Lakireddy et al). 2005;150:516-21
Bhalia V (see Fitzgerald et al). 2005;150:471-7
Bhapkar M (see Shah et al). 2005;150:893-8 (Trial design)
Bhapkar MV (see Frazier et al). 2005;150:1260-7
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cabouc P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak K-H, Mas J-L, Montalescot G, Pearson TA, Steg PG, Steinbuhl SR, Weber MA, Booth J, Topol EJ, CHARISMA Investigators. A global view of atherosclerosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. 2005;150:401.e1-401.e7
Bhatt DL (see Fathi et al). 2005;150:1190-7
Binkley PF (see Ferketich et al). 2005;150:132-6
Birnbaum A (see Nichol et al). 2005;150:202-8 (Trial design)
Birnbaum A (see Riegel et al). 2005;150:927-32
Birnbaum Y (see Barbagelata et al). 2005;150:659-65
Bishop GD, Kaur D, Tan VLM, Chua Y-L, Liew S-M, Mak K-H. Effects of a psychosocial skills training workshop on psychophysiological and psychosocial risk in patients undergoing coronary artery bypass grafting. 2005;150:602-9
Bittner V (see Sanderson and Bittner). 2005;150:1052-8
Bittner V (see Venkataraman et al). 2005;150:1140-6
Black HR (see Bhatt et al). 2005;150:401.e1-401.e7
Blackstone EH (see Hesse et al). 2005;150:307-14
Blakemore S (see Satterthwaite et al). 2005;150:488-99
Blanchard D (see Danchin et al). 2005;150:1147-53
Blann AD (see Lee et al). 2005;150:756-66
Blatt A, Cotter G, Leitman M, Krakover R, Kaluski E, Milo-Cotter O, Resnick IB, Samuel S, Gozal D, Vered Z, Slavin S, Shapira MY. Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy. 2005;150:986.e1-986.e7
Blazing M (see Goyal and Blazing). 2005;150:650-1 (Evidence-based consult)
Block P (see Aerts et al). 2005;150:251-6
Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) (see Aboufaher et al). 2005;150:455-8
Blumenthal RS (see Michos et al). 2005;150:1276-81
Boden WE (see Bhatt et al). 2005;150:401.e1-401.e7
Boersma E (see Steyerberg et al). 2005;150:920.e11-920.e17
Böhm M (see Siaplaouras et al). 2005;150:150-2
Böhm M (see Staudt et al). 2005;150:729-36
Bonan R (see Ly et al). 2005;150:933.e9-933.e13
Bonizzoni E (see Briguori et al). 2005;150:807-13
Booth J (see Bhatt et al). 2005;150:401.e1-401.e7
Booth J (see Zhang et al). 2005;150:175-81
Bordes P (see Berenguer et al). 2005;150:536-42
Borst MM (see Schulze-Neick et al). 2005;150:716.e7-716.e12
Bosch X, Théroux P. Left ventricular ejection fraction to predict early mortality in patients with non-ST-segment elevation acute coronary syndromes. 2005;150:215-20
Bosker G (see Seshadri et al). 2005;150:27-34 (Curriculum cardiol.)
Boucek MM (see Pauliks et al). 2005;150:294-301
Bourgault C (see Brophy et al). 2005;150:282-6
Bourge RC (see Teerlink et al). 2005;150:46-53 (Trial design)
Bourgoun M (see Solomon et al). 2005;150:257-62
Bowden DW, Lange LA, Langefeld CD, Brosnihan KB, Freedman BI, Carr JJ, Wagenknecht LE, Herrington DM. The

relationship between C-reactive protein and subclinical cardiovascular disease in the Diabetes Heart Study (DHS). 2005;150:1032-8

Bowers MT (see Shah et al). 2005;150:893-8 (Trial design)

Boyle NG (see Port et al). 2005;150:209-14

Bozkurt B, Deswal A. Obesity as a prognostic factor in chronic symptomatic heart failure. 2005;150:1233-9

Braddock M (see Satterthwaite et al). 2005;150:488-99

Bradstreet DC (see Konstam et al). 2005;150:123-31

Braga AMFW (see Matsumoto et al). 2005;150:144-9

Brassard P (see Brophy et al). 2005;150:282-6

Braun S, Ndrepepa G, von Beckerath N, Mehilli J, Gorciakova O, Vogt W, Schömöig A, Kastrati A. Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. 2005;150:550-6

Braun S (see Dibra et al). 2005;150:344-50

Braunwald E (see Ohman et al). 2005;150:79-88

Braunwald E (see Skali et al). 2005;150:743-9

Brazel S (see Arcand et al). 2005;150:716.e1-716.e5

Breithardt G (see Kirchhof et al). 2005;150:899.e1-899.e6 (Trial design)

Brenner SJ, Lincoff AM, Bates ER, Jia G, Armstrong PW, Guetta V, Hochman JS, Savonito S, Wilcox RG, White HD, Topol EJ. GUSTO V Investigators. The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial. 2005;150:89-93

Bricker JT (see Fisher et al). 2005;150:439-47

Brieger D (see Tiong and Brieger). 2005;150:11-8 (Progress cardiol.)

Briguori C, Colombo A, Airolidi F, Focaccio A, Iakovou I, Chieffo A, Michev I, Montorfano M, Bonizzoni E, Ricciarelli B, Condorelli G. Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease. 2005;150:807-13

Brister SJ (see Mitchell et al). 2005;150:1017-25

Brock DB (see Havlik et al). 2005;150:270-5

Bronnum-Hansen H (see Zwisler et al). 2005;150:899.e7-899.e16 (Trial design)

Brophy JM, Brassard P, Bourgault C. The benefit of cholesterol-lowering medications after coronary revascularization: a population study. 2005;150:282-6

Brosh D, Higano ST, Lennon RJ, Holmes DR Jr, Lerman A. Effect of lesion length on fractional flow reserve in intermediate coronary lesions. 2005;150:338-43

Brosnihan B (see Lakoski et al). 2005;150:907-11

Brosnihan KB (see Bowden et al). 2005;150:1032-8

Brown DW, Haldeman GA, Croft JB, Giles WH, Mensah GA. Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000. 2005;150:448-54

Brown JE (see Gwadry-Sridhar et al). 2005;150:982.e1-982.e9

Bucciarelli-Ducci C (see De Luca et al). 2005;150:563-8

Buck P (see Arteaga et al). 2005;150:1228-32

Buck PC (see Matsumoto et al). 2005;150:144-9

Budaj A (see Lewis et al). 2005;150:1177-84

Budoff MJ (see Mao et al). 2005;150:315-22

Bunch TJ (see Muhlestein et al). 2005;150:182-7

Buoh A (see Siaplaouras et al). 2005;150:150-2

Busse KL (see Wyman et al). 2005;150:1081-5

Buth KJ (see Hassan et al). 2005;150:1026-31

C

Cabell CH, Abrutyn E, Fowler VG Jr, Hoen B, Miro JM, Corey GR, Olaison L, Pappas P, Anstrom KJ, Stafford JA, Eykyn S, Habib G, Mestres CA, Wang A, ICE-MD Investigators, International Collaboration on Endocarditis Merged Database (ICE-MD) Study Group. Use of surgery in patients with native valve infective endocarditis: results from the International Collaboration on Endocarditis Merged Database. 2005;150:1092-8

Cabell CH (see Wang et al). 2005;150:1086-91

Cacoub P (see Bhatt et al). 2005;150:401.e1-401.e7

Caldwell MA, Peters KJ, Dracup KA. A simplified education program improves knowledge, self-care behavior, and disease severity in heart failure patients in rural settings. 2005;150:983.e7-983.e12

Califf RM (see Alexander et al). 2005;150:643-9 (Trial design)

Califf RM (see Barbagelata et al). 2005;150:659-65

Califf RM (see Jiang et al). 2005;150:54-78 (Meetings)

Califf RM (see Ohman et al). 2005;150:79-88

Califf RM (see Reed et al). 2005;150:323-9

Califf RM (see Shah et al). 2005;150:893-8 (Trial design)

Camacci T (see Limbruno et al). 2005;150:102-8

Cambou J-P (see Danchin et al). 2005;150:1147-53

Camenzind E (see Mehran et al). 2005;150:1171-6

Camm AJ (see Konstam et al). 2005;150:123-31

Campbell CL, Berger PB, Nuttall GA, Orford JL, Santrach PJ, Oliver WC, Ereth MH, Thompson CM, Murphy MK, McGlassen DL, Schrader LM, Steinhubl SR. Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study. 2005;150:796-9

Canadian Acute Coronary Syndromes Registries Investigators (see Segev et al). 2005;150:690-4

Candelli M (see Gabrielli et al). 2005;150(1):e9 (Letter)

Cannizzaro S (see Di Pasquale et al). 2005;150:919.e1-919.e8

Canos D (see Kuchukantaki et al). 2005;150:832-7

Canto JG, Kiefe CI. Door-to-needle time in myocardial infarction: is there an ideal benchmark? 2005;150:365-7 (Editorial)

Cantor WJ, Puley G, Natarajan MK, Dzavik V, Madan M, Fry A, Kim HH, Velianou JL, Pirani N, Strauss BH, Chisholm RJ. Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction—the RADIAL-AMI pilot randomized trial. 2005;150:543-9

Cardiovascular Outcomes Research Consortium (see Spertus et al). 2005;150:707-15

Carey CF (see Harris et al). 2005;150:1106.e1-1106.e6

Carides GW (see Konstam et al). 2005;150:123-31

Carlquist JF (see Whiting et al). 2005;150:243-50

Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. 2005;150:859-70 (Progress cardiol.)

Carnemolla G (see Cecchi et al). 2005;150:947-54

Carr JJ (see Bowden et al). 2005;150:1032-8

Carr JJ (see Pletcher et al). 2005;150:921-6

Carraway R (see Warraich et al). 2005;150:263-9

Carroll S (see Healey et al). 2005;150:288-93

Carson S (see Mao et al). 2005;150:315-22

Carstensen M (see Kaehler et al). 2005;150:987-93

Casaclang-Verzosa GC (see Hillis et al). 2005;150:1268-75

Casey CW (see Halkin et al). 2005;150:1163-70

Casey DE (see Hennekens et al). 2005;150:1115-21 (Curriculum cardiol.)

Casscells W (see Rashidi et al). 2005;150:41-5 (Curriculum cardiol.)

Caulin-Glaser T (see Hindman et al). 2005;150:1046-51

Cecchi F, Olivotto I, Betocchi S, Rapezzi C, Conte MR, Sinagra G, Zacharia E, Gavazzi A, Rordorf R, Carnemolla G, Porcu M, Nistri S, Gruppoli P, Giampaoli S. The Italian registry for

hypertrophic cardiomyopathy: a nationwide survey. 2005;150:947-54

Celotto A (see De Luca et al). 2005;150:563-8

Cenarro A, Artieda M, Gonzalo C, Merino-Ibarra E, Aristegui R, Gañán A, Díaz C, Sol JM, Pocoví M, Civeira F, ATOMIX Study Group. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response. 2005;150:1154-62

Chambless L (see McGinn et al). 2005;150:392-400

Chan AK (see So et al). 2005;150:530-5

Chan JD, Rea TD, Smith NL, Siscovich D, Heckbert SR, Lumley T, Chaves P, Furberg CD, Kuller L, Psaty BM. Association of β-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS). 2005;150:464-70

Chan K-C (see Pauliks et al). 2005;150:294-301

Chan LY, Fok WY, Wong JT, Yu CM, Leung TN, Lau TK. Reference charts of gestation-specific tissue Doppler imaging indices of systolic and diastolic functions in the normal fetal heart. 2005;150:750-5

Chang D (see Pauliks et al). 2005;150:294-301

Chang S-M (see Win et al). 2005;150:695-700

CHARISMA Investigators (see Bhatt et al). 2005;150:401.e1-401.e7

Chase S (see Agah et al). 2005;150:500-6

Chaturvedi N (see Jafar et al). 2005;150:221-6

Chaves P (see Chan et al). 2005;150:464-70

Cheneau E (see Kuchulakanti et al). 2005;150:832-7

Chew DP (see Fathi et al). 2005;150:1190-7

Chieffo A (see Briguori et al). 2005;150:807-13

Child J (see Mao et al). 2005;150:315-22

Chisholm RJ (see Cantor et al). 2005;150:543-9

Chiu A (see Fitzgerald et al). 2005;150:471-7

Chlouverakis GI (see Patrianakos et al). 2005;150:985.e9-985.e18

Cho S-Y (see Joung et al). 2005;150:1213-9

Choleva M (see Arcand et al). 2005;150:716.e1-716.e5

Chou H-T, Tsai F-J, Tsai C-H. Reply to Ogimoto. 2005;150(1):e3 (Letter reply)

Chu V (see Healey et al). 2005;150:288-93

Chua Y-L (see Bishop et al). 2005;150:602-9

Chung ML (see Moser et al). 2005;150:984.e7-984.e13

Chung N (see Joung et al). 2005;150:1213-9

Ciabatti N (see Petronio et al). 2005;150:1015.e1-1015.e9

Civeira F (see Cenarro et al). 2005;150:1154-62

Claise KA (see Shah et al). 2005;150:893-8 (Trial design)

Cleland JGF (see Teerlink et al). 2005;150:46-53 (Trial design)

Clerson P (see Danchin et al). 2005;150:1147-53

Clopton P (see Fitzgerald et al). 2005;150:471-7

Cobo J (see Martín-Dávila et al). 2005;150:1099-106

Cohen DJ (see Jacob et al). 2005;150:887-92 (Trial design)

Cohen EA (see Bhatt et al). 2005;150:401.e1-401.e7

Cohen HA (see Laskey et al). 2005;150:569-76

Cohen MG, Pascua JA, García-Ben M, Rojas-Matas CA, Gabay JM, Berrocal DH, Tan WA, Stouffer GA, Montoya M, Fernandez AD, Halac ME, Grinfeld LR. A simple prediction rule for significant renal artery stenosis in patients undergoing cardiac catheterization. 2005;150:1204-11

Colan SD (see Fisher et al). 2005;150:439-47

Colombo A (see Briguori et al). 2005;150:807-13

Conard MW (see Spertus et al). 2005;150:707-15

Condorelli G (see Briguori et al). 2005;150:807-13

Connolly SJ (see Healey et al). 2005;150:288-93

Constance C (see Segev et al). 2005;150:690-4

Conte MR (see Cecchi et al). 2005;150:947-54

Conti CR (see Michaels et al). 2005;150:1066-73

Cooke GA (see Williams et al). 2005;150:983.e1-983.e6

Cooper MJ (see Thomas et al). 2005;150(5):e3 (Letter reply)

Corey GR (see Cabell et al). 2005;150:1092-8

Corey GR (see Wang et al). 2005;150:1086-91

Corsi A (see McDermott et al). 2005;150:276-81

Cotter G (see Blatt et al). 2005;150:986.e1-986.e7

Cotter G (see Teerlink et al). 2005;150:46-53 (Trial design)

Courtney BK (see Yokoyama et al). 2005;150:287.e1-287.e7

Cox DA (see Weisz et al). 2005;150:358-64

Cozart KL (see Shah et al). 2005;150:893-8 (Trial design)

Crampton R (see Thomas et al). 2005;150(5):e3 (Letter reply)

Creager MA (see Bhatt et al). 2005;150:401.e1-401.e7

Crean P (see Tahir et al). 2005;150:302-6

Cremo R (see Fitzgerald et al). 2005;150:471-7

Croft JB (see Brown et al). 2005;150:448-54

Croft JB (see Goff et al). 2005;150:717-24

Crossman D (see Satterthwaite et al). 2005;150:488-99

Crystal E (see Healey et al). 2005;150:288-93

Cui CZ (see Muhlestein et al). 2005;150:182-7

CURE trial investigators (see Lewis et al). 2005;150:1177-84

Cutlip DE (see Rana et al). 2005;150:821-6

Cybulsky I (see Healey et al). 2005;150:288-93

D

Dabizzi RP (see Leoncini et al). 2005;150:401.e9-401.e14

Dacey IJ (see Baskett et al). 2005;150:1122-7

Dadlani GH, Gingell RL, Orié JD, Roland JM, Najdzionek J, Lipsitz SR, Pieroni DR, Lipshultz SE. Coronary artery calcifications in the long-term follow-up of Kawasaki disease. 2005;150:1016.e1-1016.e8

Dagorn J (see Lamblin et al). 2005;150:137-43

Dahm JB (see Völzke et al). 2005;150:1198-203

Damasceno A (see Warrach et al). 2005;150:263-9

Dambrink J-H (see De Luca et al). 2005;150:1248-54

Dambrink J-HE (see De Luca et al). 2005;150:557-62, 827-31, 1185-9

Danchin N, Cambou JP, Hanania G, Kadri Z, Genès N, Lablanche JM, Blanchard D, Vaur L, Clerson P, Guérat P, USIC 2000 investigators. Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. 2005;150:1147-53

Dancy M (see Salmasi et al). 2005;150:168-74

Danias PG (see Tritos et al). 2005;150:1212.e1-1212.e6

Daniell HW. Letter to the Editor. 2005;150(6):e1 (Letter)

Daniels H (see Shah et al). 2005;150:893-8 (Trial design)

DANREHAB group (see Zwislner et al). 2005;150:899.e7-899.e16 (Trial design)

Dargie HJ (see Engblom et al). 2005;150:507-12

Dasbach EJ (see Konstam et al). 2005;150:123-31

Dassen WRM (see Aerts et al). 2005;150:251-6

Davidson JRT (see Jiang and Davidson). 2005;150:871-81 (Curriculum cardioli.)

Davidson RC (see Weinberger et al). 2005;150:426-33

Davis J (see Goff et al). 2005;150:717-24

Davis RB (see McLellan et al). 2005;150:800-6

de Boer BA (see Riezebos et al). 2005;150:1255-9

de Boer MJ (see De Luca et al). 2005;150:557-62, 827-31, 1185-9, 1248-54

De Carlo M (see Limbruno et al). 2005;150:102-8

De Carlo M (see Petronio et al). 2005;150:1015.e1-1015.e9

De Caterina R (see Limbruno et al). 2005;150:102-8

de Feyter PJ (see Aoki et al). 2005;150:994-9

de Groot P (see Lamblin et al). 2005;150:137-43

de Jaegere PPT (see Aoki et al). 2005;150:994-9

de Lame P-A (see Michaels et al). 2005;150:1066-73

de Lemos JA (see Ohman et al). 2005;150:79-88

De Luca G, Ernst N, van't Hof AWJ, Ottervanger JP, Hoornstje JCA, Dambrink J-HE, Gosselink ATM, de Boer MJ, Suryapranata H. Preprocedural Thrombolysis in Myocardial Infarction (TIMI) flow significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute anterior myocardial infarction treated by primary angioplasty. 2005;150:827-31

De Luca G, Maas AC, Suryapranata H, Ottervanger JP, Hoornstje JCA, Gosselink ATM, Dambrink J-HE, de Boer MJ, van't Hof AWJ. Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. 2005;150:1248-54

De Luca G, Suryapranata H, Ottervanger JP, van't Hof AWJ, Hoornstje JCA, Gosselink ATM, Dambrink J-HE, Zijlstra F, de Boer MJ. Circadian variation in myocardial perfusion and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. 2005;150:1185-9

De Luca G, van't Hof AWJ, Ottervanger JP, Hoornstje JCA, Gosselink ATM, Dambrink J-HE, Zijlstra F, de Boer MJ, Suryapranata H. Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. 2005;150:557-62

De Luca L, Proietti P, Celotto A, Buccarelli-Ducci C, Benedetti G, Di Roma A, Sardella G, Genuini I, Fedele F. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. 2005;150:563-8

de Paola AAV (see Veloso and de Paola). 2005;150(5):e1 (Letter)

de Roos A (see Salm et al). 2005;150:775-81

De Servi S (see Leoncini et al). 2005;150:401.e9-401.e14

de Simone G (see Tang et al). 2005;150:845-51

DeBusk RF (see Solomon et al). 2005;150:620-6
(Curriculum cardiol.)

DeGroff CG (see Pauliks et al). 2005;150:294-301

Denault A (see Ly et al). 2005;150:933.e9-933.e13

Dendale P (see Aerts et al). 2005;150:251-6

Deng J (see Han et al). 2005;150:568.e1-568.e5

Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. 2005;150:1064.e7-1064.e12

Desai U (see Win et al). 2005;150:695-700

Desjardins B (see Wagner et al). 2005;150:985.e1-985.e8

Deswal A (see Bozkurt and Deswal). 2005;150:1233-9

Detre KM (see Laskey et al). 2005;150:569-76

Devereux RB (see Tang et al). 2005;150:845-51

Di Bello V (see Petronio et al). 2005;150:1015.e1-1015.e9

Di Carli MF (see Barbagelata et al). 2005;150:659-65

Di Pasquale P, Cannizzaro S, Scalzo S, Parrinello G, Fasullo S, Giambanco F, Fatta A, Paterna S. Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction. 2005;150:919.e1-919.e8

Di Roma A (see De Luca et al). 2005;150:563-8

Diakakis GF (see Patrianakos et al). 2005;150:985.e9-985.e18

Díaz C (see Cenarro et al). 2005;150:1154-62

DiBattiste P (see Ohman et al). 2005;150:79-88

Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J, Schühlein H, Schömöig A, Kastrati A. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. 2005;150:344-50

Dickstein K (see Konstam et al). 2005;150:123-31

Digitalis Investigation Group (see Mathew et al). 2005;150:968-76

Dirschinger J (see Dibra et al). 2005;150:344-50

Doering LV (see Moser et al). 2005;150:984.e7-984.e13

Donovan L (see Schull et al). 2005;150:583-7

Donovan LR (see Ko et al). 2005;150:419-25

Dörr M (see Staudt et al). 2005;150:729-36

Downey M (see Rakhit et al). 2005;150:1074-80

Dracup KA (see Caldwell et al). 2005;150:983.e7-983.e12

Drazner MH (see Katz and Drazner). 2005;150:1-3 (Editorial)

Drinko JK (see Sitges et al). 2005;150:852-8

Dubé MP (see Shankar et al). 2005;150:933.e1-933.e7

Ducharme A (see Wagner et al). 2005;150:985.e1-985.e8

Dupuis J (see Ly et al). 2005;150:933.e9-933.e13

Duren-Winfield V (see Goff et al). 2005;150:717-24

Dzavik V (see Cantor et al). 2005;150:543-9

E

Easley KA (see Fisher et al). 2005;150:439-47

Easton JD (see Bhatt et al). 2005;150:401.e1-401.e7

Egstrup K (see Husic et al). 2005;150:767-74

Egstrup K (see Nørager et al). 2005;150:522-9

Eijkemans MJC (see Steyerberg et al). 2005;150:920.e11-920.e17

Eipper V (see Thomas et al). 2005;150(5):e3 (Letter reply)

Ekici F (see Tutar et al). 2005;150:513-5

Elisaf MS (see Milionis and Elisaf). 2005;150(1):e7 (Letter reply)

ELITE II investigators (see Konstam et al). 2005;150:123-31

Elkayam U (see Seshadri et al). 2005;150:27-34
(Curriculum cardiol.)

Ellis S (see Agah et al). 2005;150:500-6

Ellis SG (see Fathi et al). 2005;150:1190-7

Ellis SG (see Halkin et al). 2005;150:1163-70

Empen K (see Staudt et al). 2005;150:729-36

Engblom H, Foster JE, Martin TN, Groenning B, Pahlm O, Dargie HJ, Wagner GS, Arheden H. The relationship between electrical axis by 12-lead electrocardiogram and anatomical axis of the heart by cardiac magnetic resonance in healthy subjects. 2005;150:507-12

Engblom H, Hedström E, Heiberg E, Wagner GS, Pahlm O, Arheden H. Size and transmural extent of first-time reperfused myocardial infarction assessed by cardiac magnetic resonance can be estimated by 12-lead electrocardiogram. 2005;150:920.e1-920.e9

Enke B (see Schulze-Neick et al). 2005;150:716.e7-716.e12

Ereth MH (see Campbell et al). 2005;150:796-9

Erhard I (see Schiele et al). 2005;150:351-7

Erkkilä AT, Herrington DM, Mozaffarian D, Lichtenstein AH. Cereal fiber and whole-grain intake are associated with reduced progression of coronary-artery atherosclerosis in postmenopausal women with coronary artery disease. 2005;150:94-101

Ernst N (see De Luca et al). 2005;150:827-31

Essop R (see Warraich et al). 2005;150:263-9

EVENT Investigators (see Jacob et al). 2005;150:887-92
(Trial design)

Ewert R (see Schulze-Neick et al). 2005;150:716.e7-716.e12

Eykyn S (see Cabell et al). 2005;150:1092-8

Ezzedine R (see Hreybe et al). 2005;150:1064.e1-1064.e5

F

Falko JM (see Hindman et al). 2005;150:1046-51

Fang J (see Solomon et al). 2005;150:257-62

FASTER (TIMI 24) Investigators (see Ohman et al). 2005;150:79-88

Fasullo S (see Di Pasquale et al). 2005;150:919.e1-919.e8

Fathi RB, Gurm HS, Chew DP, Gupta R, Bhatt DL, Ellis SG. The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention. 2005;150:1190-7

Fatta A (see Di Pasquale et al). 2005;150:919.e1-919.e8

Fedele F (see De Luca et al). 2005;150:563-8

Feeny D (see Nichol et al). 2005;150:202-8 (Trial design)

Feldschuh J (see James et al). 2005;150:984.e1-984.e6

Felix SB (see Staudt et al). 2005;150:729-36

Felix SB (see Völzke et al). 2005;150:1198-203

Ferguson JJ III (see Serebruany et al). 2005;150:882-6
(Curriculum cardioli.)

Ferguson JP (see Ferketic et al). 2005;150:132-6

Ferguson TB Jr (see Alexander et al). 2005;150:643-9 (Trial design)

Ferketic AK, Ferguson JP, Binkley PF. Depressive symptoms and inflammation among heart failure patients. 2005;150:132-6

Fernandez AD (see Cohen et al). 2005;150:1204-11

Ferrell RE (see Tang et al). 2005;150:845-51

Ferrucci L (see McDermott et al). 2005;150:276-81

Fetsch T (see Kirchhof et al). 2005;150:899.e1-899.e6 (Trial design)

Fett J (see Warraich et al). 2005;150:263-9

Fezoulidis I (see Triploskiadi et al). 2005;150:782-9

Fiedler M (see Rahimi et al). 2005;150:1282-9

Figulla HR (see Kueth et al). 2005;150:115.e1-115.e7

Fischer-Hansen J (see Zwisler et al). 2005;150:899.e7-899.e16
(Trial design)

Fisher SD, Easley KA, Orav EJ, Colan SD, Kaplan S, Starc TJ, Bricker JT, Lai WW, Moodie DS, Sopko G, Lipschultz SE. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P²C² HIV) Study Group. Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the Prospective P²C² HIV Multicenter Study. 2005;150:439-47

Fishman EK (see Michos et al). 2005;150:1276-81

Fitzgerald PJ (see Yokoyama et al). 2005;150:287.e1-287.e7

Fitzgerald RL, Cremo R, Gardetto N, Chiu A, Clopton P, Bhalla V, Maisel AS. Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. 2005;150:471-7

Flather M (see Gödicke et al). 2005;150:1015.e11-1015.e17

Flather MD (see Bhatt et al). 2005;150:401.e1-401.e7

Fleg JL (see Lim et al). 2005;150:941-6

Flygenring BP (see Henry et al). 2005;150:373-84 (Trial design)

Focaccio A (see Briguori et al). 2005;150:807-13

Fok WY (see Chan et al). 2005;150:750-5

Foley B (see Tahir et al). 2005;150:302-6

Fonarow GC (see Ralli et al). 2005;150:1220-7

Fontanini G (see Limbruno et al). 2005;150:102-8

Foody JM (see Rathore et al). 2005;150:402-10

Forssmann K (see Mitrovic et al). 2005;150:1239.e1-1239.e8

Forssmann W-G (see Mitrovic et al). 2005;150:1239.e1-1239.e8

Fortún J (see Martín-Dávila et al). 2005;150:1099-106

Foster JE (see Engblom et al). 2005;150:507-12

Fouad-Tarazi F (see James et al). 2005;150:984.e1-984.e6

Fowler VG Jr (see Cabell et al). 2005;150:1092-8

Fowler VG Jr (see Wang et al). 2005;150:1086-91

Fox KA (see Bhatt et al). 2005;150:401.e1-401.e7

Fox KAA (see Lewis et al). 2005;150:1177-84

Fraizer MC (see Wyman et al). 2005;150:1081-5

Francis SE (see Satterthwaite et al). 2005;150:488-99

Franken U (see Sievers et al). 2005;150:737-42

Frazier CG, Shah SH, Armstrong PW, Bhapkar MV, McGuire DK, Sadowski Z, Kristinsson A, Aylward PE, Klein WW, Weaver WD, Newby LK, SYMPHONY and Second SYMPHONY Investigators. Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials. 2005;150:1260-7

Freedman BI (see Bowden et al). 2005;150:1032-8

Frey A (see Teerlink et al). 2005;150:46-53 (Trial design)

Fricke K (see Mitrovic et al). 2005;150:1239.e1-1239.e8

Frielingdorf J (see Straumann et al). 2005;150:1000-6

Fritzenwanger M (see Kuethe et al). 2005;150:115.e1-115.e7

Froelicher VF (see Hsieh et al). 2005;150:161-7

Frost P (see Salmasi et al). 2005;150:168-74

Fry A (see Cantor et al). 2005;150:543-9

Fu M (see Gou et al). 2005;150:1039-45

Fujii S (see Kasanuki et al). 2005;150:411-8

Funatsu A (see Liu et al). 2005;150:681-8

Furberg CD (see Chan et al). 2005;150:464-70

Furrer M (see Straumann et al). 2005;150:1000-6

G

Gabay JM (see Cohen et al). 2005;150:1204-11

Gabriel HM (see Gödicke et al). 2005;150:1015.e11-1015.e17

Gabrielli M, Candelli M, Santarelli L, Pola P, Gasbarrini A. Azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome. 2005;150(1):e9 (Letter)

Gaede A (see Kaehler et al). 2005;150:987-93

Galbraith PD (see McLellan et al). 2005;150:800-6

Galderisi M (see Agricola et al). 2005;150:610-5

Gañán A (see Cenarro et al). 2005;150:1154-62

Garcia-Ben M (see Cohen et al). 2005;150:1204-11

Garcia E (see Weisz et al). 2005;150:358-64

Gardetto N (see Fitzgerald et al). 2005;150:471-7

Gardin J (see Aboufakher et al). 2005;150:455-8

Garg J (see Barbagelata et al). 2005;150:659-65

Garg R (see Kontos et al). 2005;150:666-73, 674-80

Garg R (see Mathew et al). 2005;150:968-76

Gasbarrini A (see Gabrielli et al). 2005;150(1):e9 (Letter)

Gauldin LH (see Shah et al). 2005;150:893-8 (Trial design)

Gavazzi A (see Cecchi et al). 2005;150:947-54

Ge J (see Han et al). 2005;150:568.e1-568.e5

Genès N (see Danchin et al). 2005;150:1147-53

Gennevois D (see Alexander et al). 2005;150:643-9 (Trial design)

Gentles PJ, Wiley T, Taylor AJ. A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy. 2005;150:478-83

Genuini I (see De Luca et al). 2005;150:563-8

George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. 2005;150:484-7

Ghali JK (see Solomon et al). 2005;150:257-62

Ghali WA (see Baskett et al). 2005;150:1122-7

Ghali WA (see Hassan et al). 2005;150:1026-31

Ghali WA (see McLellan et al). 2005;150:800-6

Giambanco F (see Di Pasquale et al). 2005;150:919.e1-919.e8

Giampaoli S (see Cecchi et al). 2005;150:947-54

Gibbons RJ (see Barbagelata et al). 2005;150:659-65

Gibson CM (see Alexander et al). 2005;150:643-9 (Trial design)

Gibson CM (see Ly et al). 2005;150:933.e9-933.e13

Gibson CM (see Ohman et al). 2005;150:79-88

Gilbert N (see Schulze-Neick et al). 2005;150:716.e7-716.e12

Giles WH (see Brown et al). 2005;150:448-54

Gingell RL (see Dadlani et al). 2005;150:1016.e1-1016.e8

Girkay MJ (see Mao et al). 2005;150:315-22

Glassman A (see Jiang et al). 2005;150:54-78 (Meetings)

Gliuud C (see Zwilzer et al). 2005;150:899.e7-899.e16 (Trial design)

Gödicke J, Flather M, Noc M, Gyöngyösi M, Arntz H-R, Grip L, Gabriel HM, Huber K, Nugara F, Schröder J, Svensson L, Wang D, Zorman S, Montalescot G. Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. 2005;150:1015.e11-1015.e17

Goepfert L (see Tritos et al). 2005;150:1212.e1-1212.e6

Goff DC Jr, Massing MW, Bertoni AG, Davis J, Ambrosius WT, McArdle J, Duran-Winfield V, Sucta CA, Croft JB. Enhancing quality of heart failure care in managed Medicare and Medicaid in North Carolina: results of the North Carolina Achieving Cardiac Excellence (NC ACE) Project. 2005;150:717-24

Goff DC Jr (see McGinn et al). 2005;150:392-400

Goldberg A, Hammerman H, Petcherski S, Zdrovovych A, Yalonetsky S, Kapeliovich M, Agmon Y, Markiewicz W, Aronson D. In-hospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. 2005;150:330-7

Goldberg RJ (see Spencer et al). 2005;150:838-44

Goldhaber SZ (see Seshadri et al). 2005;150:27-34 (Curriculum cardiol.)

Gómez S (see Berenguer et al). 2005;150:536-42

Gonzalvo C (see Cenarro et al). 2005;150:1154-62

Goodarzi MO (see Port et al). 2005;150:209-14

Goodman SG (see Barbagelata et al). 2005;150:659-65

Goodman SG (see Hackam et al). 2005;150:35-40 (Curriculum cardiol.)

Goodman SG (see Segev et al). 2005;150:690-4

Gorchakova O (see Braun et al). 2005;150:550-6

Gordon P (see Halkin et al). 2005;150:1163-70

Gore JM (see Mohapatra et al). 2005;150:19-26 (Progress cardiol.)

Gore JM (see Spencer et al). 2005;150:838-44

Gorski JC (see Shankar et al). 2005;150:933.e1-933.e7

Gosselink ATM (see De Luca et al). 2005;150:557-62, 827-31, 1185-9, 1248-54

Goswami R (see Aboufakher et al). 2005;150:455-8

Gottschall D (see Kueche et al). 2005;150:115.e1-115.e7

Gou L, Fu M, Xu Y, Tian Y, Yan B, Yang L. Alterations of high-density lipoprotein subclasses in endogenous hypertriglyceridemia. 2005;150:1039-45

Goudevenos JA (see Katsouras et al). 2005;150:385-91

Goyal A, Blazing M. Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event? 2005;150:650-1 (Evidence-based consult)

Gozal D (see Blatt et al). 2005;150:986.e1-986.e7

Granger CB (see Barbagelata et al). 2005;150:659-65

Granillo GAR (see Aoki et al). 2005;150:994-9

Griffin JJ (see Weisz et al). 2005;150:358-64

Grimm RA (see Seshadri et al). 2005;150:27-34 (Curriculum cardiol.)

Grines CL (see Weisz et al). 2005;150:358-64

Grinfeld L (see Barbagelata et al). 2005;150:659-65

Grinfeld LR (see Cohen et al). 2005;150:1204-11

Grip L (see Gödicke et al). 2005;150:1015.e11-1015.e17

Groce JB III (see Seshadri et al). 2005;150:27-34 (Curriculum cardiol.)

Gronning B (see Engblom et al). 2005;150:507-12

Gross ER (see Gross et al). 2005;150(6):e3 (Letter)

Gross GJ, Gross ER, Peart JN. Letter to the Editor. 2005;150(6):e3 (Letter)

Gruenig E (see Schulze-Neick et al). 2005;150:716.e7-716.e12

Gruppollo P (see Cecchi et al). 2005;150:947-54

Gu C (see Tang et al). 2005;150:845-51

Guagliumi G (see Weisz et al). 2005;150:358-64

Guérat P (see Danchin et al). 2005;150:1147-53

Guetta V (see Brener et al). 2005;150:89-93

Gula LJ (see Rockx et al). 2005;150:1065.e1-1065.e5

Gupta R (see Fathi et al). 2005;150:1190-7

Guralnik JM (see McDermott et al). 2005;150:276-81

Gurm HS (see Fathi et al). 2005;150:1190-7

GUSTO V Investigators (see Brener et al). 2005;150:89-93

Guy D (see Thomas et al). 2005;150(5):e3 (Letter reply)

Guyatt G (see Gwadry-Sridhar et al). 2005;150:982.e1-982.e9

Gwadry-Sridhar FH, Arnold JMO, Zhang Y, Brown JE, Marchiori G, Guyatt G. Pilot study to determine the impact of a multidisciplinary educational intervention in patients hospitalized with heart failure. 2005;150:982.e1-982.e9

Gyöngyösi M (see Gödicke et al). 2005;150:1015.e11-1015.e17

H

Ha J-W (see Joung et al). 2005;150:1213-9

Haar A (see Kaehler et al). 2005;150:987-93

Habbema JDF (see Steyerberg et al). 2005;150:920.e11-920.e17

Habib G (see Cabell et al). 2005;150:1092-8

Hackam DG, Goodman SG, Anand SS. Management of risk in peripheral artery disease: recent therapeutic advances. 2005;150:35-40 (Curriculum cardiol.)

Hacke W (see Bhatt et al). 2005;150:401.e1-401.e7

Hadamitzky M (see Dibra et al). 2005;150:344-50

Haffner SM (see Bhatt et al). 2005;150:401.e1-401.e7

Halac ME (see Cohen et al). 2005;150:1204-11

Halderman GA (see Brown et al). 2005;150:448-54

Halkin A, Mehran R, Casey CW, Gordon P, Matthews R, Wilson BH, Leon MB, Russell ME, Ellis SG, Stone GW. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. 2005;150:1163-70

Halon DA (see Lewis et al). 2005;150:1177-84

Haluska B (see Smart et al). 2005;150:1240-7

Hamada M (see Ogimoto et al). 2005;150(1):e1 (Letter)

Hamm CW (see Bhatt et al). 2005;150:401.e1-401.e7

Hammerman H (see Goldberg et al). 2005;150:330-7

Han KH (see Lee et al). 2005;150:577-82

Han Y, Wang S, Li Y, Jing Q, Ma Y, Deng J, Yang G, Yu H, Ge J. Cilostazol improves long-term outcomes after coronary stent implantation. 2005;150:568.e1-568.e5

Hanada H (see Onodera et al). 2005;150:689.e11-689.e16

Hanania N (see Danchin et al). 2005;150:1147-53

Hancock SL (see Heidenreich et al). 2005;150:977-82

Hankey GJ (see Bhatt et al). 2005;150:401.e1-401.e7

Hanrath P (see Kirchhof et al). 2005;150:899.e1-899.e6 (Trial design)

Hara H (see Liu et al). 2005;150:681-8

Hara H (see Liu et al). 2005;150:681-8

Hare JM (see Ardehali et al). 2005;150:459-63

Harel F (see Ly et al). 2005;150:933.e9-933.e13

Hariri A (see Ardehali et al). 2005;150:459-63

Harrelson L (see Ohman et al). 2005;150:79-88

Harrington RA (see Alexander et al). 2005;150:643-9 (Trial design)

Harris KM, Aepli DM, Carey CF. Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity. 2005;150:1106.e1-1106.e6

Harrison JK (see Krasuski et al). 2005;150:725-8
Harvey PJ (see Mitchell et al). 2005;150:1017-25
Haschke M (see Scharhag et al). 2005;150:1128-34
Haskell W (see Havlik et al). 2005;150:270-5
Hassan A, Butch KJ, Baskett RJF, Ali IS, Maitland A, Sullivan JAP, Ghali WA, Hirsch GM. The association between prior percutaneous coronary intervention and short-term outcomes after coronary artery bypass grafting. 2005;150:1026-31
Hatori T (see Kasama et al). 2005;150:477.e1-477.e8
Havlik RJ, Phillips CL, Brock DB, Lohman K, Haskell W, Snell P, O'Toole M, Ribisl P, Vaitkevicius P, Spurgeon HA, Lakatta EG, Pullen P. Walking may be related to less vascular stiffness in the Activity Counseling Trial (ACT). 2005;150:270-5
Hayerizadeh B-F (see Rahimi et al). 2005;150:1282-9
Haze K (see Kasanuki et al). 2005;150:411-8
Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, Cybulsky I, Abouzahr L, Sawchuck C, Carroll S, Morillo C, Kleine P, Chu V, Lonn E, Connolly SJ. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. 2005;150:288-93
Heckbert SR (see Chan et al). 2005;150:464-70
Hedström E (see Engblom et al). 2005;150:920.e1-920.e9
Heiberg E (see Engblom et al). 2005;150:920.e1-920.e9
Heidenreich PA, Hancock SL, Vagelos RH, Lee BK, Schnittger I. Diastolic dysfunction after mediastinal irradiation. 2005;150:977-82
Heidenreich PA (see Spertus et al). 2005;150:707-15
Heit JA (see Seshadri et al). 2005;150:27-34 (Curriculum cardiol.)
Helm RE (see Baskett et al). 2005;150:1122-7
Henderson M (see Agah et al). 2005;150:500-6
Hennekens AR (see Hennekens et al). 2005;150:1115-21 (Curriculum cardiol.)
Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. 2005;150:1115-21 (Curriculum cardiol.)
Henry D (see Solomon et al). 2005;150:257-62
Henry M (see Nichol et al). 2005;150:202-8 (Trial design)
Henry MC (see Riegel et al). 2005;150:927-32
Henry TD, Unger BT, Sharkey SW, Lips DL, Pedersen WR, Madison JD, Mooney MR, Flygenring BP, Larson DM. Design of a standardized system for transfer of patients with ST-elevation myocardial infarction for percutaneous coronary intervention. 2005;150:373-84 (Trial design)
Herlitz J (see Thuresson et al). 2005;150:234-42
Hernandez F (see Baskett et al). 2005;150:1122-7
Herrington DM (see Bowden et al). 2005;150:1032-8
Herrington DM (see Erkkila et al). 2005;150:94-101
Herrington DM (see Lakoski et al). 2005;150:907-11
Hermann M (see Scharhag et al). 2005;150:1128-34
Herrmann W (see Scharhag et al). 2005;150:1128-34
Herzau M (see Kuethé et al). 2005;150:115.e1-115.e7
Hesse B, Morise A, Pothier CE, Blackstone EH, Lauer MS. Can we reliably predict long-term mortality after exercise testing? An external validation. 2005;150:307-14
Higaki J (see Ogimoto et al). 2005;150(1):e1 (Letter)
Higano ST (see Brosh et al). 2005;150:338-43
Higuma T (see Onodera et al). 2005;150:689.e11-689.e16
HIJAMI Investigators (see Kasanuki et al). 2005;150:411-8
Hillis G. Reply to Gasbarrini. 2005;150(1):e11 (Letter reply)
Hillis GS, Möller JE, Pellicka PA, Bell MR, Casaclang-Verzosa GC, Oh JK. Prognostic significance of echocardiographically defined mitral regurgitation early after acute myocardial infarction. 2005;150:1268-75
Hindman L, Falko JM, LaLonde M, Snow R, Caulin-Glaser T. Clinical profile and outcomes of diabetic and nondiabetic patients in cardiac rehabilitation. 2005;150:1046-51
Hirai H (see Liu et al). 2005;150:681-8
Hirooka H (see Ishihara et al). 2005;150:814-20
Hirayama A (see Nakatani et al). 2005;150:652-8
Hirayama A (see Ohtani et al). 2005;150:227-33
Hirsch GM (see Baskett et al). 2005;150:1122-7
Hirsch GM (see Hassan et al). 2005;150:1026-31
Ho KK (see Rana et al). 2005;150:821-6
Hoch JS (see Rockx et al). 2005;150:1065.e1-1065.e5
Hochman JS (see Brener et al). 2005;150:89-93
Hoë B (see Cabell et al). 2005;150:1092-8
Hoë B (see Wang et al). 2005;150:1086-91
Hoepfer MM (see Schulze-Neick et al). 2005;150:716.e7-716.e12
Hohnloser SH (see Healey et al). 2005;150:288-93
Hollar D (see Hennekens et al). 2005;150:1115-21 (Curriculum cardiol.)
Holmes DR Jr (see Brosh et al). 2005;150:338-43
Holmes DR Jr (see Laskey et al). 2005;150:569-76
Honda T (see Kasanuki et al). 2005;150:411-8
Hong M-K (see Lee et al). 2005;150:577-82
Hoornje JCA (see De Luca et al). 2005;150:557-62, 827-31, 1185-9, 1248-54
Hori M (see Nakatani et al). 2005;150:652-8
Hori M (see Ohtani et al). 2005;150:227-33
Horie T (see Kasanuki et al). 2005;150:411-8
Horne BD (see Muhlestein et al). 2005;150:182-7
Horne BD (see Whiting et al). 2005;150:243-50
Horwitz TB (see Ralli et al). 2005;150:1220-7
Horwitz R (see Lampert et al). 2005;150:153-60
Howard DL (see Ardehali et al). 2005;150:459-63
Hreyfe H, Bedi M, Ezzeddine R, Barrington W, Jain S, Ngwu O, Saba S. Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of β -blockers. 2005;150:1064.e1-1064.e5
Hsieh BP, Pham MX, Froelicher VF. Prognostic value of electrocardiographic criteria for left ventricular hypertrophy. 2005;150:161-7
Huber K (see Gödicke et al). 2005;150:1015.e11-1015.e17
Hughes K (see Agah et al). 2005;150:500-6
Hulley SB (see Pletcher et al). 2005;150:921-6
Hummel A (see Staudt et al). 2005;150:729-36
Hummel A (see Völzke et al). 2005;150:1198-203
Husic M, Nørgaard B, Egstrup K, Lang RM, Möller JE. Diastolic wall motion abnormality after myocardial infarction: relation to neurohormonal activation and prognostic implications. 2005;150:767-74
Husic M (see Nørgaard et al). 2005;150:522-9
Huszt E (see Nichol et al). 2005;150:202-8 (Trial design)

Iakovou I (see Briguori et al). 2005;150:807-13
Ianni BM (see Arteaga et al). 2005;150:1228-32
Ianni BM (see Matsumoto et al). 2005;150:144-9
ICE-MD Investigators, International Collaboration on Endocarditis Merged Database (ICE-MD) Study Group (see Cabell et al). 2005;150:1092-8
Ichikawa S (see Kasama et al). 2005;150:477.e1-477.e8
Ickovics J (see Lampert et al). 2005;150:153-60
Ikeda LS (see Konstam et al). 2005;150:123-31
Ikeda Y (see Ishihara et al). 2005;150:814-20
Ikonomidis I. Does alcohol affect CRP levels? 2005;150(6):e7 (Letter reply)

Inai K, Nakanishi T, Nakazawa M. Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation. 2005;150:588-94

Inoue T (see Ishihara et al). 2005;150:814-20

Intermountain Heart Collaborative (IHC) Study Group (see Whiting et al). 2005;150:243-50

International Collaboration on Endocarditis Investigators (see Wang et al). 2005;150:1086-91

IONA Study Group. Determinants of coronary events in patients with stable angina: results from the Impact of Nicorandil in Angina Study. 2005;150:689.e1-689.e9

Ishihara M, Kojima S, Sakamoto T, Asada Y, Tei C, Kimura K, Miyazaki S, Sonoda M, Tsuchihashi K, Yamagishi M, Ikeda Y, Shirai M, Hiraoka H, Inoue T, Saito F, Ogawa H. Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. 2005;150:814-20

Ishii Y (see Kasanuki et al). 2005;150:411-8

Ishizaka H (see Onodera et al). 2005;150:689.e11-689.e16

Ito H (see Nakatani et al). 2005;150:652-8

Ivanov J (see Mitchell et al). 2005;150:1017-25

Iversen L (see Zwilser et al). 2005;150:899.e7-899.e16 (Trial design)

J

Jackson G (see Solomon et al). 2005;150:620-6 (Curriculum cardiol.)

Jackson M (see Williams et al). 2005;150:983.e1-983.e6

Jacob S, Cohen DJ, Massaro J, Niemyski P, Maresch K, Kleiman N, EVENT Investigators. Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. 2005;150:887-92 (Trial design)

Jafar TH, Jafary FH, Jessani S, Chaturvedi N. Heart disease epidemic in Pakistan: women and men at equal risk. 2005;150:221-6

Jafary FH (see Jafar et al). 2005;150:221-6

Jain S (see Hreyber et al). 2005;150:1064.e1-1064.e5

James KB, Troughton RW, Feildschuh J, Soltis D, Thomas D, Fouad-Tarazi F. Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study. 2005;150:984.e1-984.e6

Jang Y (see Joung et al). 2005;150:1213-9

Jani SM (see Aboufakher et al). 2005;150:455-8

Japanese Acute Coronary Syndrome Study (JACSS) Investigators (see Ishihara et al). 2005;150:814-20

Jariöv MB (see Thuresson et al). 2005;150:234-42

Jeffries L (see Rakhit et al). 2005;150:1074-80

Jeffriess L (see Smart et al). 2005;150:1240-7

Jennrich RI (see Port et al). 2005;150:209-14

Jessani S (see Jafar et al). 2005;150:221-6

Jesse RL (see Kontos et al). 2005;150:666-73, 674-80

Jia G (see Brener et al). 2005;150:89-93

Jiang W, Davidson JRT. Antidepressant therapy in patients with ischemic heart disease. 2005;150:871-81 (Curriculum cardiol.)

Jiang W, Glassman A, Krishnan R, O'Connor CM, Califf RM. Depression and ischemic heart disease: what have we learned so far and what must we do in the future? 2005;150:54-78 (Meetings)

Jiménez-Mena M (see Martín-Dávila et al). 2005;150:1099-106

Jing Q (see Han et al). 2005;150:568.e1-568.e5

John U (see Völzke et al). 2005;150:1198-203

Johnson BD (see Kip et al). 2005;150:900-6

Johnston SC (see Bhatty et al). 2005;150:401.e1-401.e7

Joliffe C (see Arcand et al). 2005;150:716.e1-716.e5

Jondeau G (see Teerlink et al). 2005;150:46-53 (Trial design)

Jones P (see Spartus et al). 2005;150:707-15

Jones PG (see Rumsfeld et al). 2005;150:961-7

Joseph DM (see Alexander et al). 2005;150:643-9 (Trial design)

Joung B, Ha J-W, Ko YG, Kang S-M, Rim SJ, Jang Y, Chung N, Shim W-H, Cho S-Y. Can pro-brain natriuretic peptide be used as a noninvasive predictor of elevated left ventricular diastolic pressures in patients with normal systolic function? 2005;150:1213-9

Jude B (see Lamblin et al). 2005;150:137-43

Jukema JW (see Salm et al). 2005;150:775-81

Jung J (see Siaplaouras et al). 2005;150:150-2

K

Kadri Z (see Danchin et al). 2005;150:1147-53

Kaelhler J, Haar A, Schaps K-P, Gaede A, Carstensen M, Schalwitz I, Koester R, Laufs R, Meinertz T, Terres W. A randomized trial in patients undergoing percutaneous coronary angioplasty: roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against Chlamydia pneumoniae. 2005;150:987-93

Kaluski E (see Blatt et al). 2005;150:986.e1-986.e7

Kamlesh M, Subramanian U, Ariana A, Sawada S, Peterson E. Diabetes status and racial differences in post-myocardial infarction mortality. 2005;150:912-9

Kang S-M (see Joung et al). 2005;150:1213-9

Kapadia SR (see Sitges et al). 2005;150:852-8

Kapeliovich M (see Goldberg et al). 2005;150:330-7

Kaplan S (see Fisher et al). 2005;150:439-47

Kasama S, Toyama T, Hatori T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy. 2005;150:477.e1-477.e8

Kasanuki H, Honda T, Haze K, Sumiyoshi T, Horie T, Yagi M, Yamaguchi I, Ishii Y, Fujii S, Nagashima M, Okada H, Koganei H, Koyanagi R, Tsurumi Y, Kimura H, Ogawa H, HIJAMI Investigators. A large-scale prospective cohort study on the current status of therapeutic modalities for acute myocardial infarction in Japan: rationale and initial results of the HIJAMI Registry. 2005;150:411-8

Kasper EK (see Ardehali et al). 2005;150:459-63

Kastrati A (see Braun et al). 2005;150:550-6

Kastrati A (see Dibra et al). 2005;150:344-50

Katsimiglis G (see Tritos et al). 2005;150:1212.e1-1212.e6

Katsouras C, Michalis LK, Papamichael N, Adamides K, Naka KK, Nikas D, Goudevenos JA, Sideris DA. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVE) trial at 6 months. 2005;150:385-91

Katz JN, Drazner MH. Assessing prognosis in heart failure: is hepatocyte growth factor the next B-type natriuretic peptide? 2005;150:1-5 (Editorial)

Kaur D (see Bishop et al). 2005;150:602-9

Kearney MT (see Zaman and Kearney). 2005;150(1):e5 (Letter reply)

Keevil JG (see Wyman et al). 2005;150:1081-5

Kelsey SF (see Marroquin et al). 2005;150:109-15

Keltai M (see Lewis et al). 2005;150:1177-84

Kern KM (see Kuchulakanti et al). 2005;150:832-7

Keren G (see George et al). 2005;150:484-7

Kern MJ (see Lim and Kern). 2005;150(1):e13 (Letter)

Kickler T (see Williams et al). 2005;150:434-8

Kiefe CI (see Canto and Kiefe). 2005;150:365-7 (Editorial)

Kiefe CI (see Pletcher et al). 2005;150:921-6
Kijvanit P (see Thomas et al). 2005;150(5):e3 (Letter reply)
Kim HH (see Cantor et al). 2005;150:543-9
Kim J-J (see Lee et al). 2005;150:577-82
Kim Y-H (see Lee et al). 2005;150:577-82
Kimura H (see Kasanuki et al). 2005;150:411-8
Kimura K (see Ishihara et al). 2005;150:814-20
Kinard T (see Shah et al). 2005;150:893-8 (Trial design)
Kindermann W (see Scharhag et al). 2005;150:1128-34
Kinjo K (see Nakatani et al). 2005;150:652-8
Kip KE, Marroquin OC, Shaw IJ, Arant CB, Wessel TR, Olson MB, Johnson BD, Mulukutla S, Sopko G, Bairey Merz CN, Reis SE. Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. 2005;150:900-6
Kip KE (see Laskey et al). 2005;150:569-76
Kip KE (see Marroquin et al). 2005;150:109-15
Kirby SK (see Pauliks et al). 2005;150:294-301
Kirchberg S (see Sievers et al). 2005;150:737-42
Kirchhof P, Fetsch T, Hanrath P, Meinertz T, Steinbeck G, Lehman W, Breithardt G. Targeted pharmacological reversal of electrical remodeling after cardioversion—rationale and design of the Flecainide Short-Long (Flec-SL) trial. 2005;150:899.e1-899.e6 (Trial design)
Kissinger KV (see Tritos et al). 2005;150:1212.e1-1212.e6
Klaunig JE (see Shankar et al). 2005;150:933.e1-933.e7
Klauss V (see Schiele et al). 2005;150:351-7
Kleiman N (see Jacob et al). 2005;150:887-92 (Trial design)
Klein AL (see Seshadri et al). 2005;150:27-34 (Curriculum cardiol.)
Klein GJ (see Rockx et al). 2005;150:1065.e1-1065.e5
Klein GJ (see Walker et al). 2005;150:1059-63
Klein WW (see Frazier et al). 2005;150:1260-7
Kleine P (see Healey et al). 2005;150:288-93
Kleine V (see Völzke et al). 2005;150:1198-203
Klempner JD (see Baskett et al). 2005;150:1122-7
Kligfield P (see Michaels et al). 2005;150:1066-73
Kline-Rogers E (see Aboufakher et al). 2005;150:455-8
Klingman D, Williams SA, Benner JS, Smith TW, Ahn J, O'Donnell JC. Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. 2005;150:595-601
Knudtson ML (see McLellan et al). 2005;150:800-6
Ko DT, Alter DA, Newman AM, Donovan LR, Tu JV. Association between lipid testing and statin therapy in acute myocardial infarction patients. 2005;150:419-25
Ko YG (see Joung et al). 2005;150:1213-9
Kobrin I (see Teerlink et al). 2005;150:46-53 (Trial design)
Kocher T (see Völzke et al). 2005;150:1198-203
Kodama K (see Ohtani et al). 2005;150:227-33
Koester R (see Kaehler et al). 2005;150:987-93
Koganei H (see Kasanuki et al). 2005;150:411-8
Koizumi T (see Yokoyama et al). 2005;150:287.e1-287.e7
Kojima S (see Ishihara et al). 2005;150:814-20
Komatsu H (see Liu et al). 2005;150:681-8
Komiyama N (see Yokoyama et al). 2005;150:287.e1-287.e7
Komuro I (see Yokoyama et al). 2005;150:287.e1-287.e7
König A (see Schiele et al). 2005;150:351-7
Konstam MA, Neaton JD, Poole-Wilson PA, Pitt B, Segal R, Sharma D, Dasbach EJ, Carides GW, Dickstein K, Riegger G, Camm AJ, Martinez FA, Bradstreet DC, Ikeda LS, Santoro EP, ELITE II investigators. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). 2005;150:123-31
Kontos MC, Garg R, Anderson FP, Tatum JL, Ornato JP, Jesse RL. Outcomes in patients admitted for chest pain with renal failure and troponin I elevations. 2005;150:674-80
Kontos MC, Garg R, Anderson FP, Tatum JL, Ornato JP, Jesse RL. Predictive power of ejection fraction and renal failure in patients admitted for chest pain without ST elevation in the troponin era. 2005;150:666-73
Korcarz CE (see Tsou et al). 2005;150:1135-9
Korcarz CE (see Wyman et al). 2005;150:1081-5
Koretzune Y (see Nakatani et al). 2005;150:652-8
Korlakunta HL (see Lakkireddy et al). 2005;150:516-21
Kostoulas J (see Triploskiadi et al). 2005;150:782-9
Kouchoukos NT (see Alexander et al). 2005;150:643-9 (Trial design)
Kovacs AH, Sears SF, Saidi AS. Biopsychosocial experiences of adults with congenital heart disease: review of the literature. 2005;150:193-201 (Curriculum cardiol.)
Koyanagi R (see Kasanuki et al). 2005;150:411-8
Krack A (see Kuehne et al). 2005;150:115.e1-115.e7
Krahn AD (see Rockx et al). 2005;150:1065.e1-1065.e5
Krahn AD (see Walker et al). 2005;150:1059-63
Krakover R (see Blatt et al). 2005;150:986.e1-986.e7
Kranjec I (see Mehran et al). 2005;150:1171-6
Krasuski RA, Wang A, Harrison JK, Tapson VF, Bashore TM. The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use. 2005;150:725-8
Krause SL (see Weinberger et al). 2005;150:426-33
Krishnan R (see Jiang et al). 2005;150:54-78 (Meetings)
Kristinsson A (see Frazier et al). 2005;150:1260-7
Krum H (see Teerlink et al). 2005;150:46-53 (Trial design)
Krumholz HM (see Rathore et al). 2005;150:402-10
Krumholz HM (see Spertus et al). 2005;150:707-15
Kubota T (see Liu et al). 2005;150:681-8
Kuchulakanti P, Wolfram R, Torgerson R, Rha S-W, Cheneau E, Pinnow EE, Canos D, Satler LF, Pichard AD, Kent KM, Waksman R. Brachytherapy and bivalirudin evaluation study. 2005;150:832-7
Kuethe F, Figulla HR, Herzau M, Voith M, Fritzenwanger M, Opfermann T, Pachmann K, Krack A, Sayer HG, Gottschald D, Werner GS. Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. 2005;150:115.e1-115.e7
Kuller L (see Chan et al). 2005;150:464-70
Kumakura H (see Kasama et al). 2005;150:477.e1-477.e8
Kuntz K (see Nichol et al). 2005;150:202-8 (Trial design)
Kuntz RE, Rogers C, Bain DS. Percutaneous coronary intervention-induced emboli during primary PCI for STEMI: too little, too much, or too late? 2005;150:4-6 (Editorial)
Kurabayashi M (see Kasama et al). 2005;150:477.e1-477.e8
Kuriyama N (see Yokoyama et al). 2005;150:287.e1-287.e7
Kurz DJ (see Straumann et al). 2005;150:1000-6

I

Laarman G-J (see Riezebos et al). 2005;150:1255-9
Labina M (see McLellan et al). 2005;150:800-6
Lablanche J-M (see Danchin et al). 2005;150:1147-53
Lahey SJ (see Baskett et al). 2005;150:1122-7
Lai WW (see Fisher et al). 2005;150:439-47
Lakkireddy DR, Bhakkad J, Korlakunta HL, Ryschon K, Shen X, Mooss AN, Mohiuddin SM. Prognostic value of the Duke Treadmill Score in diabetic patients. 2005;150:516-21
Lakoski SG, Brosnihan B, Herrington DM. Hormone therapy, C-reactive protein, and progression of atherosclerosis:

data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial. 2005;150:907-11

Laks T (see Solomon et al). 2005;150:257-62

LaLonde M (see Hindman et al). 2005;150:1046-51

Lam WW (see So et al). 2005;150:530-5

Lamas GA (see Skali et al). 2005;150:743-9

Lamb HJ (see Salm et al). 2005;150:775-81

Lamblin N, Susen S, Dagorn J, Mouquet F, Jude B, Van Belle E, Bauters C, de Groot P. Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure. 2005;150:137-43

Lampert R, Ickovics J, Horwitz R, Lee F. Depressed autonomic nervous system function in African Americans and individuals of lower social class: a potential mechanism of race- and class-related disparities in health outcomes. 2005;150:153-60

Lamy A (see Healey et al). 2005;150:288-93

Lan YP (see Muhlestein et al). 2005;150:182-7

Lang RM (see Husic et al). 2005;150:767-74

Lange LA (see Bowden et al). 2005;150:1032-8

Lange PE (see Schulze-Nieck et al). 2005;150:716.e7-716.e12

Langefeld CD (see Bowden et al). 2005;150:1032-8

Langer A (see Segev et al). 2005;150:690-4

Lansky A (see Weisz et al). 2005;150:358-64

Larson DM (see Henry et al). 2005;150:373-84 (Trial design)

Laskey WK, Selzer F, Holmes DR Jr, Wilensky RL, Cohen HA, Williams DO, Kip KE, Detre KM, NHLBI Dynamic Registry Investigators. Temporal variation in inhospital mortality with percutaneous coronary intervention: a report from the National Heart, Lung and Blood Institute Dynamic Registry. 2005;150:569-76

LASMAL II Investigators (see Rodriguez et al). 2005;150:188.e1-188.e7

Lau HK (see Segev et al). 2005;150:1007-14

Lau TK (see Chan et al). 2005;150:750-5

Lauer MS (see Hesse et al). 2005;150:307-14

Laufs R (see Kaehler et al). 2005;150:987-93

Lee BK (see Heidenreich et al). 2005;150:977-82

Lee CW (see Lee et al). 2005;150:577-82

Lee F (see Lampert et al). 2005;150:153-60

Lee KL (see Alexander et al). 2005;150:643-9 (Trial design)

Lee KW, Blann AD, Lip GHY. Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation. 2005;150:756-66

Lee S-W, Park S-W, Hong M-K, Kim Y-H, Han KH, Moon DH, Oh SJ, Lee CW, Kim JJ, Park SJ. Comparison of angiographic and clinical outcomes between rotational atherectomy and cutting balloon angioplasty followed by radiation therapy with a rhenium 188-mercaptoproacetyltriglycine-filled balloon in the treatment of diffuse in-stent restenosis. 2005;150:577-82

Lehmacher W (see Kirchhof et al). 2005;150:899.e1-899.e6 (Trial design)

Leibig M (see Schiele et al). 2005;150:351-7

Leitman M (see Blatt et al). 2005;150:986.e1-986.e7

Lemaire ML (see Michaels et al). 2005;150:1066-73

Lennon RJ (see Brosh et al). 2005;150:338-43

Leon MB (see Halkin et al). 2005;150:1163-70

Leoncini M, Toso A, Maioli M, Bellandi F, Badia T, Politi A, De Servi S, Dabizzi RP. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream Tirofiban, in cath Lab Downstream Abciximab (CLOTILDA) study. 2005;150:401.e9-401.e14

Lerman A (see Brosh et al). 2005;150:338-43

Lessard D (see Spencer et al). 2005;150:838-44

Leung TN (see Chan et al). 2005;150:750-5

Lever HM (see Sitges et al). 2005;150:852-8

Lewis BS, Mehta SR, Fox KAA, Halon DA, Zhao F, Peters RJG, Keltai M, Budaj A, Yusuf S, CURE trial investigators. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. 2005;150:1177-84

Lewis CE (see Pletcher et al). 2005;150:921-6

Li D (see So et al). 2005;150:530-5

Li Y (see Han et al). 2005;150:568.e1-568.e5

Lichtenstein AH (see Erkili et al). 2005;150:94-101

Liew S-M (see Bishop et al). 2005;150:602-9

Lim JG, McAvaney TJ, Fleg JL, Shapiro EP, Turner KL, Bacher AC, Ouyang P, Stewart KJ. Oxygen pulse during exercise is related to resting systolic and diastolic left ventricular function in older persons with mild hypertension. 2005;150:941-6

Lim JG, Shapiro EP, Vaidya D, Najjar SS, Turner KL, Bacher AC, Ouyang P, Stewart KJ. Sex differences in left ventricular function in older persons with mild hypertension. 2005;150:934-40

Lim MJ, Kern MJ. To the Editor. 2005;150(1):e13 (Letter)

Limbruno U, De Carlo M, Pistolesi S, Micheli A, Petronio AS, Camacci T, Fontanini G, Balbarini A, Mariani M, De Caterina R. Distal embolization during primary angioplasty: histopathologic features and predictability. 2005;150:102-8

Limbruno U (see Petronio et al). 2005;150:1015.e1-1015.e9

Lincoff AM (see Brener et al). 2005;150:89-93

Lindahl B (see Thuresson et al). 2005;150:234-42

Lins S (see Aboufakher et al). 2005;150:455-8

Lip GHY (see Lee et al). 2005;150:756-66

Lips DL (see Henry et al). 2005;150:373-84 (Trial design)

Lipshultz SE (see Dadlani et al). 2005;150:1016.e1-1016.e8

Lipshultz SE (see Fisher et al). 2005;150:439-47

Lipsitz SR (see Dadlani et al). 2005;150:1016.e1-1016.e8

Little J (see Shah et al). 2005;150:893-8 (Trial design)

Liu R, Yamamoto M, Moroi M, Kubota T, Ono T, Funatsu A, Komatsu H, Tsuji T, Hara H, Nakamura M, Hirai H, Yamaguchi T. *Cblamydia pneumoniae* immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology. 2005;150:681-8

Logan L (see Pauliks et al). 2005;150:294-301

Lohman K (see Havlik et al). 2005;150:270-5

Longstreth W (see Nichol et al). 2005;150:202-8 (Trial design)

Lonn E (see Healey et al). 2005;150:288-93

Lorenz TJ (see Alexander et al). 2005;150:643-9 (Trial design)

Lotan C (see Mehran et al). 2005;150:1171-6

Lozano T (see Berenguer et al). 2005;150:536-42

Lucas R (see Nichol et al). 2005;150:202-8 (Trial design)

Luepker RV. Delay in acute myocardial infarction: why don't they come to the hospital more quickly and what can we do to reduce delay? 2005;150:368-70 (Editorial)

Lumley T (see Chan et al). 2005;150:464-70

Lüss H (see Mitrovic et al). 2005;150:1239.e1-1239.e8

Ly HQ, Denault A, Dupuis J, Vadéboncoeur A, Harel F, Arseneault A, Gibson CM, Bonan R. A pilot study: The Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (The NICAMI Study). 2005;150:933.e9-933.e13

Lytle BW (see Sitges et al). 2005;150:852-8

M

Ma Y (see Han et al). 2005;150:568.e1-568.e5
Maas AC (see De Luca et al). 2005;150:1248-54
Macchi C (see McDermott et al). 2005;150:276-81
MacDonald TM (see Weinberger et al). 2005;150:426-33
MacI MJ (see Alexander et al). 2005;150:643-9 (Trial design)
Madan M (see Cantor et al). 2005;150:543-9
Madison JD (see Henry et al). 2005;150:373-84 (Trial design)
Madjid M (see Rashidi et al). 2005;150:41-5 (Curriculum cardiol.)
Madsen M (see Zwilser et al). 2005;150:899.e7-899.e16
(Trial design)
Mady C (see Arteaga et al). 2005;150:1228-32
Mady C (see Matsumoto et al). 2005;150:144-9
Maeda N (see Onodera et al). 2005;150:689.e11-689.e16
Mahaffey KW (see Barbagelata et al). 2005;150:659-65
Mahmalian JJ (see Win et al). 2005;150:695-700
Mahoney B (see Nichol et al). 2005;150:202-8 (Trial design)
Mahoney EM (see Zhang et al). 2005;150:175-81
Mainar V (see Berenguer et al). 2005;150:536-42
Maioli M (see Leoncini et al). 2005;150:401.e9-401.e14
Maisel AS (see Fitzgerald et al). 2005;150:471-7
Maisel WH (see Nazarian et al). 2005;150:955-60
Maisel WH (see Parkash et al). 2005;150:701-6
Maitland A (see Bassett et al). 2005;150:1122-7
Maitland A (see Hassan et al). 2005;150:1026-31
Mak K-H (see Bhatt et al). 2005;150:401.e1-401.e7
Mak K-H (see Bishop et al). 2005;150:602-9
Malinin AI (see Serebruany et al). 2005;150:882-6
(Curriculum cardiol.)
Mancinelli KL (see Shah et al). 2005;150:893-8 (Trial design)
Mancini DM (see Shah et al). 2005;150:893-8 (Trial design)
Mankad S (see Marroquin et al). 2005;150:109-15
Mann C (see Nichol et al). 2005;150:202-8 (Trial design)
Manning WJ (see Tritos et al). 2005;150:1212.e1-1212.e6
Mao S, Shimbane JS, Girskey MJ, Child J, Carson S, Oudiz RJ,
Budoff MJ. Coronary venous imaging with electron beam
computed tomographic angiography: three-dimensional
mapping and relationship with coronary arteries.
2005;150:315-22
Marchand E (see Rodriguez et al). 2005;150:188.e1-188.e7
Marchant K (see Agah et al). 2005;150:500-6
Marchiori G (see Gwadry-Sridhar et al). 2005;150:982.e1-982.e9
Maresh K (see Jacob et al). 2005;150:887-92 (Trial design)
Margonato A (see Agricola et al). 2005;150:610-5
Mariani M (see Limbruno et al). 2005;150:102-8
Mariani M (see Petronio et al). 2005;150:1015.e1-1015.e9
Markiewicz W (see Goldberg et al). 2005;150:330-7
Maronde E (see Mitrovic et al). 2005;150:1239.e1-1239.e8
Marroquin OC, Kip KE, Mulukutla SR, Ridker PM, Pepine CJ,
Tjandrawan T, Kelsey SF, Mankad S, Rogers WJ, Bairey Merz CN,
Sopko G, Sharaf BL, Reis SE. Inflammation, endothelial cell
activation, and coronary microvascular dysfunction in women
with chest pain and no obstructive coronary artery disease.
2005;150:109-15
Marroquin OC (see Kip et al). 2005;150:900-6
Martelet M (see Solomon et al). 2005;150:257-62
Martín-Dávila P, Navas E, Fortún J, Moya JL, Cobo J, Pintado V,
Quereda C, Jiménez-Mena M, Moreno S. Analysis of mortality
and risk factors associated with native valve endocarditis in
drug users: the importance of vegetation size.
2005;150:1099-106
Martin TN (see Engblom et al). 2005;150:507-12
Martinez FA (see Konstam et al). 2005;150:123-31
Marwick TH (see Rakhit et al). 2005;150:1074-80
Marwick TH (see Smart et al). 2005;150:1240-7
Mas J-L (see Bhatt et al). 2005;150:401.e1-401.e7
Maschke HE (see Staudt et al). 2005;150:729-36
Mascitelli L, Pezzetta F. Anti-inflammatory effect of alcohol and
cigarette smoking. 2005;150(6):e5 (Letter)
Massaro J (see Jacob et al). 2005;150:887-92 (Trial design)
Masselink LE (see Reed et al). 2005;150:323-9
Massing MW (see Goff et al). 2005;150:717-24
Mathew J, Wittes J, McSherry F, Williford W, Garg R, Probstfield J,
Yusuf S, Digitalis Investigation Group. Racial differences in
outcome and treatment effect in congestive heart failure.
2005;150:968-76
Matsumoto AY, Arteaga E, Ianni BM, Braga AMFW, Buck PC,
Mady C. Relationships among exercise capacity, hypertrophy,
and left ventricular diastolic function in nonobstructive
hypertrophic cardiomyopathy. 2005;150:144-9
Matsunaga T (see Onodera et al). 2005;150:689.e11-689.e16
Matthews R (see Halkin et al). 2005;150:1163-70
Mavrakis HE (see Patrianakos et al). 2005;150:985.e9-985.e18
Mays ME (see Tzou et al). 2005;150:1135-9
McArdle J (see Goff et al). 2005;150:717-24
McAvaney TJ (see Lim et al). 2005;150:941-6
McCabe C (see Ohman et al). 2005;150:79-88
McCarroll N (see Tahir et al). 2005;150:302-6
McCullough PA (see Spertus et al). 2005;150:707-15
McDermott MM, Guralnik JM, Corsi A, Albay M, Macchi C,
Bandinelli S, Ferrucci L. Patterns of inflammation associated
with peripheral arterial disease: the InCHIANTI study.
2005;150:276-81
McFadden EP (see Aoki et al). 2005;150:994-9
McGinn AP, Rosamond WD, Goff DC Jr, Taylor HA, Miles JS,
Chambless L. Trends in prehospital delay time and use of
emergency medical services for acute myocardial infarction:
experience in 4 US communities from 1987-2000.
2005;150:392-400
McGlassen DL (see Campbell et al). 2005;150:796-9
McGuire DK (see Frazier et al). 2005;150:1260-7
McKee VK (see Shah et al). 2005;150:893-8 (Trial design)
McLellan CS, Ghali WA, Labinaz M, Davis RB, Galbraith PD,
Southern DA, Shrive FM, Knudtson ML, Alberta Provincial
Project for Outcomes Assessment in Coronary Heart Disease
(APPROACH) Investigators. Association between completeness
of percutaneous coronary revascularization and postprocedure
outcomes. 2005;150:800-6
McMurray JV (see Reed et al). 2005;150:323-9
McMurray JV (see Teerlink et al). 2005;150:46-53 (Trial design)
McSherry F (see Mathew et al). 2005;150:968-76
Mehilli J (see Braun et al). 2005;150:550-6
Mehilli J (see Dibra et al). 2005;150:344-50
Mehrani R, Nikolsky E, Camenzind E, Zelizko M, Kranjec I,
Seabra-Gomes R, Negrota M, Slack S, Lotan C. An Internet-based
registry examining the efficacy of heparin coating in patients
undergoing coronary stent implantation. 2005;150:1171-6
Mehrani R (see Halkin et al). 2005;150:1163-70
Mehrani R (see Weisz et al). 2005;150:358-64
Mehta SR (see Lewis et al). 2005;150:1177-84
Meilleur M-C (see Wagner et al). 2005;150:985.e1-985.e8
Meinertz T (see Kaehler et al). 2005;150:987-93
Meinertz T (see Kirchhof et al). 2005;150:899.e1-899.e6
(Trial design)
Melisurgo G (see Agricola et al). 2005;150:610-5
Memisha G (see Parodi et al). 2005;150:220.e1-220.e5
Mensah GA (see Brown et al). 2005;150:448-54
Merino-Ibarra E (see Cenarro et al). 2005;150:1154-62

Mestres CA (see Cabell et al). 2005;150:1092-8

Mestres CA (see Wang et al). 2005;150:1086-91

Metra M (see Teerlink et al). 2005;150:46-53 (Trial design)

Metreweli C (see So et al). 2005;150:530-5

Meyer M (see Mitrovic et al). 2005;150:1239.e1-1239.e8

Michaels AD, Raisinghani A, Soran O, de Lame P-A, Lemaire ML, Kligfield P, Watson DD, Conti CR, Beller G. The effects of enhanced external counterpulsation on myocardial perfusion in patients with stable angina: a multicenter radionuclide study. 2005;150:1066-73

Michalis LK (see Katsouras et al). 2005;150:385-91

Michelangelo OASIS 5 Steering Committee. Design and rationale of the Michelangelo Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. 2005;150:1107-14 (Trial design)

Micheli A (see Limbruno et al). 2005;150:102-8

Michelson AD (see Serebruany et al). 2005;150:882-6 (Curriculum cardiol.)

Michev I (see Briguori et al). 2005;150:807-13

Michos ED, Vasamreddy CR, Becker DM, Yanek LR, Moy TF, Fishman EK, Becker LC, Blumenthal RS. Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis. 2005;150:1276-81

Migliorini A (see Parodi et al). 2005;150:220.e1-220.e5

Miki T (see Ogimoto et al). 2005;150(1):e1 (Letter)

Miles JS (see McGinn et al). 2005;150:392-400

Miles JS (see Nazarian et al). 2005;150:955-60

Milionis HJ, Elisaf MS. Reply to Al-Shaer, Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome (Am Heart J 2005;149:e17). 2005;150(1):e7 (Letter reply)

Miller MB (see Tang et al). 2005;150:845-51

Milo-Cotter O (see Blatt et al). 2005;150:986.e1-986.e7

Miro JM (see Cabell et al). 2005;150:1092-8

Miro JM (see Wang et al). 2005;150:1086-91

Mitchell RHB, Robertson E, Harvey PJ, Nolan R, Rodin G, Romans S, Abramson BL, Brister SJ, Ivanov J, Stewart DE. Sex differences in depression after coronary artery bypass graft surgery. 2005;150:1017-25

Mitrovic V, Lüss H, Nitsche K, Forssmann K, Maronde E, Fricke K, Forssmann W-G, Meyer M. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. 2005;150:1239.e1-1239.e8

Mittleman MA (see Rana et al). 2005;150:821-6

Miyazaki S (see Ishihara et al). 2005;150:814-20

Mizote I (see Ohtani et al). 2005;150:227-33

Mizuno H (see Nakatani et al). 2005;150:652-8

Mlady I (see Agah et al). 2005;150:500-6

Mohapatra R, Tran M, Gore JM, Spencer FA. A review of the oral direct thrombin inhibitor ximelagatan: not yet the end of the warfarin era... 2005;150:19-26 (Progress cardiol.)

Mohiuddin SM (see Lakkireddy et al). 2005;150:516-21

Moir S (see Rakhit et al). 2005;150:1074-80

Möller JE (see Hillis et al). 2005;150:1268-75

Möller JE (see Husic et al). 2005;150:767-74

Möller JE (see Nørager et al). 2005;150:522-9

Montalescot G (see Bhatt et al). 2005;150:401.e1-401.e7

Montalescot G (see Gödicke et al). 2005;150:1015.e11-1015.e17

Montorfano M (see Briguori et al). 2005;150:807-13

Montoya M (see Cohen et al). 2005;150:1204-11

Moodie DS (see Fisher et al). 2005;150:439-47

Moon DH (see Lee et al). 2005;150:577-82

Mooney MR (see Henry et al). 2005;150:373-84 (Trial design)

Moore D (see Tahir et al). 2005;150:302-6

Mooss AN (see Lakkireddy et al). 2005;150:516-21

Moreno S (see Martín-Dávila et al). 2005;150:1099-106

Mori Y (see Onodera et al). 2005;150:689.e11-689.e16

Morillo C (see Healey et al). 2005;150:288-93

Morise A (see Hesse et al). 2005;150:307-14

Moroi M (see Liu et al). 2005;150:681-8

Morton JR (see Baskett et al). 2005;150:1122-7

Moschi G (see Parodi et al). 2005;150:220.e1-220.e5

Moscucci M (see Aboufakher et al). 2005;150:455-8

Moser DK, Doering LV, Chung ML. Vulnerabilities of patients recovering from an exacerbation of chronic heart failure. 2005;150:984.e7-984.e13

Mouquet F (see Lamblin et al). 2005;150:137-43

Moy TF (see Michos et al). 2005;150:1276-81

Moya JL (see Martín-Dávila et al). 2005;150:1099-106

Moyé LA (see Skali et al). 2005;150:743-9

Mozaffarian D (see Erkkilä et al). 2005;150:94-101

Muhlestein JB, Anderson JL, Cui CZ, Lan YP, Bair TL, Bunch TJ, Pearson RR, Sorensen SG, Renlund DG, Zhang L, Horne BD, Vincent GM. Improved long-term survival associated with stent deployment during percutaneous coronary interventions: results from a registry of 3399 patients. 2005;150:182-7

Muhlestein JB (see Whiting et al). 2005;150:243-50

Mulukutla S (see Kip et al). 2005;150:900-6

Mulukutla SR (see Marroquin et al). 2005;150:109-15

Muntwyler J (see Straumann et al). 2005;150:1000-6

Murphy MK (see Campbell et al). 2005;150:796-9

Murugesan G (see Agah et al). 2005;150:500-6

Mury R (see Straumann et al). 2005;150:1000-6

N

Nacar N (see Tutar et al). 2005;150:513-5

Naegeli B (see Straumann et al). 2005;150:1000-6

Nagashima M (see Kasanuki et al). 2005;150:411-8

Najdzionek J (see Dadlani et al). 2005;150:1016.e1-1016.e8

Najjar SS (see Lim et al). 2005;150:934-40

Naka KK (see Katsouras et al). 2005;150:385-91

Nakamura M (see Liu et al). 2005;150:681-8

Nakanishi T (see Inai et al). 2005;150:588-94

Nakatani D, Sato H, Sakata Y, Shiotani I, Kinjo K, Mizuno H, Shimizu M, Ito H, Koretsune Y, Hirayama A, Hori M, Osaka Acute Coronary Insufficiency Study (OACIS) Group. Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction. 2005;150:652-8

Nakayama T (see Yokoyama et al). 2005;150:287.e1-287.e7

Nakazawa M (see Inai et al). 2005;150:588-94

Nameki M (see Yokoyama et al). 2005;150:287.e1-287.e7

Namikawa S (see Yokoyama et al). 2005;150:287.e1-287.e7

Natarajan MK (see Cantor et al). 2005;150:543-9

Navas E (see Martín-Dávila et al). 2005;150:1099-106

Nazarian S, Maisel WH, Miles JS, Tsang S, Stevenson LW, Stevenson WG. Impact of implantable cardioverter defibrillators on survival and recurrent hospitalization in advanced heart failure. 2005;150:955-60

Ndrepepa G (see Braun et al). 2005;150:550-6

Neaton JD (see Konstam et al). 2005;150:123-31

Negoita M (see Mehran et al). 2005;150:1171-6

Newby LK (see Frazier et al). 2005;150:1260-7

Newman A (see Schull et al). 2005;150:583-7

Newman AM (see Ko et al). 2005;150:419-25
Newton GE (see Arcand et al). 2005;150:716.e1-716.e5
Ngwu O (see Hreybe et al). 2005;150:1064.e1-1064.e5
NHLBI Dynamic Registry Investigators (see Laskey et al). 2005;150:569-76
Nichol G, Wells GA, Kuntz K, Feeny D, Longstreth W, Mahoney B, Mann C, Lucas R, Henry M, Huszti E, Birnbaum A. Methodological design for economic evaluation in Public Access Defibrillation (PAD) trial. 2005;150:202-8 (Trial design)
Niemycki P (see Jacob et al). 2005;150:887-92 (Trial design)
Nikas D (see Katsouras et al). 2005;150:385-91
Nikolsky E (see Mehran et al). 2005;150:1171-6
Nistri S (see Cecchi et al). 2005;150:947-54
Nitsche K (see Mitrovic et al). 2005;150:1239.e1-1239.e8
Noc M (see Gödicke et al). 2005;150:1015.e1-1015.e17
Nohria A (see Shah et al). 2005;150:893-8 (Trial design)
Nolan R (see Mitchell et al). 2005;150:1017-25
Nørager B, Husic M, Møller JE, Pellikka PA, Appleton CP, Egstrup K. The Doppler myocardial performance index during low-dose dobutamine echocardiography predicts mortality and left ventricular dilation after a first acute myocardial infarction. 2005;150:522-9
Nørager B (see Husic et al). 2005;150:767-74
Nugara F (see Gödicke et al). 2005;150:1015.e1-1015.e17
Nugara F (see Zhang et al). 2005;150:175-81
Nugent WC (see Baskett et al). 2005;150:1122-7
Nuttall GA (see Campbell et al). 2005;150:796-9

○

Occluded Artery Trial (OAT) Research Group. Design and methodology of the Occluded Artery Trial (OAT). 2005;150:627-42 (Trial design)
O'Connor CM (see Jiang et al). 2005;150:54-78 (Meetings)
O'Connor CM (see Shah et al). 2005;150:893-8 (Trial design)
O'Connor CM (see Teerlink et al). 2005;150:46-53 (Trial design)
O'Connor GT (see Baskett et al). 2005;150:1122-7
O'Donnell JC (see Klingman et al). 2005;150:595-601
Ogawa H (see Ishihara et al). 2005;150:814-20
Ogawa H (see Kasanuki et al). 2005;150:411-8
Ogimoto A, Hamada M, Miki T, Higaki J. Angiotensin I-converting enzyme insertion/insertion genotype as a genetic risk factor for cardiovascular disease. 2005;150(1):e1 (Letter)
Oh JK (see Hillis et al). 2005;150:1268-75
Oh SJ (see Lee et al). 2005;150:577-82
Ohman EM, Van de Werf F, Antman EM, Califf RM, de Lemos JA, Gibson CM, Oliverio RL, Harrelson L, McCabe C, DiBattiste P, Braunwald E, FASTER (TIMI 24) Investigators. Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. 2005;150:79-88
Ohtani T, Ueda Y, Shimizu M, Mizote I, Hirayama A, Hori M, Kodama K. Association between cardiac troponin T elevation and angiographic morphology of culprit lesion in patients with non-ST-segment elevation acute coronary syndrome. 2005;150:227-33
Okada H (see Kasanuki et al). 2005;150:411-8
Okumura K (see Onodera et al). 2005;150:689.e1-689.e16
Olaison L (see Cabell et al). 2005;150:1092-8
Olaison L (see Wang et al). 2005;150:1086-91
Oliver WC (see Campbell et al). 2005;150:796-9
Oliverio RL (see Ohman et al). 2005;150:79-88
Olivotto I (see Cecchi et al). 2005;150:947-54
Olson MB (see Kip et al). 2005;150:900-6
Ong ATL (see Aoki et al). 2005;150:994-9
Ono T (see Liu et al). 2005;150:681-8

Onodera H, Matsunaga T, Tamura Y, Maeda N, Higuma T, Sasaki S, Mori Y, Yoshimachi F, Ishizaka H, Hanada H, Osanai T, Okumura K. Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction. 2005;150:689.e11-689.e16

Opfermann T (see Kuethé et al). 2005;150:115.e1-115.e7

Oppizzi M (see Agricola et al). 2005;150:610-5

Orav EJ (see Fisher et al). 2005;150:439-47

Orford JL (see Campbell et al). 2005;150:796-9

Orie JD (see Dadlani et al). 2005;150:1016.e1-1016.e8

Ornat JP (see Kontos et al). 2005;150:666-73, 674-80

Osaka Acute Coronary Insufficiency Study (OACIS) Group (see Nakatani et al). 2005;150:652-8

Osanai T (see Onodera et al). 2005;150:689.e11-689.e16

Oshrine BR (see Serebruany et al). 2005;150:882-6 (Curriculum cardiol.)

O'Toole M (see Havlik et al). 2005;150:270-5

Ottervanger JP (see De Luca et al). 2005;150:557-62, 827-31, 1185-9, 1248-54

Oudiz RJ (see Mao et al). 2005;150:315-22

Ouyang P (see Lim et al). 2005;150:934-40, 941-6

Ouyang P (see Williams et al). 2005;150:434-8

OVERTURE Investigators (see Solomon et al). 2005;150:257-62

●

Pachmann K (see Kuethé et al). 2005;150:115.e1-115.e7

Packer M (see Solomon et al). 2005;150:257-62

PAD Investigators (see Riegel et al). 2005;150:927-32

Pahlm O (see Engblom et al). 2005;150:507-12, 920.e1-920.e9

Palacios IF (see Rodriguez et al). 2005;150:188.e1-188.e7

Palagi C (see Petronio et al). 2005;150:1015.e1-1015.e9

Panagiotou D (see Tang et al). 2005;150:845-51

Panaretou M (see Dernellis and Panaretou).

2005;150:1064.e7-1064.e12

Papanicolaou N (see Katsouras et al). 2005;150:385-91

Pappas P (see Cabell et al). 2005;150:1092-8

Pappas P (see Wang et al). 2005;150:1086-91

Park SJ (see Lee et al). 2005;150:577-82

Park SW (see Lee et al). 2005;150:577-82

Parkash R, Maisel WH, Toca FM, Stevenson WG. Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. 2005;150:701-6

Parker JD (see Teerlink et al). 2005;150:46-53 (Trial design)

Parati G, Sciaigra R, Migliorini A, Memisha G, Moschi G, Valenti R, Pupi A, Antonucci D. A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. 2005;150:220.e1-220.e5

Parrinello G (see Di Pasquale et al). 2005;150:919.e1-919.e8

Parthenakis FI (see Patrianakos et al). 2005;150:985.e9-985.e18

Pascua JA (see Cohen et al). 2005;150:1204-11

Patal S (see George et al). 2005;150:484-7

Pate G (see Tahir et al). 2005;150:302-6

Paterno S (see Di Pasquale et al). 2005;150:919.e1-919.e8

Patrianakos AP, Parthenakis FI, Mavrakis HE, Diakakis GF, Chlouverakis GI, Vardas PE. Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study. 2005;150:985.e9-985.e18

Patrick JL (see Weinberger et al). 2005;150:426-33

Patwala A (see Williams et al). 2005;150:983.e1-983.e6

Paukliks LB, Chan K-C, Chang D, Kirby SK, Logan L, DeGroff CG, Boucek MM, Valdes-Cruz LM. Regional myocardial velocities and isovolumic contraction acceleration before and after device

closure of atrial septal defects: a color tissue Doppler study. 2005;150:294-301

Fearson RR (see Muhlestein et al). 2005;150:182-7

Pearson RR (see Whiting et al). 2005;150:243-50

Pearson TA (see Bhatt et al). 2005;150:401.e1-401.e7

Peart JN (see Gross et al). 2005;150(6):e3 (Letter)

Pedersen WR (see Henry et al). 2005;150:373-84 (Trial design)

Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group (see Fisher et al). 2005;150:439-47

Pellikka PA (see Hillis et al). 2005;150:1268-75

Pellikka PA (see Norager et al). 2005;150:522-9

Pepine CJ (see Marroquin et al). 2005;150:109-15

Pereira CF (see Rodriguez et al). 2005;150:188.e1-188.e7

Petcherski S (see Goldberg et al). 2005;150:330-7

Peters KJ (see Caldwell et al). 2005;150:983.e7-983.e12

Peters RJG (see Lewis et al). 2005;150:1177-84

Peterson E (see Kamlesh et al). 2005;150:912-9

Peterson E (see Spertus et al). 2005;150:707-15

Peterson ED (see Alexander et al). 2005;150:643-9 (Trial design)

Petronio AS, De Carlo M, Ciabatti N, Amoroso G, Limbruno U, Palagi C, Di Bello V, Romano MF, Mariani M. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. 2005;150:1015.e1-1015.e9

Petronio AS (see Limbruno et al). 2005;150:102-8

Pezzetta F (see Mascitelli and Pezzetta). 2005;150(6):e5 (Letter)

Pfeffer MA (see Reed et al). 2005;150:323-9

Pfeffer MA (see Skali et al). 2005;150:743-9

Pfeffer MA (see Solomon et al). 2005;150:257-62

Pham MX (see Hsieh et al). 2005;150:161-7

Phillips CL (see Havlik et al). 2005;150:270-5

Pichard AD (see Kuchulakanti et al). 2005;150:832-7

Pieroni DR (see Dadlani et al). 2005;150:1016.e1-1016.e8

Pina I (see Spertus et al). 2005;150:707-15

Pinnow EE (see Kuchulakanti et al). 2005;150:832-7

Pintado V (see Martin-Dávila et al). 2005;150:1099-106

Pirani N (see Cantor et al). 2005;150:543-9

Pistolesi S (see Limbruno et al). 2005;150:102-8

Pitt B (see Konstam et al). 2005;150:123-31

Pitt B (see Rumsfeld et al). 2005;150:961-7

Plana JC (see Win et al). 2005;150:695-700

Plappert T (see Skali et al). 2005;150:743-9

Pletcher MJ, Kiefe CI, Sidney S, Carr JJ, Lewis CE, Hulley SB. Cocaine and coronary calcification in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. 2005;150:921-6

Plötz S (see Staudt et al). 2005;150:729-36

Pocoví M (see Cenarro et al). 2005;150:1154-62

Pola P (see Gabrielli et al). 2005;150(1):e9 (Letter)

Politi A (see Leoncini et al). 2005;150:401.e9-401.e14

Poole-Wilson PA (see Konstam et al). 2005;150:123-31

Porcu M (see Cecchi et al). 2005;150:947-54

Port SC, Goodarzi MO, Boyle NG, Jennrich RI. Blood glucose: a strong risk factor for mortality in nondiabetic patients with cardiovascular disease. 2005;150:209-14

Pothier CE (see Hesse et al). 2005;150:307-14

PREVENT IV Investigators (see Alexander et al). 2005;150:643-9 (Trial design)

Prins JB (see Rakhit et al). 2005;150:1074-80

Probst M (see Staudt et al). 2005;150:729-36

Probstfield J (see Mathew et al). 2005;150:968-76

Proietti P (see De Luca et al). 2005;150:563-8

Province MA (see Tang et al). 2005;150:845-51

Psaty BM (see Chan et al). 2005;150:464-70

Puley G (see Cantor et al). 2005;150:543-9

Pullen P (see Havlik et al). 2005;150:270-5

Pupi A (see Parodi et al). 2005;150:220.e1-220.e5

Puthenveettil BJ (see Sievers et al). 2005;150:737-42

Q

Qasim A (see Ardehali et al). 2005;150:459-63

Qin JX (see Sitges et al). 2005;150:852-8

Quereda C (see Martín-Dávila et al). 2005;150:1099-106

Quinones MA (see Win et al). 2005;150:695-700

R

Rabello R (see Arteaga et al). 2005;150:1228-32

Radeva JI (see Reed et al). 2005;150:323-9

Rahimi K, Secknus M-A, Adam M, Hayerizadeh B-F, Fiedler M, Thiery J, Schuler G. Correlation of exercise capacity with high-sensitive C-reactive protein in patients with stable coronary artery disease. 2005;150:1282-9

Rainis M (see Teerlink et al). 2005;150:46-53 (Trial design)

Raisinghani A (see Michaels et al). 2005;150:1066-73

Raizner M (see Win et al). 2005;150:695-700

Rakhit DJ, Downey M, Jeffries L, Moir S, Prins JB, Marwick TH. Screening for coronary artery disease in patients with diabetes: a Bayesian strategy of clinical risk evaluation and exercise echocardiography. 2005;150:1074-80

Raili S, Horwitz TB, Fonarow GC. Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. 2005;150:1220-7

Rana JS, Mittleman MA, Ho KK, Cutlip DE. Obesity and clinical restenosis after coronary stent placement. 2005;150:821-6

Rapezzi C (see Cecchi et al). 2005;150:947-54

Rashidi A, Casscells W, Madjid M, Adler DS. Is it time to prescribe statins to patients with calcified aortic stenosis? 2005;150:41-5 (Curriculum cardiol.)

Rathore SS, Weinert KP, Foody JM, Krumholz HM. Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients. 2005;150:402-10

Rea TD (see Chan et al). 2005;150:464-70

Reed SD, Radeva JI, Weinert KP, McMurray JJJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Calif RM, Schulman KA, VALIANT Investigators. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). 2005;150:323-9

Regar E (see Aoki et al). 2005;150:994-9

Reis SE (see Kip et al). 2005;150:900-6

Reis SE (see Marroquin et al). 2005;150:109-15

Renlund DG (see Muhlestein et al). 2005;150:182-7

Resnick IB (see Blatt et al). 2005;150:986.e1-986.e7

Rha S-W (see Kuchulakanti et al). 2005;150:832-7

Riba A (see Aboufakher et al). 2005;150:455-8

Ribisl P (see Havlik et al). 2005;150:270-5

Ricciardelli B (see Briguori et al). 2005;150:807-13

Ridker PM (see Marroquin et al). 2005;150:109-15

Rieber J (see Schiele et al). 2005;150:351-7

Riegel B, Birnbaum A, Aufderheide TP, Thode HC Jr, Henry MC, Van Ottingham L, Swor R, PAD Investigators. Predictors of cardiopulmonary resuscitation and automated external defibrillator skill retention. 2005;150:927-32

Rieger G (see Konstam et al). 2005;150:123-31

Riezebos RK, Ronner E, de Boer BA, Slaats EH, Tijssen JGP, Laarman G-J. Dynamics in N-terminal pro-brain natriuretic

peptide concentration in patients with non-ST-elevation acute coronary syndrome. 2005;150:1255-9

Rim SJ (see Joung et al). 2005;150:1213-9

Rindress D (see Wagner et al). 2005;150:985.e1-985.e8

Robertson E (see Mitchell et al). 2005;150:1017-25

Robinson DM (see Völzke et al). 2005;150:1198-203

Rockx MA, Hoch JS, Klein GJ, Yee R, Skanes AC, Gula LJ, Krahn AD. Is ambulatory monitoring for "community-acquired" syncope economically attractive? A cost-effectiveness analysis of a randomized trial of external loop recorders versus Holter monitoring. 2005;150:1065.e1-1065.e5

Rodin G (see Mitchell et al). 2005;150:1017-25

Rodriguez AE, Alemparte MR, Pereira CF, Vigo CF, Sampaolesi A, Bernardi V, Marchand E, Tronge J, Palacios IF, LASMAL II Investigators. Latin American randomized trial of balloon angioplasty versus coronary stenting in diabetic patients with small vessel reference size (Latin American Small Vessel [LASMAL II] Trial): immediate and long-term results. 2005;150:188.e1-188.e7

Roger VL. To score or not to score? 2005;150:371-2 (Editorial)

Rogers C (see Kuntz et al). 2005;150:4-6 (Editorial)

Rogers WJ (see Marroquin et al). 2005;150:109-15

Rojas-Matas CA (see Cohen et al). 2005;150:1204-11

Roland J-M (see Dadlani et al). 2005;150:1016.e1-1016.e8

Romano MF (see Petronio et al). 2005;150:1015.e1-1015.e9

Romans S (see Mitchell et al). 2005;150:1017-25

Roniker B (see Weinberger et al). 2005;150:426-33

Ronner E (see Riezebos et al). 2005;150:1255-9

Rordorf R (see Cecchi et al). 2005;150:947-54

Rosamond WD (see McGinn et al). 2005;150:392-400

Ross CS (see Baskett et al). 2005;150:1122-7

Ross DL (see Thomas et al). 2005;150(5):e3 (Letter reply)

Roth A (see George et al). 2005;150:484-7

Rötter C (see Siaplaouras et al). 2005;150:150-2

Rouleau JL (see Skali et al). 2005;150:743-9

Rouse C (see Agah et al). 2005;150:500-6

Ruiloche L-M (see Weinberger et al). 2005;150:426-33

Rumsfeld JS, Jones PG, Wooley MA, Sullivan MD, Pitt B, Weintraub WS, Spertus JA. Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. 2005;150:961-7

Rumsfeld JS (see Spertus et al). 2005;150:707-15

Russell ME (see Halkin et al). 2005;150:1163-70

Rutherford BD (see Weisz et al). 2005;150:358-64

Ryschon K (see Lakkireddy et al). 2005;150:516-21

S

Saba S (see Hreybe et al). 2005;150:1064.e1-1064.e5

Sabadosa KA (see Baskett et al). 2005;150:1122-7

Sadowski Z (see Frazier et al). 2005;150:1260-7

Saidi AS (see Kovacs et al). 2005;150:193-201 (Curriculum cardiol.)

Saito F (see Ishihara et al). 2005;150:814-20

Sakamoto T (see Ishihara et al). 2005;150:814-20

Sakata Y (see Nakatani et al). 2005;150:652-8

Salm LP, Bax JJ, Jukema JW, Schuijff JD, Vliegen HW, Lamb HJ, van der Wall EE, de Roos A. Comprehensive assessment of patients after coronary artery bypass grafting by 16-detector-row computed tomography. 2005;150:775-81

Salmasi A-M, Frost P, Dancy M. Left ventricular diastolic function in normotensive subjects 2 months after acute myocardial infarction is related to glucose intolerance. 2005;150:168-74

Sampaolesi A (see Rodriguez et al). 2005;150:188.e1-188.e7

Samuel S (see Blatt et al). 2005;150:986.e1-986.e7

Sanderson B (see Venkataraman et al). 2005;150:1140-6

Sanderson BK, Bittner V. Women in cardiac rehabilitation: outcomes and identifying risk for dropout. 2005;150:1052-8

Sanderson JE (see So et al). 2005;150:530-5

Santarelli L (see Gabrielli et al). 2005;150(1):e9 (Letter)

Santoro EP (see Konstam et al). 2005;150:123-31

Santrach PJ (see Campbell et al). 2005;150:796-9

Sardella G (see De Luca et al). 2005;150:563-8

Sasaki S (see Onodera et al). 2005;150:689.e11-689.e16

Satler LF (see Kuchulakanti et al). 2005;150:832-7

Sato H (see Nakatani et al). 2005;150:652-8

Satterthwaite G, Francis SE, Suvarna K, Blakemore S, Ward C, Wallace D, Braddock M, Crossman D. Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis. 2005;150:488-99

Savonitto S (see Brener et al). 2005;150:89-93

Sawada S (see Kamlesh et al). 2005;150:912-9

Sawchuck C (see Healey et al). 2005;150:288-93

Sayer HG (see Kuether et al). 2005;150:115.e1-115.e7

Scalzo S (see Di Pasquale et al). 2005;150:919.e1-919.e8

Schalwat I (see Kaehler et al). 2005;150:987-93

Schaps K-P (see Kaehler et al). 2005;150:987-93

Scharhag J, Herrmann M, Urhausen A, Haschke M, Herrmann W, Kindermann W. Independent elevations of N-terminal pro-brain natriuretic peptide and cardiac troponins in endurance athletes after prolonged strenuous exercise. 2005;150:1128-34

Schiele TM, König A, Rieber J, Erhard I, Leibig M, Theisen K, Siebert U, Klauss V. Sirolimus-eluting stent implantation and γ-irradiation for the treatment of in-stent restenotic lesions: comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound. 2005;150:351-7

Schnittger I (see Heidenreich et al). 2005;150:977-82

Schömig A (see Braun et al). 2005;150:550-6

Schömig A (see Dibra et al). 2005;150:344-50

Schou L (see Zwisler et al). 2005;150:899.e7-899.e16 (Trial design)

Schrader LM (see Campbell et al). 2005;150:796-9

Schröder J (see Gödicke et al). 2005;150:1015.e11-1015.e17

Schühlen H (see Dibra et al). 2005;150:344-50

Schuijff JD (see Salm et al). 2005;150:775-81

Schulki E (see Straumann et al). 2005;150:1000-6

Schuler G (see Rahimi et al). 2005;150:1282-9

Schull MJ, Vermeulen M, Donovan L, Newman A, Tu JV. Can the wrong statistic be bad for health? Improving the reporting of door-to-needle time performance in acute myocardial infarction. 2005;150:583-7

Schulman KA (see Reed et al). 2005;150:323-9

Schulze-Nieck I, Gilbert N, Ewert R, Witt C, Gruenig E, Enke B, Borst MM, Lange PE, Hoeper MM. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. 2005;150:716.e7-716.e12

Schwahn C (see Völzke et al). 2005;150:1198-203

Schwartz S (see Aboufakher et al). 2005;150:455-8

Sciagrà R (see Parodi et al). 2005;150:220.e1-220.e5

Seabra-Gomes R (see Mehran et al). 2005;150:1171-6

Sears SF (see Kovacs et al). 2005;150:193-201 (Curriculum cardiol.)

Secknus M-A (see Rahimi et al). 2005;150:1282-9

Segal R (see Konstam et al). 2005;150:123-31

Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG, Canadian Acute Coronary Syndromes Registries Investigators. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. 2005;150:690-4

Segev A, Strauss BH, Witztum JL, Lau HK, Tsimikas S. Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. 2005;150:1007-14

Sellers MA (see Reed et al). 2005;150:323-9

Selzer F (see Laskey et al). 2005;150:569-76

Semelhago L (see Healey et al). 2005;150:288-93

Serebruany VL, Oshrine BR, Malinin AI, Atar D, Michelson AD, Ferguson JJ III. Noncompliance in cardiovascular clinical trials. 2005;150:882-6 (Curriculum cardiol.)

Serruys PW (see Aoki et al). 2005;150:994-9

Seshadri N, Goldhaber SZ, Elkayam U, Grimm RA, Groce JB III, Heit JA, Spinler SA, Turpie AGG, Bosker G, Klein AL. The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients. 2005;150:27-34 (Curriculum cardiol.)

Shah G (see Win et al). 2005;150:695-700

Shah MR, Claise KA, Bowers MT, Bhapkar M, Little J, Nohria A, Gaulden LH, McKee VK, Cozart KL, Mancinelli KL, Daniels H, Kinard T, Stevenson LW, Mancini DM, O'Connor CM, Califf RM. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRAIN Natrileuretic Peptide Versus the Clinical CongesTion Score (STARBRIT) trial. 2005;150:893-8 (Trial design)

Shah SH (see Frazier et al). 2005;150:1260-7

Shankar SS, Dubé MP, Gorski JC, Klaunig JE, Steinberg HO. Indinavir impairs endothelial function in healthy HIV-negative men. 2005;150:933.e1-933.e7

Shapiro MY (see Blatt et al). 2005;150:986.e1-986.e7

Shapiro EP (see Lim et al). 2005;150:934-40, 941-6

Sharaf BL (see Marroquin et al). 2005;150:109-15

Share D (see Aboufakher et al). 2005;150:455-8

Sharkey SW (see Henry et al). 2005;150:373-84 (Trial design)

Sharma D (see Konstam et al). 2005;150:123-31

Shaw IJ (see Kip et al). 2005;150:900-6

Shen X (see Lakkaraju et al). 2005;150:516-21

Sheps D (see George et al). 2005;150:484-7

Shim W-H (see Joung et al). 2005;150:1213-9

Shimizu M (see Nakatani et al). 2005;150:652-8

Shimizu M (see Ohtani et al). 2005;150:227-33

Shinbane JS (see Mao et al). 2005;150:315-22

Shiota T (see Sitges et al). 2005;150:852-8

Shiotani I (see Nakatani et al). 2005;150:652-8

Shirai M (see Ishihara et al). 2005;150:814-20

Shirai N (see Yamagishi et al). 2005;150:790-5

Shrime FM (see McLellan et al). 2005;150:800-6

Sianos G (see Aoki et al). 2005;150:994-9

Siaplouras S, Buob A, Rötter C, Böhm M, Jung J. Randomized comparison of anterolateral versus anteroposterior electrode position for biphasic external cardioversion of atrial fibrillation. 2005;150:150-2

Sideris DA (see Katsouras et al). 2005;150:385-91

Sidney S (see Pletcher et al). 2005;150:921-6

Siebert U (see Schiele et al). 2005;150:351-7

Sievers B, Kirchberg S, Franken U, Puthenveettil BJ, Bakan A, Trappe H-J. Visual estimation versus quantitative assessment of left ventricular ejection fraction: a comparison by cardiovascular magnetic resonance imaging. 2005;150:737-42

Sigurd B (see Zwisler et al). 2005;150:899.e7-899.e16 (Trial design)

Sinagra G (see Cecchi et al). 2005;150:947-54

Siscovick D (see Chan et al). 2005;150:464-70

Sisto D (see Baskett et al). 2005;150:1122-7

Sitafidis G (see Tripodiadis et al). 2005;150:782-9

Sitges M, Qin JX, Lever HM, Bauer F, Drisko JK, Agler DA, Kapadia SR, Tuzcu EM, Smedira NG, Lytle BW, Thomas JD, Shiota T. Evaluation of left ventricular outflow tract area after septal reduction in obstructive hypertrophic cardiomyopathy: a real-time 3-dimensional echocardiographic study. 2005;150:852-8

Skali H, Zornoff LM, Pfeffer MA, Arnold MO, Lamas GA, Moyé LA, Plappert T, Rouleau JL, Sussex BA, St John Sutton M, Braunwald E, Solomon SD, Survival and Ventricular Enlargement (SAVE) Investigators. Prognostic use of echocardiography 1 year after a myocardial infarction. 2005;150:743-9

Skali H (see Solomon et al). 2005;150:257-62

Skanes AC (see Rockx et al). 2005;150:1065.e1-1065.e5

Skanes AC (see Walker et al). 2005;150:1059-63

Skards J (see Solomon et al). 2005;150:257-62

Skoularigis J (see Tripodiadis et al). 2005;150:782-9

Slats EH (see Riezebos et al). 2005;150:1255-9

Slack S (see Mehran et al). 2005;150:1171-6

Slavin S (see Blatt et al). 2005;150:986.e1-986.e7

Sliwa K (see Warraich et al). 2005;150:263-9

Smart N, Haluska B, Jeffress L, Marwick TH. Predictors of a sustained response to exercise training in patients with chronic heart failure: a telemonitoring study. 2005;150:1240-7

Smedira NG (see Sitges et al). 2005;150:852-8

Smith DE (see Aboufakher et al). 2005;150:455-8

Smith NL (see Chan et al). 2005;150:464-70

Smith TW (see Klingman et al). 2005;150:595-601

Snell P (see Havlik et al). 2005;150:270-5

Snow R (see Hindman et al). 2005;150:1046-51

So NM, Lam WW, Li D, Chan AK, Sanderson JE, Metreweli C. Magnetic resonance angiography of coronary arteries with a 3-dimensional magnetization-prepared true fast imaging with steady-state precession sequence compared with conventional coronary angiography. 2005;150:530-5

Soja AMB (see Zwisler et al). 2005;150:899.e7-899.e16 (Trial design)

Sol JM (see Cenaro et al). 2005;150:1154-62

Solomon H, DeBusk RF, Jackson G. Erectile dysfunction: the need to be evaluated, the right to be treated. 2005;150:620-6 (Curriculum cardiol.)

Solomon SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M, Wojciechowski D, Ansmitz B, Skards J, Laks T, Henry D, Packer M, Pfeffer MA, OVERTURE Investigators. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. 2005;150:257-62

Solomon SD (see Skali et al). 2005;150:743-9

Soltis D (see James et al). 2005;150:984.e1-984.e6

Sonoda M (see Ishihara et al). 2005;150:814-20

Sopko G (see Fisher et al). 2005;150:439-47

Sopko G (see Kip et al). 2005;150:900-6

Sopko G (see Marroquin et al). 2005;150:109-15

Soran O (see Michaels et al). 2005;150:1066-73

Sorensen SG (see Muhlestein et al). 2005;150:182-7

Southern DA (see McLellan et al). 2005;150:800-6

Spencer FA, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction. 2005;150:838-44

Spencer FA (see Mohapatra et al). 2005;150:19-26 (Progress cardiol.)

Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, McCullough PA, Pina I, Tooley J, Weintraub WS, Rumsfeld JS, Cardiovascular Outcomes Research Consortium. Monitoring clinical changes in patients with heart failure: a comparison of methods. 2005;150:707-15

Spertus JA (see Rumsfeld et al). 2005;150:961-7

Spertus JA (see Zhang et al). 2005;150:175-81

Spinias GA (see Straumann et al). 2005;150:1000-6

Spinler SA (see Seshadri et al). 2005;150:27-34
(Curriculum cardiol.)

Spurgeon HA (see Havlik et al). 2005;150:270-5

St John Sutton M (see Skali et al). 2005;150:743-9

Stables RH (see Zhang et al). 2005;150:175-81

Stafford JA (see Cabell et al). 2005;150:1092-8

Stafford JA (see Wang et al). 2005;150:1086-91

Starc TJ (see Fisher et al). 2005;150:439-47

Staudt A, Dörr M, Staudt Y, Böhm M, Probst M, Empen K, Plötz S, Maschke HE, Hummel A, Baumann G, Felix SB. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoabsorption. 2005;150:729-36

Staudt Y (see Staudt et al). 2005;150:729-36

Steg PG (see Bhatt et al). 2005;150:401.e1-401.e7

Stein JH (see Tzou et al). 2005;150:1135-9

Stein JH (see Wyman et al). 2005;150:1081-5

Steinbeck G (see Kirchhof et al). 2005;150:899.e1-899.e6
(Trial design)

Steinberg HO (see Shankar et al). 2005;150:933.e1-933.e7

Steinhubl SR (see Bhatt et al). 2005;150:401.e1-401.e7

Steinhubl SR (see Campbell et al). 2005;150:796-9

Stettler I (see Straumann et al). 2005;150:1000-6

Stevenson LW (see Nazarian et al). 2005;150:955-60

Stevenson LW (see Shah et al). 2005;150:893-8 (Trial design)

Stevenson WG (see Nazarian et al). 2005;150:955-60

Stevenson WG (see Parkash et al). 2005;150:701-6

Stewart DE (see Mitchell et al). 2005;150:1017-25

Stewart KJ (see Lim et al). 2005;150:934-40, 941-6

Steyerberg EW, Eijkemans MJC, Boersma E, Habbema JDF. Applicability of clinical prediction models in acute myocardial infarction: a comparison of traditional and empirical Bayes adjustment methods. 2005;150:920.e11-920.e17

Stone GW (see Halkin et al). 2005;150:1163-70

Stone GW (see Weisz et al). 2005;150:358-64

Stouffer GA (see Cohen et al). 2005;150:1204-11

Straumann E, Kurz DJ, Muntry J, Stettler I, Furrer M, Naegeli B, Frielingsdorf J, Schuiki E, Murry R, Bertel O, Spinias GA. Admission glucose concentrations independently predict early and late mortality in patients with acute myocardial infarction treated by primary or rescue percutaneous coronary intervention. 2005;150:1000-6

Strauss BH (see Cantor et al). 2005;150:543-9

Strauss BH (see Segev et al). 2005;150:690-4, 1007-14

Stuckey TD (see Weisz et al). 2005;150:358-64

Subramanian U (see Kamalesh et al). 2005;150:912-9

Sueta CA (see Goff et al). 2005;150:717-24

Sullivan JAP (see Hassan et al). 2005;150:1026-31

Sullivan MD (see Rumsfeld et al). 2005;150:961-7

Sumiyoshi T (see Kasanuki et al). 2005;150:411-8

Sundstrom B (see Warraich et al). 2005;150:263-9

Survival and Ventricular Enlargement (SAVE) Investigators (see Skali et al). 2005;150:743-9

Suryapranata H (see De Luca et al). 2005;150:557-62, 827-31, 1185-9, 1248-54

Susen S (see Lamblin et al). 2005;150:137-43

Sussex BA (see Skali et al). 2005;150:743-9

Suvarna K (see Satterthwaite et al). 2005;150:488-99

Al Suwaidi J, Berger PB. Do stents reduce mortality compared with balloon angioplasty? A critical review of all the evidence. 2005;150:7-10 (Editorial)

Suzuki T (see Kasama et al). 2005;150:477.e1-477.e8

Svensson L (see Gödicke et al). 2005;150:1015.e11-1015.e17

Svensson L (see Thuresson et al). 2005;150:234-42

Swor R (see Riegel et al). 2005;150:927-32

SYMPHONY and Second SYMPHONY Investigators (see Frazier et al). 2005;150:1260-7

T

Tahir M, Foley B, Pate G, Crean P, Moore D, McCarroll N, Walsh M. Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial. 2005;150:302-6

Takayama Y (see Kasama et al). 2005;150:477.e1-477.e8

Takeuchi K (see Yamagishi et al). 2005;150:790-5

Tamura Y (see Onodera et al). 2005;150:689.e11-689.e16

Tan L-B (see Williams et al). 2005;150:983.e1-983.e6

Tan M (see Segev et al). 2005;150:690-4

Tan VLM (see Bishop et al). 2005;150:602-9

Tan WA (see Cohen et al). 2005;150:1204-11

Tang W, Arnett DK, Devereux RB, Panagiotou D, Province MA, Miller MB, de Simone G, Gu C, Ferrell RE. Identification of a novel 5-base pair deletion in calcineurin B (PPP3R1) promoter region and its association with left ventricular hypertrophy. 2005;150:845-51

Tapson VF (see Krasuski et al). 2005;150:725-8

Tardif J-C (see Wagner et al). 2005;150:985.e1-985.e8

Tatum JL (see Kontos et al). 2005;150:666-73, 674-80

Taylor AJ (see Gentleski et al). 2005;150:478-83

Taylor HA (see McGinn et al). 2005;150:392-400

Tcheng JE (see Weisz et al). 2005;150:358-64

Teerlink JR, McMurray JJV, Bourge RC, Cleland JGF, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I, VERITAS Investigators. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). 2005;150:46-53 (Trial design)

Tei C (see Ishihara et al). 2005;150:814-20

Teoh K (see Healey et al). 2005;150:288-93

Terres W (see Kaehler et al). 2005;150:987-93

Theisen K (see Schiele et al). 2005;150:351-7

Théroux P (see Bosch and Théroux). 2005;150:215-20

Thierry J (see Rahimi et al). 2005;150:1282-9

Thode HC Jr (see Riegel et al). 2005;150:927-32

Thomas D (see James et al). 2005;150:984.e1-984.e6

Thomas JD (see Sitges et al). 2005;150:852-8

Thomas SP, Guy D, Wallace E, Crampton R, Kijvanit P, Eipper V, Ross DL, Cooper MJ. Reply to Veloso. 2005;150(5):e3
(Letter reply)

Thompson CM (see Campbell et al). 2005;150:796-9

Thuresson M, Jarlöv MB, Lindahl B, Svensson L, Zedigh C, Herlitz J. Symptoms and type of symptom onset in acute coronary syndrome in relation to ST elevation, sex, age, and a history of diabetes. 2005;150:234-42

Tian Y (see Gou et al). 2005;150:1039-45

Tijssen JGP (see Riezebos et al). 2005;150:1255-9

Tiong AY, Briege D. Inflammation and coronary artery disease. 2005;150:11-8 (Progress cardiol.)

Tjandrawan T (see Marroquin et al). 2005;150:109-15

Toca FM (see Parkash et al). 2005;150:701-6

Tooley J (see Spertus et al). 2005;150:707-15

Topol EJ (see Agah et al). 2005;150:500-6
 Topol EJ (see Bhatt et al). 2005;150:401.e1-401.e7
 Topol EJ (see Brener et al). 2005;150:89-3
 Torguson R (see Kuchulakanti et al). 2005;150:832-7
 Torre-Amione G (see Teerlink et al). 2005;150:46-53 (Trial design)
 Toso A (see Leoncini et al). 2005;150:401.e9-401.e14
 Toyama T (see Kasama et al). 2005;150:477.e1-477.e8
 Tran M (see Mohapatra et al). 2005;150:19-26 (Progress cardiol.)
 Trappe H-J (see Sievers et al). 2005;150:737-42
 Triposkiadis F, Sifatidis G, Kostoulas J, Skoularigis J, Zintzaras E, Fezoulidis I. Carotid plaque composition in stable and unstable coronary artery disease. 2005;150:782-9
 Tritos NA, Goepfert L, Kissinger KV, Katsimaglis G, Manning WJ, Danias PG. Effect of raloxifene on aortic elasticity in healthy postmenopausal women. 2005;150:1212.e1-1212.e6
 Tronge J (see Rodriguez et al). 2005;150:188.e1-188.e7
 Trougton RW (see James et al). 2005;150:984.e1-984.e6
 Tsai C-H (see Chou et al). 2005;150(1):e3 (Letter reply)
 Tsai F-J (see Chou et al). 2005;150(1):e3 (Letter reply)
 Tsang S (see Nazarian et al). 2005;150:955-60
 Tsimikas S (see Segev et al). 2005;150:1007-14
 Tsuchida K (see Aoki et al). 2005;150:994-9
 Tsuchihashi K (see Ishihara et al). 2005;150:814-20
 Tsuji T (see Liu et al). 2005;150:681-8
 Tsurumi Y (see Kasanuki et al). 2005;150:411-8
 Tu JV (see Ko et al). 2005;150:419-25
 Tu JV (see Schull et al). 2005;150:583-7
 Tubbs R (see Agah et al). 2005;150:500-6
 Turner GO. Letter to the Editor. 2005;150(2):e1-e2 (Letter)
 Turner KL (see Lim et al). 2005;150:934-40, 941-6
 Turpie AGG (see Seshadri et al). 2005;150:27-34
 (Curriculum cardioli.)
 Tutar E, Ekici F, Atalay S, Nacar N. The prevalence of bicuspid aortic valve in newborns by echocardiographic screening. 2005;150:513-5
 Tuzcu EM (see Sitges et al). 2005;150:852-8
 Tzou WS, Mays ME, Korcarz CE, Aeschlimann SE, Stein JH. Skin cholesterol content identifies increased carotid intima-media thickness in asymptomatic adults. 2005;150:1135-9

U

Ueda Y (see Ohtani et al). 2005;150:227-33
 Unger BT (see Henry et al). 2005;150:373-84 (Trial design)
 Urhausen A (see Scharhag et al). 2005;150:1128-34
 USIC 2000 investigators (see Danchin et al). 2005;150:1147-53

V

Vadeboncoeur A (see Ly et al). 2005;150:933.e9-933.e13
 Vagelos RH (see Heidenreich et al). 2005;150:977-82
 Vaidya D (see Lim et al). 2005;150:934-40
 Vaidya D (see Williams et al). 2005;150:434-8
 Vaitkevicius P (see Havlik et al). 2005;150:270-5
 Valdes-Cruz LM (see Pauliks et al). 2005;150:294-301
 Valencia J (see Berenguer et al). 2005;150:536-42
 Valentini R (see Parodi et al). 2005;150:220.e1-220.e5
 Valgimigli M (see Aoki et al). 2005;150:994-9
 VALIANT Investigators (see Reed et al). 2005;150:323-9
 Van Belle E (see Lambin et al). 2005;150:137-43
 Van de Werf F (see Ohman et al). 2005;150:79-88
 van der Giessen WJ (see Aoki et al). 2005;150:994-9
 van der Wall EE (see Salm et al). 2005;150:775-81
 van Domburg RT (see Aoki et al). 2005;150:994-9
 van Mieghem CAG (see Aoki et al). 2005;150:994-9
 Van Ottingham L (see Riegel et al). 2005;150:927-32

Van Veldhuisen DJ (see Teerlink et al). 2005;150:46-53
 (Trial design)
 van't Hof AWJ (see De Luca et al). 2005;150:557-62, 827-31, 1185-9, 1248-54
 Vardas PE (see Patrianakos et al). 2005;150:985.e9-985.e18
 Vasamreddy CR (see Michos et al). 2005;150:1276-81
 Vaur L (see Danchin et al). 2005;150:1147-53
 Velazquez EJ (see Reed et al). 2005;150:323-9
 Velianou JL (see Cantor et al). 2005;150:543-9
 Veloso HH, de Paola AAV. Sotalol and amiodarone versus digoxin for conversion of recent onset atrial fibrillation. 2005;150(5):e1 (Letter)
 Venkataraman R, Sanderson B, Bittner V. Outcomes in patients with chronic kidney disease undergoing cardiac rehabilitation. 2005;150:1140-6
 Vered Z (see Blatt et al). 2005;150:986.e1-986.e7
 VERITAS Investigators (see Teerlink et al). 2005;150:46-53
 (Trial design)
 Vermeulen M (see Schull et al). 2005;150:583-7
 Vigo CF (see Rodriguez et al). 2005;150:188.e1-188.e7
 Vincent GM (see Muhslestein et al). 2005;150:182-7
 Vliegen HW (see Salm et al). 2005;150:775-81
 Vogt W (see Braun et al). 2005;150:550-6
 Völzke H, Schwahn C, Hummel A, Wolff B, Kleine V, Robinson DM, Dahm JB, Felix SB, John U, Kocher T. Tooth loss is independently associated with the risk of acquired aortic valve sclerosis. 2005;150:1198-203
 von Beckerath N (see Braun et al). 2005;150:550-6
 Voth M (see Kueth et al). 2005;150:115.e1-115.e7

W

Wagenknecht LE (see Bowden et al). 2005;150:1032-8
 Wagner GS (see Barbagelata et al). 2005;150:659-65
 Wagner GS (see Engblom et al). 2005;150:507-12, 920.e1-920.e9
 Wagner M, Rindress D, Desjardins B, Meilleur M-C, Ducharme A, Tardif JC. Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril. 2005;150:985.e1-985.e8
 Waksman R (see Kuchulakanti et al). 2005;150:832-7
 Walker BD, Krahn AD, Klein GJ, Skanes AC, Yee R. Burst bicycle exercise facilitates diagnosis of latent long QT syndrome. 2005;150:1059-63
 Wallace D (see Satterthwaite et al). 2005;150:488-99
 Wallace E (see Thomas et al). 2005;150(5):e3 (Letter reply)
 Walsh M (see Taher et al). 2005;150:302-6
 Wang A, Pappas P, Anstrom KJ, Abrutyn E, Fowler VG Jr, Hoen B, Miro JM, Corey GR, Olaison L, Stafford JA, Mestres CA, Cabell CH, International Collaboration on Endocarditis Investigators. The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort. 2005;150:1086-91
 Wang A (see Cabell et al). 2005;150:1092-8
 Wang A (see Krasuski et al). 2005;150:725-8
 Wang D (see Gödicke et al). 2005;150:1015.e11-1015.e17
 Wang S (see Han et al). 2005;150:568.e1-568.e5
 Ward C (see Satterthwaite et al). 2005;150:488-99
 Warraich RS, Sliwa K, Damasceno A, Carraway R, Sundstrom B, Arif G, Essop R, Ansari A, Fett J, Yacoub M. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. 2005;150:263-9
 Warshawsky I (see Agah et al). 2005;150:500-6
 Watson DD (see Michaels et al). 2005;150:1066-73
 Weaver WD (see Frazier et al). 2005;150:1260-7

Weber MA (see Bhatt et al). 2005;150:401.e1-401.e7
Weinberger MH, White WB, Ruilope L-M, MacDonald TM, Davidson RC, Roniker B, Patrick JL, Krause SL. Effects of eplerenone versus losartan in patients with low-renin hypertension. 2005;150:426-33
Weinfurt KP (see Rathore et al). 2005;150:402-10
Weinfurt KP (see Reed et al). 2005;150:323-9
Weintraub WS (see Rumsfeld et al). 2005;150:961-7
Weintraub WS (see Spertus et al). 2005;150:707-15
Weintraub WS (see Zhang et al). 2005;150:175-81
Weisz G, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Rutherford BD, Mehran R, Aymong E, Lansky A, Grines CL, Stone GW. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—the smoker's paradox revisited. 2005;150:358-64
Welch P (see Agah et al). 2005;150:500-6
Wells GA (see Nichol et al). 2005;150:202-8 (Trial design)
Werner GS (see Kuethe et al). 2005;150:115.e1-115.e7
Wessel TR (see Kip et al). 2005;150:900-6
Wexler D (see George et al). 2005;150:484-7
White HD (see Brener et al). 2005;150:89-93
White WB (see Weinberger et al). 2005;150:426-33
Whiting BM, Anderson JL, Muhlestein JB, Horne BD, Bair TL, Pearson RR, Carlquist JF, Intermountain Heart Collaborative (IHC) Study Group. Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease. 2005;150:243-50
Whooley MA (see Rumsfeld et al). 2005;150:961-7
Wilcox RG (see Brener et al). 2005;150:89-93
Wilensky RL (see Laskey et al). 2005;150:569-76
Wiley T (see Gentleski et al). 2005;150:478-83
Williams DO (see Laskey et al). 2005;150:569-76
Williams MS, Vaidya D, Kickler T, Ouyang P. Long-term hormone replacement therapy does not cause increased platelet activation. 2005;150:434-8
Williams RB. Treating depression after myocardial infarction: can selecting patients on the basis of genetic susceptibility improve psychiatric and medical outcomes? 2005;150:617-9 (Editorial)
Williams SA (see Klingman et al). 2005;150:595-601
Williams SG, Jackson M, Cooke GA, Barker D, Patwala A, Wright DJ, Albuwaini K, Tan L-B. How do different indicators of cardiac pump function impact upon the long-term prognosis of patients with chronic heart failure? 2005;150:983.e1-983.e6
Williford W (see Mathew et al). 2005;150:968-76
Wilson BH (see Halkin et al). 2005;150:1163-70
Win HK, Chang S-M, Raizner M, Shah G, Al Basky F, Desai U, Plana JC, Mahmarian JJ, Quinones MA, Zoghbi WA. Percent change in B-type natriuretic peptide levels during treadmill exercise as a screening test for exercise-induced myocardial ischemia. 2005;150:695-700
Witt C (see Schulze-Nieck et al). 2005;150:716.e7-716.e12
Wittes J (see Mathew et al). 2005;150:968-76
Witztum JL (see Segev et al). 2005;150:1007-14
Wojciechowski D (see Solomon et al). 2005;150:257-62
Wolf RK (see Alexander et al). 2005;150:643-9 (Trial design)
Wolff B (see Völzke et al). 2005;150:1198-203
Wolfram R (see Kuchulakanti et al). 2005;150:832-7
Wong JT (see Chan et al). 2005;150:750-5
Wright DJ (see Williams et al). 2005;150:983.e1-983.e6
Wyman RA, Fraizer MC, Keevil JG, Busse KL, Aeschlimann SE, Korcarz CE, Stein JH. Ultrasound-detected carotid plaque as a screening tool for advanced subclinical atherosclerosis. 2005;150:1081-5

X

Xu Y (see Gou et al). 2005;150:1039-45

Y

Yacoub M (see Warraich et al). 2005;150:263-9
Yagi M (see Kasanuki et al). 2005;150:411-8
Yalonetsky S (see Goldberg et al). 2005;150:330-7
Yamagishi H, Yoshiyama M, Shirai N, Akioka K, Takeuchi K, Yoshikawa J. Protective effect of high diastolic blood pressure during exercise against exercise-induced myocardial ischemia. 2005;150:790-5
Yamagishi M (see Ishihara et al). 2005;150:814-20
Yamaguchi J (see Kasanuki et al). 2005;150:411-8
Yamaguchi T (see Liu et al). 2005;150:681-8
Yamamoto M (see Liu et al). 2005;150:681-8
Yan B (see Gou et al). 2005;150:1039-45
Yanek LR (see Michos et al). 2005;150:1276-81
Yang G (see Han et al). 2005;150:568.e1-568.e5
Yang L (see Gou et al). 2005;150:1039-45
Yarzebski J (see Spencer et al). 2005;150:838-44
Yee R (see Rockx et al). 2005;150:1065.e1-1065.e5
Yee R (see Walker et al). 2005;150:1059-63
Yokoyama M, Komiyama N, Courtney BK, Nakayama T, Namikawa S, Kuriyama N, Koizumi T, Nameki M, Fitzgerald PJ, Komuro I. Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study. 2005;150:287.e1-287.e7
Yoshikawa J (see Yamagishi et al). 2005;150:790-5
Yoshimachi F (see Onodera et al). 2005;150:689.e11-689.e16
Yoshiyama M (see Yamagishi et al). 2005;150:790-5
Yu CM (see Chan et al). 2005;150:750-5
Yu H (see Han et al). 2005;150:568.e1-568.e5
Yusuf S (see Lewis et al). 2005;150:1177-84
Yusuf S (see Mathew et al). 2005;150:968-76

Z

Zachara E (see Cecchi et al). 2005;150:947-54
Zaman AG, Kearney MT. Reply to Ogimoto, Angiotensin-converting enzyme inhibitors as a new therapy for atrial fibrillation? Controversy (Am Heart J 2005;149:e19). 2005;150(1):e5 (Letter reply)
Zdorovak A (see Goldberg et al). 2005;150:330-7
Zedigh C (see Thuresson et al). 2005;150:234-42
Zelikow M (see Mehran et al). 2005;150:1171-6
Zhang L (see Muhlestein et al). 2005;150:182-7
Zhang Y (see Gwadry-Sridhar et al). 2005;150:982.e1-982.e9
Zhang Z, Spertus JA, Mahoney EM, Booth J, Nugara F, Stables RH, Weintraub WS. The impact of acute coronary syndrome on clinical, economic, and cardiac-specific health status after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: 1-year results from the stent or surgery (SoS) trial. 2005;150:175-81
Zhao F (see Lewis et al). 2005;150:1177-84
Zijlstra F (see De Luca et al). 2005;150:557-62, 1185-9
Zintzaras E (see Triposkiadis et al). 2005;150:782-9
Zoghbi WA (see Win et al). 2005;150:695-700
Zorman S (see Gödicke et al). 2005;150:1015.e11-1015.e17
Zornoff LAM (see Skali et al). 2005;150:743-9
Zwissler A-DO, Schou L, Soja AMB, Bronnum-Hansen H, Gluud C, Iversen L, Sigurd B, Madsen M, Fischer-Hansen J, DANREHAB group. A randomized clinical trial of hospital-based, comprehensive cardiac rehabilitation versus usual care for patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease (the DANREHAB trial)—design, intervention, and population. 2005;150:899.e7-899.e16 (Trial design)

Subject Index*

A

Abciximab

Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies (Gödicke et al). 2005;150:1015.e11-1015.e17

Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream Tirofiban, in cath Lab Downstream Abciximab (CLOTILDA) study (Leoncini et al). 2005;150:401.e9-401.e14

Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—the smoker's paradox revisited (Weisz et al). 2005;150:358-64

Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine (Petronio et al). 2005;150:1015.e1-1015.e9

A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy (Parodi et al). 2005;150:220.e1-220.e5

ACE-I; see Angiotensin-converting enzyme inhibitors

Acetylcysteine

Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An *in vivo* and *in vitro* study (Campbell et al). 2005;150:796-9

Acute coronary syndromes; see Angina, unstable; Myocardial infarction; Myocardial ischemia

Adaptation, psychological

Biopsychosocial experiences of adults with congenital heart disease: review of the literature (Kovacs et al). 2005;150:193-201 (Curriculum cardiol.)

Adenosine

Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial (Barbagelata et al). 2005;150:659-65

Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine (Petronio et al). 2005;150:1015.e1-1015.e9

Adrenergic beta-antagonists

Association of beta-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS) (Chan et al). 2005;150:464-70

Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction (Spencer et al). 2005;150:838-44

Enhancing quality of heart failure care in managed Medicare and Medicaid in North Carolina: results of the North Carolina Achieving Cardiac Excellence (NC ACE) Project (Goff Jr et al). 2005;150:717-24

Adrenergic beta-antagonists (continued)

Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry (Danchin et al). 2005;150:1147-53

Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of beta-blockers (Hreybe et al). 2005;150:1064.e1-1064.e5

African Americans

Depressed autonomic nervous system function in African Americans and individuals of lower social class: a potential mechanism of race- and class-related disparities in health outcomes (Lampert et al). 2005;150:153-60

Age factors

Symptoms and type of symptom onset in acute coronary syndrome in relation to ST elevation, sex, age, and a history of diabetes (Thuresson et al). 2005;150:234-42

Aged

A large-scale prospective cohort study on the current status of therapeutic modalities for acute myocardial infarction in Japan: rationale and initial results of the HIJAMI Registry (Kasanuki et al). 2005;150:411-8

Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients (Rathore et al). 2005;150:402-10

Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000 (Brown et al). 2005;150:448-54

To score or not to score? (Roger). 2005;150:371-2

Alcohol drinking

Anti-inflammatory effect of alcohol and cigarette smoking (Mascitelli and Pezzetta) (Letter); (Ikonomidis) (Reply). 2005;150(6):e5, e7

Aldosterone

Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation (Inai et al). 2005;150:588-94

Alpha-tocopherol

Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial (Tahir et al). 2005;150:302-6

Amiodarone

Sotalol and amiodarone versus digoxin for conversion of recent onset atrial fibrillation (Veloso and de Paola) (Letter); (Thomas et al) (Reply). 2005;150(5):e1, e3

Anemia

Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure (Ralli et al). 2005;150:1220-7

Angina, unstable; see also Myocardial ischemia

Association between cardiac troponin T elevation and angiographic morphology of culprit lesion in patients with non-ST-segment elevation acute coronary syndrome (Ohtani et al). 2005;150:227-33

Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study (Lewis et al). 2005;150:1177-84

Chlamydia pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology (Liu et al). 2005;150:681-8

*July, pp. 1-188; August, pp. 189-364; September, pp. 365-616; October, pp. 617-858; November, pp. 859-1106; December, pp. 1107-1342.

Angina, unstable; see also Myocardial ischemia (continued)

Design and rationale of the Michelangelo Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes (Michelangelo OASIS 5 Steering Committee). 2005;150:1107-14 (Trial design)

Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months (Katsouras et al). 2005;150:385-91

The impact of acute coronary syndrome on clinical, economic, and cardiac-specific health status after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: 1-year results from the stent or surgery (SoS) trial (Zhang et al). 2005;150:175-81

Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting (Dibra et al). 2005;150:344-50

Left ventricular ejection fraction to predict early mortality in patients with non-ST-segment elevation acute coronary syndromes (Bosch and Théroux). 2005;150:215-20

Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials (Frazier et al). 2005;150:1260-7

Angina pectoris

*C*hlamydia pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology (Liu et al). 2005;150:681-8

Determinants of coronary events in patients with stable angina: results from the Impact of Nicorandil in Angina study (IONA study group). 2005;150:689.e1-689.e9

The effects of enhanced external counterpulsation on myocardial perfusion in patients with stable angina: a multicenter radionuclide study (Michaels et al). 2005;150:1066-73

Angiography

Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease (Whiting et al). 2005;150:243-50

Comparison of angiographic and clinical outcomes between rotational atherectomy and cutting balloon angioplasty followed by radiation therapy with a rhodium 88-mercaptoacetyltriglycine-filled balloon in the treatment of diffuse in-stent restenosis (Lee et al). 2005;150:577-82

Coronary venous imaging with electron beam computed tomographic angiography: three-dimensional mapping and relationship with coronary arteries (Mao et al). 2005;150:315-22

Latin American randomized trial of balloon angioplasty versus coronary stenting in diabetic patients with small vessel reference size (Latin American Small Vessel [LASMAL II] Trial): immediate and long-term results (Rodriguez et al). 2005;150:188.e1-188.e7

Magnetic resonance angiography of coronary arteries with a 3-dimensional magnetization-prepared true fast imaging with steady-state precession sequence compared with conventional coronary angiography (So et al). 2005;150:530-5

Prognostic value of the Duke Treadmill Score in diabetic patients (Lakkireddy et al). 2005;150:516-21

Angiography (continued)

Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina (Segev et al). 2005;150:1007-14

Angioplasty

Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era (Ishihara et al). 2005;150:814-20

Admission glucose concentrations independently predict early and late mortality in patients with acute myocardial infarction treated by primary or rescue percutaneous coronary intervention (Straumann et al). 2005;150:1000-6

The benefit of cholesterol-lowering medications after coronary revascularization: a population study (Brophy et al). 2005;150:282-6

Brachytherapy and bivalirudin evaluation study (Kuchulakanti et al). 2005;150:832-7

Circadian variation in myocardial perfusion and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty (De Luca et al). 2005;150:1185-9

Design of a standardized system for transfer of patients with ST-elevation myocardial infarction for percutaneous coronary intervention (Henry et al). 2005;150:373-84 (Trial design)

Distal embolization during primary angioplasty: histopathologic features and predictability (Limbruno et al). 2005;150:102-8

Do stents reduce mortality compared with balloon angioplasty? a critical review of all the evidence (Al Suwaidi and Berger). 2005;150:7-10 (Editorial)

Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies (Gödicke et al). 2005;150:1015.e11-1015.e17

Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADDressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial (ADVANCE MI Investigators). 2005;150:116-22

Incidence, risk factors, and prognosis of inhospital heart failure after percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) (Aboufakher et al). 2005;150:455-8

Latin American randomized trial of balloon angioplasty versus coronary stenting in diabetic patients with small vessel reference size (Latin American Small Vessel [LASMAL II] Trial): immediate and long-term results (Rodriguez et al). 2005;150:188.e1-188.e7

Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine (Petrovino et al). 2005;150:1015.e1-1015.e9

Percutaneous coronary intervention-induced emboli during primary PCI for STEMI: too little, too much, or too late? (Kuntz et al). 2005;150:4-6 (Editorial)

Preprocedural Thrombolysis in Myocardial Infarction (TIMI) flow significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute anterior myocardial infarction treated by primary angioplasty (De Luca et al). 2005;150:827-31

Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction (De Luca et al). 2005;150:1248-54

Angioplasty (continued)

Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction—the RADIAL-AMI pilot randomized trial (Cantor et al). 2005;150:543-9

Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina (Segev et al). 2005;150:1007-14

Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty (De Luca et al). 2005;150:557-62

Angioplasty, balloon

Comparison of angiographic and clinical outcomes between rotational atherectomy and cutting balloon angioplasty followed by radiation therapy with a rhenium 88-mercaptoacetyltriglycine-filled balloon in the treatment of diffuse in-stent restenosis (Lee et al). 2005;150:577-82

Angioplasty, transluminal, percutaneous coronary

Association between completeness of percutaneous coronary revascularization and postprocedure outcomes (McLellan et al). 2005;150:800-6

Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era (Jacob et al). 2005;150:887-92 (Trial design)

Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—the smoker's paradox revisited (Weisz et al). 2005;150:358-64

Latin American randomized trial of balloon angioplasty versus coronary stenting in diabetic patients with small vessel reference size (Latin American Small Vessel [LASMAL II] Trial): immediate and long-term results (Rodriguez et al). 2005;150:188.e1-188.e7

A randomized trial in patients undergoing percutaneous coronary angioplasty: roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against *Clostridium pneumoniae* (Kaehtler et al). 2005;150:987-93

Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina (Segev et al). 2005;150:1007-14

Angioscopy

Association between cardiac troponin T elevation and angioscopic morphology of culprit lesion in patients with non-ST-segment elevation acute coronary syndrome (Ohtani et al). 2005;150:227-33

Angiotensin-converting enzyme inhibitors

Angiotensin-converting enzyme inhibitors as a new therapy for atrial fibrillation? Controversy (Zaman and Kearney). 2005;150(1):e5 (Letter)

Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction (Spencer et al). 2005;150:838-44

Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study (Solomon et al). 2005;150:257-62

Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity (Harris et al). 2005;150:1106.e1-1106.e6

Angiotensin-converting enzyme inhibitors (continued)

Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute inferior myocardial infarction (Di Pasquale et al). 2005;150:919.e1-919.e8

Enhancing quality of heart failure care in managed Medicare and Medicaid in North Carolina: results of the North Carolina Achieving Cardiac Excellence (NC ACE) Project (Goff Jr et al). 2005;150:717-24

Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry (Danchin et al). 2005;150:1147-53

Angiotensin I-converting enzyme; see Peptidyl-dipeptidase A**Angiotensin II**

Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation (Inai et al). 2005;150:588-94

Antibodies, bacterial

A randomized trial in patients undergoing percutaneous coronary angioplasty: roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against *Clostridium pneumoniae* (Kaehtler et al). 2005;150:987-93

Antibody formation

Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy (Warraich et al). 2005;150:263-9

Anticholesteremic agents

The benefit of cholesterol-lowering medications after coronary revascularization: a population study (Brophy et al). 2005;150:282-6

Anticoagulants

The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients (Seshadri et al). 2005;150:27-34 (Curriculum cardiol.)

Antidepressive agents

Antidepressant therapy in patients with ischemic heart disease (Jiang and Davidson). 2005;150:871-81 (Curriculum cardiol.)

Antilipemic agents

Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction (Spencer et al). 2005;150:838-44

Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response (Cenarriz et al). 2005;150:1154-62

Aorta

Effect of raloxifene on aortic elasticity in healthy postmenopausal women (Tritos et al). 2005;150:1212.e1-1212.e6

Aortic regurgitation; see Aortic valve insufficiency**Aortic valve**

The prevalence of bicuspid aortic valve in newborns by echocardiographic screening (Tutar et al). 2005;150:513-5

Aortic valve insufficiency

The prevalence of bicuspid aortic valve in newborns by echocardiographic screening (Tutar et al). 2005;150:513-5

Aortic valve sclerosis

Tooth loss is independently associated with the risk of acquired aortic valve sclerosis (Völzke et al). 2005;150:1198-1203

Aortic valve stenosis

To the Editor (Lim et al). 2005;150(1):e13 (Letter)

Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial (Tahir et al). 2005;150:302-6

Is it time to prescribe statins to patients with calcified aortic stenosis? (Rashidi et al). 2005;150:41-5 (Curriculum cardioli.)

Apolipoprotein E

Creation of large-scale genetic data bank for cardiovascular association studies (Agah et al). 2005;150:500-6

Apoptosis

Assessing prognosis in heart failure: is hepatocyte growth factor the next B-type natriuretic peptide? (Katz and Drazner). 2005;150:1-3 (Editorial)

Atherosclerosis

Cereal fiber and whole-grain intake are associated with reduced progression of coronary-artery atherosclerosis in postmenopausal women with coronary artery disease (Erkkila et al). 2005;150:94-101

Chlamydia pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology (Liu et al). 2005;150:681-8

Cocaine and coronary calcification in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study (Pletcher et al). 2005;150:921-6

Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis (Satterthwaite et al). 2005;150:488-99

A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial (Bhatt et al). 2005;150:401.e1-401.e7

Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial (Lakoski et al). 2005;150:907-11

Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study (Yokoyama et al). 2005;150:287.e1-287.e7

Ultrasound-detected carotid plaque as a screening tool for advanced subclinical atherosclerosis (Wyman et al). 2005;150:1081-5

Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis (Michos et al). 2005;150:1276-81

Aspirin

Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction (Spencer et al). 2005;150:838-44

Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream Tirofiban, in cath Lab Downstream Abciximab (CLOTILDA) study (Leontini et al). 2005;150:401.e9-401.e14

Atherectomy, coronary

Comparison of angiographic and clinical outcomes between rotational atherectomy and cutting balloon angioplasty followed by radiation therapy with a rhodium 88-mercaptoproacetyltriglycine-filled balloon in the treatment of diffuse in-stent restenosis (Lee et al). 2005;150:577-82

Atherosclerosis; see Arteriosclerosis

Atorvastatin

Effect of C-reactive protein reduction on paroxysmal atrial fibrillation (Dernellis and Panaretou). 2005;150:1064.e7-1064.e12

Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response (Cenarro et al). 2005;150:1154-62

Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Milionis and Elisaf). 2005;150(1):e7 (Letter)

Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study (Yokoyama et al). 2005;150:287.e1-287.e7

Atrial appendage

Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke (Healey et al). 2005;150:288-93

Atrial fibrillation

Angiotensin-converting enzyme inhibitors as a new therapy for atrial fibrillation? Controversy (Zaman and Kearney). 2005;150(1):e5 (Letter)

Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved (Parkash et al). 2005;150:701-6

Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril (Wagner et al). 2005;150:985.e1-985.e8

Effect of C-reactive protein reduction on paroxysmal atrial fibrillation (Dernellis and Panaretou). 2005;150:1064.e7-1064.e12

Randomized comparison of anterolateral versus anteroposterior electrode position for biphasic external cardioversion of atrial fibrillation (Siaplouras et al). 2005;150:150-2

Sotalol and amiodarone versus digoxin for conversion of recent onset atrial fibrillation (Veloso and de Paola) (Letter); (Thomas et al) (Reply). 2005;150:e1, e3

Atrial natriuretic factor

Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation (Inai et al). 2005;150(5):588-94

Automated external defibrillators; see Defibrillators

Autonomic nervous system

Depressed autonomic nervous system function in African Americans and individuals of lower social class: a potential mechanism of race- and class-related disparities in health outcomes (Lampert et al). 2005;150:153-60

AVS; see Aortic valve sclerosis

Azithromycin

Azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome (Gabrielli et al) (Letter); (Hillis) (Reply). 2005;150(1):e9, e11

B

B-type natriuretic peptide; see Natriuretic peptide, brain

Bayes theorem

Applicability of clinical prediction models in acute myocardial infarction: a comparison of traditional and empirical Bayes adjustment methods (Steyerberg et al).

2005;150:920.e11-920.e17

Bayes theorem (continued)

Screening for coronary artery disease in patients with diabetes: a Bayesian strategy of clinical risk evaluation and exercise echocardiography (Rakhit et al). 2005;150:1074-80

Benchmarking

Can the wrong statistic be bad for health? Improving the reporting of door-to-needle time performance in acute myocardial infarction (Schull et al). 2005;150:583-7

Door-to-needle time in myocardial infarction: is there an ideal benchmark? (Canto and Kiefe). 2005;150:365-7 (Editorial)

beta-Blockers; see Adrenergic beta-antagonists

Beta rays

Sirolimus-eluting stent implantation and β -irradiation for the treatment of in-stent restenotic lesions: comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound (Schiele et al). 2005;150:351-7

Bezafibrate

Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response (Cenarro et al). 2005;150:1154-62

Bicycle ergometry; see Exercise test**Biological markers**

Azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome (Gabrielli et al) (Letter); (Hillis) (Reply). 2005;150(1):e9, e11

Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream Tirofiban, in cath Lab Downstream Abciximab (CLOTILDA) study (Leoncini et al). 2005;150:401.e9-401.e14

Biopsy

A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy (Ardehali et al). 2005;150:459-63

Bivalirudin

Brachytherapy and bivalirudin evaluation study (Kuchulakanti et al). 2005;150:832-7

Bleeding; see Hemorrhage**Bleeding time**

Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study (Campbell et al). 2005;150:796-9

Blood glucose

Blood glucose: a strong risk factor for mortality in nondiabetic patients with cardiovascular disease (Port et al). 2005;150:209-14

Blood pressure

Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity (Harris et al). 2005;150:1106.e1-1106.e6

Effects of eplerenone versus losartan in patients with low-renin hypertension (Weinberger et al). 2005;150:426-33

Protective effect of high diastolic blood pressure during exercise against exercise-induced myocardial ischemia (Yamagishi et al). 2005;150:790-5

Blood viscosity

Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation (Lee et al). 2005;150:756-66

Blood volume

Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study (James et al). 2005;150:984.e1-984.e6

Bone marrow cells

Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy (Blatt et al). 2005;150:986.e1-986.e7

Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction (Kuethe et al). 2005;150:115.e1-115.e7

Bosentan

Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy (Schulze-Neick et al). 2005;150:716.e7-716.e12

Brachytherapy

Brachytherapy and bivalirudin evaluation study (Kuchulakanti et al). 2005;150:832-7

Sirolimus-eluting stent implantation and β -irradiation for the treatment of in-stent restenotic lesions: comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound (Schiele et al). 2005;150:351-7

C**C-reactive protein**

Anti-inflammatory effect of alcohol and cigarette smoking (Mascitelli and Pezzetta) (Letter); (Ikonomidis) (Reply). 2005;150:e5, e7

Correlation of exercise capacity with high-sensitive C-reactive protein in patients with stable coronary artery disease (Rahimi et al). 2005;150:1282-9

Effect of C-reactive protein reduction on paroxysmal atrial fibrillation (Dernellis and Panaretou). 2005;150:1064.e7-1064.e12

Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial (Lakoski et al). 2005;150:907-11

Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial (Tahir et al). 2005;150:302-6

Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting (Dibra et al). 2005;150:344-50

The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention (Fathi et al). 2005;150:1190-7

Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study (McDermott et al). 2005;150:276-81

A randomized trial in patients undergoing percutaneous coronary angioplasty: roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against *Chlamydia pneumoniae* (Kaehler et al). 2005;150:987-93

The relationship between C-reactive protein and subclinical cardiovascular disease in the Diabetes Heart Study (DHS) (Bowden et al). 2005;150:1032-8

C-reactive protein (continued)

Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event? (Goyal and Blazing). 2005;150:650-1

Calcineurin

Identification of a novel 5-base pair deletion in calcineurin B (PPP3R1) promoter region and its association with left ventricular hypertrophy (Tang et al). 2005;150:845-51

Calcinosis

Cocaine and coronary calcification in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study (Pletcher et al). 2005;150:921-6

Coronary artery calcifications in the long-term follow-up of Kawasaki disease (Dadlani et al). 2005;150:1016.e1-1016.e8

Canrenoate

Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute inferior myocardial infarction (Di Pasquale et al). 2005;150:919.e1-919.e8

Captopril

Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II) (Konstam et al). 2005;150:123-31

Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT) (Reed et al). 2005;150:323-9

Carvedilol

Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study (Patraniakos et al). 2005;150:985.e9-985.e18

Cardiac pump function

How do different indicators of cardiac pump function impact upon the long-term prognosis of patients with chronic failure? (Williams et al). 2005;150:983.e1-983.e6

Cardiac rehabilitation

Clinical profile and outcomes of diabetic and nondiabetic patients in cardiac rehabilitation (Hindman et al). 2005;150:1046-51

Outcomes in patients with chronic kidney disease undergoing cardiac rehabilitation (Venkataraman et al). 2005;150:1140-6

A randomized clinical trial of hospital-based, comprehensive cardiac rehabilitation versus usual care for patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease (the DANREHAB trial)—design, intervention, and population (Zwister et al). 2005;150:899.e7-899.e16 (Trial design)

Women in cardiac rehabilitation: outcomes and identifying risk for dropout (Sanderson and Bittner). 2005;150:1052-8

Cardiac surgery; see Thoracic surgical procedures

Cardiomyopathies

Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy (Kasama et al). 2005;150:477.e1-477.e8

Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy (Blatt et al). 2005;150:986.e1-986.e7

A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy (Ardehali et al). 2005;150:459-63

Cardiomyopathy, dilated

Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study (Patraniakos et al). 2005;150:985.e9-985.e18

Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P²C² HIV multicenter study (Fisher et al). 2005;150:439-47

A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy (Gentleski et al). 2005;150:478-83

Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoabsorption (Staudt et al). 2005;150:729-36

Cardiomyopathy, hypertrophic

Evaluation of left ventricular outflow tract area after septal reduction in obstructive hypertrophic cardiomyopathy: a real-time 3-dimensional echocardiographic study (Sitges et al). 2005;150:852-8

The Italian registry for hypertrophic cardiomyopathy: a nationwide survey (Cecchi et al). 2005;150:947-54

Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy (Arteaga et al). 2005;150:1228-32

Relationships among exercise capacity, hypertrophy, and left ventricular diastolic function in nonobstructive hypertrophic cardiomyopathy (Matsumoto et al). 2005;150:144-9

Cardiomyopathy, peripartum

Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy (Warraich et al). 2005;150:263-9

Cardiopulmonary resuscitation

Predictors of cardiopulmonary resuscitation and automated external defibrillator skill retention (Riegel et al). 2005;150:927-32

Cardiovascular diseases

Angiotensin I-converting enzyme insertion/insertion genotype as a genetic risk factor for cardiovascular disease (Ogimoto et al) (Letter); (Chou et al) (Reply). 2005;150:(1)e1, e3

Blood glucose: a strong risk factor for mortality in nondiabetic patients with cardiovascular disease (Port et al). 2005;150:209-14

Heart disease epidemic in Pakistan: women and men at equal risk (Jafar et al). 2005;150:221-6

Noncompliance in cardiovascular clinical trials (Serebruany et al). 2005;150:882-6 (Curriculum cardiol.)

The relationship between C-reactive protein and subclinical cardiovascular disease in the Diabetes Heart Study (DHS) (Bowden et al). 2005;150:1032-8

Schizophrenia and increased risks of cardiovascular disease (Hennekens et al). 2005;150:1115-21 (Curriculum cardiol.)

Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance (Carmena). 2005;150:859-70 (Progress cardiol.)

Cardioversion; see Electric countershock

Carotid artery

Skin cholesterol content identifies increased carotid intima-media thickness in asymptomatic adults (Tzou et al). 2005;150:1135-9

Carotid stenosis

Carotid plaque composition in stable and unstable coronary artery disease (Triposkiadis et al). 2005;150:782-9

Cell adhesion molecules

Azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome (Gabrielli et al) (Letter); (Hillis) (Reply). 2005;150(1):e9, e11
Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial (Tahir et al). 2005;150:302-6

Cereal

Cereal fiber and whole-grain intake are associated with reduced progression of coronary-artery atherosclerosis in postmenopausal women with coronary artery disease (Erkkila et al). 2005;150:94-101

Cerebrovascular accident

Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke (Healey et al). 2005;150:288-93

Chest pain

To the Editor (Turner). 2005;150(4):e1-e2 (Letter)

Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease (Marroquin et al). 2005;150:109-15

Outcomes in patients admitted for chest pain with renal failure and troponin I elevations (Kontos et al). 2005;150:674-80

Predictive power of ejection fraction and renal failure in patients admitted for chest pain without ST elevation in the troponin era (Kontos et al). 2005;150:666-73

Chlamydia infections

Cblamydia pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology (Liu et al). 2005;150:681-8

Cblamydophila pneumoniae

Azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome (Gabrielli et al) (Letter); (Hillis) (Reply). 2005;150(1):e9, e11

Cblamydia pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology (Liu et al). 2005;150:681-8

A randomized trial in patients undergoing percutaneous coronary angioplasty: roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against *Cblamydia pneumoniae* (Kaehler et al). 2005;150:987-93

Cholesterol

Skin cholesterol content identifies increased carotid intima-media thickness in asymptomatic adults (Tzou et al). 2005;150:1135-9

Chronic kidney disease; see Kidney diseases**Cilostazol**

Cilostazol improves long-term outcomes after coronary stent implantation (Han et al). 2005;150:568.e1-568.e5

Circadian rhythm

Circadian variation in myocardial perfusion and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty (De Luca et al). 2005;150:1185-9

Clinical trials

Noncompliance in cardiovascular clinical trials (Serebruany et al). 2005;150:882-6 (Curriculum cardiol.)

Clopidogrel

Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study (Lewis et al). 2005;150:1177-84

Clopidogrel (continued)

Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study (Campbell et al). 2005;150:796-9

Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream Tirofiban, in cath Lab Downstream Abciximab (CLOTILDA) study (Leoncini et al). 2005;150:401.e9-401.e14

A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial (Bhatt et al). 2005;150:401.e1-401.e7

A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy (Parodi et al). 2005;150:220.e1-220.e5

Cocaine

Cocaine and coronary calcification in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study (Pletcher et al). 2005;150:921-6

Congenital heart disease; see Heart defects, congenital

Congestive heart failure; see Heart failure, congestive

Coronary artery bypass

Association between completeness of percutaneous coronary revascularization and postprocedure outcomes (McLellan et al). 2005;150:800-6

The association between prior percutaneous coronary intervention and short-term outcomes after coronary artery bypass grafting (Hassan et al). 2005;150:1026-31

The benefit of cholesterol-lowering medications after coronary revascularization: a population study (Brophy et al). 2005;150:282-6

Comprehensive assessment of patients after coronary artery bypass grafting by 16-detector-row computed tomography (Salm et al). 2005;150:775-81

Effects of a psychosocial skills training workshop on psychophysiological and psychosocial risk in patients undergoing coronary artery bypass grafting (Bishop et al). 2005;150:602-9

The impact of acute coronary syndrome on clinical, economic, and cardiac-specific health status after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: 1-year results from the stent or surgery (SoS) trial (Zhang et al). 2005;150:175-81

Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke (Healey et al). 2005;150:288-93

The preoperative intraaortic balloon pump in coronary bypass surgery: a lack of evidence of effectiveness (Baskett et al). 2005;150:1122-7

The Project of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics (Alexander et al). 2005;150:643-9 (Trial design)

Sex differences in depression after coronary artery bypass graft surgery (Mitchell et al). 2005;150:1017-25

Coronary circulation

Evaluation of left ventricular outflow tract area after septal reduction in obstructive hypertrophic cardiomyopathy: a real-time 3-dimensional echocardiographic study (Sitges et al). 2005;150:852-8

Coronary disease

Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease (Whiting et al). 2005;150:243-50

Carotid plaque composition in stable and unstable coronary artery disease (Triposkiadis et al). 2005;150:782-9

Cereal fiber and whole-grain intake are associated with reduced progression of coronary-artery atherosclerosis in postmenopausal women with coronary artery disease (Erkkila et al). 2005;150:94-101

Cocaine and coronary calcification in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study (Pletcher et al). 2005;150:921-6

Comprehensive assessment of patients after coronary artery bypass grafting by 16-detector-row computed tomography (Salm et al). 2005;150:775-81

Coronary artery calcifications in the long-term follow-up of Kawasaki disease (Dadlani et al). 2005;150:1016.e1-1016.e8

Correlation of exercise capacity with high-sensitive C-reactive protein in patients with stable coronary artery disease (Rahimi et al). 2005;150:1282-9

Creation of large-scale genetic data bank for cardiovascular association studies (Agah et al). 2005;150:500-6

Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis (Satterthwaite et al). 2005;150:488-99

Effect of lesion length on fractional flow reserve in intermediate coronary lesions (Brosh et al). 2005;150:338-43

Heart disease epidemic in Pakistan: women and men at equal risk (Jafar et al). 2005;150:221-6

Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial (Lakoski et al). 2005;150:907-11

Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation (Lee et al). 2005;150:756-66

Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease (Marroquin et al). 2005;150:109-15

Inflammation and coronary artery disease (Tiong and Brieger). 2005;150:11-18 (Progress cardiol.)

Schizophrenia and increased risks of cardiovascular disease (Hennekens et al). 2005;150:1115-21 (Curriculum cardiol.)

Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event? (Goyal and Blazing). 2005;150:650-1

Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease (Briguori et al). 2005;150:807-13

Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis (Michos et al). 2005;150:1276-81

Coronary disease, diagnosis

Screening for coronary artery disease in patients with diabetes: a Bayesian strategy of clinical risk evaluation and exercise echocardiography (Rakhit et al). 2005;150:1074-80

Coronary disease, drug therapy

Long-term hormone replacement therapy does not cause increased platelet activation (Williams et al). 2005;150:434-8

Coronary disease, therapy

Cilostazol improves long-term outcomes after coronary stent implantation (Han et al). 2005;150:568.e1-568.e5

"Full metal jacket" (stented length ≥ 64 mm) using drug-eluting stents for de novo coronary artery lesions (Aoki et al). 2005;150:994-9

An internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation (Mehran et al). 2005;150:1171-6

Coronary flow reserve

Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction (De Luca et al). 2005;150:563-8

Coronary plaque; see Carotid stenosis

Coronary restenosis

Comparison of angiographic and clinical outcomes between rotational atherectomy and cutting balloon angioplasty followed by radiation therapy with a rhodium 106-mercaptopropyltriglycine-filled balloon in the treatment of diffuse in-stent restenosis (Lee et al). 2005;150:577-82

Impact of moderate renal insufficiency on restenosis an adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial (Halkin et al). 2005;150:1163-70

Incidence and predictors of restenosis after sirolimus-eluting stent implantation in high-risk patients (Berenguer et al). 2005;150:536-42

Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting (Dibra et al). 2005;150:344-50

Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting (Braun et al). 2005;150:550-6

Latin American randomized trial of balloon angioplasty versus coronary stenting in diabetic patients with small vessel reference size (Latin American Small Vessel [LASMAL II] Trial): immediate and long-term results (Rodriguez et al). 2005;150:188.e1-188.e7

Obesity and clinical restenosis after coronary stent placement (Rana et al). 2005;150:821-6

A randomized trial in patients undergoing percutaneous coronary angioplasty: roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against *Chlamydia pneumoniae* (Kaeble et al). 2005;150:987-93

Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina (Segev et al). 2005;150:1007-14

Sirolimus-eluting stent implantation and β -irradiation for the treatment of in-stent restenotic lesions: comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound (Schiele et al). 2005;150:351-7

Coronary stenosis

Effect of lesion length on fractional flow reserve in intermediate coronary lesions (Brosh et al). 2005;150:338-43

Magnetic resonance angiography of coronary arteries with a 3-dimensional magnetization-prepared true fast imaging with steady-state precession sequence compared with conventional coronary angiography (So et al). 2005;150:530-5

Coronary vessels

Coronary venous imaging with electron beam computed tomographic angiography: three-dimensional mapping and relationship with coronary arteries (Mao et al). 2005;150:315-22

Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis (Satterthwaite et al). 2005;150:488-99

Latin American randomized trial of balloon angioplasty versus coronary stenting in diabetic patients with small vessel reference size (Latin American Small Vessel [LASMAL II] Trial): immediate and long-term results (Rodriguez et al). 2005;150:188.e1-188.e7

Magnetic resonance angiography of coronary arteries with a 3-dimensional magnetization-prepared true fast imaging with steady-state precession sequence compared with conventional coronary angiography (So et al). 2005;150:530-5

Corrections

Behavior of both epicardial and intramural coronary artery flow velocities in various models of myocardial hypertrophy: role for left ventricular outflow tract obstruction (De Gregorio et al) (2005;149:1091-8). 2005;150:143

Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial (ADVANCE MI Investigators) (2005;150:116-22). 2005;150:391

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease (Mix et al) (2005;149:408-13). 2005;150:53

Correspondence; see Letters to the Editor**Cortisol; see Hydrocortisone****Cost-benefit analysis**

Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril (Wagner et al). 2005;150:985.e1-985.e8

Is ambulatory monitoring for "community-acquired" syncope economically attractive? A cost-effectiveness analysis of a randomized trial of external loop recorders versus Holter monitoring (Rockx et al). 2005;150:1065.e1-1065.e5

Methodological design for economic evaluation in Public Access Defibrillation (PAD) trial (Nichol et al). 2005;150:202-8 (Trial design)

Costs and cost analysis

Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT) (Reed et al). 2005;150:323-9

Counselling

Education by a dietitian in patients with heart failure results in improved adherence with a sodium-restricted diet: a randomized trial (Arcand et al). 2005;150:716.e1-716.e5

Counterpulsation

The effects of enhanced external counterpulsation on myocardial perfusion in patients with stable angina: a multicenter radionuclide study (Michaels et al). 2005;150:1066-73

Cytokines

Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study (McDermott et al). 2005;150:276-81

Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure (Lamblin et al). 2005;150:137-43

D**Data collection**

The Italian registry for hypertrophic cardiomyopathy: a nationwide survey (Cecchi et al). 2005;150:947-54

Databases, nucleic acid

Creation of large-scale genetic data bank for cardiovascular association studies (Agah et al). 2005;150:500-6

Defibrillators

Methodological design for economic evaluation in Public Access Defibrillation (PAD) trial (Nichol et al). 2005;150:202-8 (Trial design)

Predictors of cardiopulmonary resuscitation and automated external defibrillator skill retention (Riegel et al). 2005;150:927-32

Defibrillators, implantable

Impact of implantable cardioverter defibrillators on survival and recurrent hospitalization in advanced heart failure (Nazarian et al). 2005;150:955-60

Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of β -blockers (Hreybe et al). 2005;150:1064.e1-1064.e5

Depression

Depression and ischemic heart disease: what have we learned so far and what must we do in the future? (Jiang et al). 2005;150:54-78 (Meetings)

Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure (Rumsfeld et al). 2005;150:961-7

Depressive symptoms and inflammation among heart failure patients (Ferketich et al). 2005;150:132-6

Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction (Nakatani et al). 2005;150:652-8

Sex differences in depression after coronary artery bypass graft surgery (Mitchell et al). 2005;150:1017-25

Treating depression after myocardial infarction: can selecting patients on the basis of genetic susceptibility improve psychiatric and medical outcomes? (Williams). 2005;150:617-19 (Editorial)

Women in cardiac rehabilitation: outcomes and identifying risk for dropout (Sanderson and Bittner). 2005;150:1052-8

Diabetes mellitus

Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era (Ishihara et al). 2005;150:814-20

Clinical profile and outcomes of diabetic and nondiabetic patients in cardiac rehabilitation (Hindman et al). 2005;150:1046-51

Diabetes status and racial differences in post-myocardial infarction mortality (Kamlesh et al). 2005;150:912-19

Latin American randomized trial of balloon angioplasty versus coronary stenting in diabetic patients with small vessel reference size (Latin American Small Vessel [LASMAL II] Trial): immediate and long-term results (Rodriguez et al). 2005;150:188.e1-188.e7

Diabetes mellitus (continued)

Left ventricular diastolic function in normotensive subjects 2 months after acute myocardial infarction is related to glucose intolerance (Salmasi et al). 2005;150:168-74

Prognostic value of the Duke Treadmill Score in diabetic patients (Lakkireddy et al). 2005;150:516-21

The relationship between C-reactive protein and subclinical cardiovascular disease in the Diabetes Heart Study (DHS) (Bowden et al). 2005;150:1032-8

Screening for coronary artery disease in patients with diabetes: a Bayesian strategy of clinical risk evaluation and exercise echocardiography (Rakhit et al). 2005;150:1074-80

Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease (Briguori et al). 2005;150:807-13

Symptoms and type of symptom onset in acute coronary syndrome in relation to ST elevation, sex, age, and a history of diabetes (Thuresson et al). 2005;150:234-42

Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance (Carmena). 2005;150:859-70 (Progress cardiol.)

Diastole

Can pro-brain natriuretic peptide be used as a noninvasive predictor of elevated left ventricular diastolic pressures in patients with normal systolic function? (Joung et al). 2005;150:1213-19

Diastolic dysfunction after mediastinal irradiation (Heidenreich et al). 2005;150:977-82

Diastolic wall motion abnormality after myocardial infarction: relation to neurohormonal activation and prognostic implications (Husic et al). 2005;150:767-74

Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute inferior myocardial infarction (Di Pasquale et al). 2005;150:919.e1-919.e8

Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation (Lee et al). 2005;150:756-66

Left ventricular diastolic function in normotensive subjects 2 months after acute myocardial infarction is related to glucose intolerance (Salmasi et al). 2005;150:168-74

Oxygen pulse during exercise is related to resting systolic and diastolic left ventricular function in older persons with mild hypertension (Lim et al). 2005;150:941-6

Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy (Arteaga et al). 2005;150:1228-32

Protective effect of high diastolic blood pressure during exercise against exercise-induced myocardial ischemia (Yamagishi et al). 2005;150:790-5

Reference charts of gestation-specific tissue Doppler imaging indices of systolic and diastolic functions in the normal fetal heart (Chan et al). 2005;150:750-5

Relationships among exercise capacity, hypertrophy, and left ventricular diastolic function in nonobstructive hypertrophic cardiomyopathy (Matsumoto et al). 2005;150:144-9

Diet, sodium-restricted

Education by a dietitian in patients with heart failure results in improved adherence with a sodium-restricted diet: a randomized trial (Arcand et al). 2005;150:716.e1-716.e5

Dietary supplements

Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial (Tahir et al). 2005;150:302-6

Dietetics

Education by a dietitian in patients with heart failure results in improved adherence with a sodium-restricted diet: a randomized trial (Arcand et al). 2005;150:716.e1-716.e5

Digoxin

Sotalol and amiodarone versus digoxin for conversion of recent onset atrial fibrillation (Veloso and de Paola) (Letter); (Thomas et al) (Reply). 2005;150(5):e1, e3

Dilated cardiomyopathy; see Cardiomyopathy, dilated

Direct thrombin inhibitors

A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era (Mohapatra et al). 2005;150:19-26 (Progress cardiol.)

Disease outbreaks

Heart disease epidemic in Pakistan: women and men at equal risk (Jafar et al). 2005;150:221-6

Disease progression

Cereal fiber and whole-grain intake are associated with reduced progression of coronary-artery atherosclerosis in postmenopausal women with coronary artery disease (Erkkila et al). 2005;150:94-101

Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial (Lakoski et al). 2005;150:907-11

Dobutamine

The Doppler myocardial performance index during low-dose dobutamine echocardiography predicts mortality and left ventricular dilation after a first acute myocardial infarction (Nørager et al). 2005;150:522-9

Door-to-needle time interval

Can the wrong statistic be bad for health? Improving the reporting of door-to-needle time performance in acute myocardial infarction (Schull et al). 2005;150:583-7

Door-to-needle time in myocardial infarction: is there an ideal benchmark? (Canto and Kiefe). 2005;150:365-7 (Editorial)

Dose-response relationship, drug

Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending dose trial (Mitrovic et al). 2005;150:1239.e1-1239.e8

Drug therapy, combination

Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream Tirofiban, in cath Lab Downstream Abciximab (CLOTILDA) study (Leoncini et al). 2005;150:401.e9-401.e14

Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Milionis and Elisaf). 2005;150(1):e7 (Letter)

Dyslipidemia; see Hyperlipidemia

E

E-selectin

Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial (Tahir et al). 2005;150:302-6

E2F transcription factors

The Project of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics (Alexander et al). 2005;150:643-9
(Trial design)

Echocardiography

Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy (Kasama et al). 2005;150:477.e1-477.e8

Diastolic wall motion abnormality after myocardial infarction: relation to neurohormonal activation and prognostic implications (Husic et al). 2005;150:767-74

Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study (Solomon et al). 2005;150:257-62

The prevalence of bicuspid aortic valve in newborns by echocardiographic screening (Tutar et al). 2005;150:513-5

Prognostic significance of echocardiographically defined mitral regurgitation early after acute myocardial infarction (Hillis et al). 2005;150:1268-75

Prognostic use of echocardiography 1 year after a myocardial infarction (Skali et al). 2005;150:743-9

Screening for coronary artery disease in patients with diabetes: a Bayesian strategy of clinical risk evaluation and exercise echocardiography (Rakhit et al). 2005;150:1074-80

Echocardiography, Doppler

The Doppler myocardial performance index during low-dose dobutamine echocardiography predicts mortality and left ventricular dilation after a first acute myocardial infarction (Norager et al). 2005;150:522-9

Doppler tissue imaging: a reliable method for estimation of left ventricular filling pressure in patients with mitral regurgitation (Agricola et al). 2005;150:610-5

Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation (Lee et al). 2005;150:756-66

Reference charts of gestation-specific tissue Doppler imaging indices of systolic and diastolic functions in the normal fetal heart (Chan et al). 2005;150:750-5

Echocardiography, Doppler, color

Regional myocardial velocities and isovolumic contraction acceleration before and after device closure of atrial septal defects: a color tissue Doppler study (Pauliks et al). 2005;150:294-301

Echocardiography, stress

The Doppler myocardial performance index during low-dose dobutamine echocardiography predicts mortality and left ventricular dilation after a first acute myocardial infarction (Norager et al). 2005;150:522-9

Echocardiography, three-dimensional

Evaluation of left ventricular outflow tract area after septal reduction in obstructive hypertrophic cardiomyopathy: a real-time 3-dimensional echocardiographic study (Sitges et al). 2005;150:852-8

Edifoligide

The Project of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics (Alexander et al). 2005;150:643-9
(Trial design)

Editorials

Assessing prognosis in heart failure: is hepatocyte growth factor the next B-type natriuretic peptide? (Katz and Drazner). 2005;150:1-3

Delay in acute myocardial infarction: why don't they come to the hospital more quickly and what can we do to reduce delay? (Luepker). 2005;150:368-70

Do stents reduce mortality compared with balloon angioplasty: a critical review of all the evidence (Al Suwaidi and Berger). 2005;150:7-10

Door-to-needle time in myocardial infarction: is there an ideal benchmark? (Canto and Kiefe). 2005;150:365-7

Percutaneous coronary intervention-induced emboli during primary PCI for STEMI: too little, too much, or too late? (Kuntz et al). 2005;150:4-6

To score or not to score? (Roger). 2005;150:371-2

Treating depression after myocardial infarction: can selecting patients on the basis of genetic susceptibility improve psychiatric and medical outcomes? (Williams). 2005;150:617-19

The vulnerable endothelium—priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Becker). 2005;150:189-92

Electron beam computed tomography; see Tomography, x-ray computed

Ejection fraction; see Stroke volume

Elasticity

Effect of raloxifene on aortic elasticity in healthy postmenopausal women (Tritos et al). 2005;150:1212.e1-1212.e6

Elderly; see Aged**Electric countershock**

Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of β -blockers (Hreybe et al). 2005;150:1064.e1-1064.e5

Randomized comparison of anterolateral versus anteroposterior electrode position for biphasic external cardioversion of atrial fibrillation (Siaplouras et al). 2005;150:150-2

Targeted pharmacological reversal of electric remodeling after cardioversion—rationale and design of the Flecainide Short-Long (Flec-SL) trial (Kirchhof et al). 2005;150:899.e1-899.e6 (Trial design)

Electrocardiography

Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial (Barbagelata et al). 2005;150:659-65

Prognostic value of electrocardiographic criteria for left ventricular hypertrophy (Hsieh et al). 2005;150:161-7

The relationship between electrical axis by 12-lead electrocardiogram and anatomical axis of the heart by cardiac magnetic resonance in healthy subjects (Engblom et al). 2005;150:507-12

Size and transmural extent of first-time reperfused myocardial infarction assessed by cardiac magnetic resonance can be estimated by 12-lead electrocardiogram (Engblom et al). 2005;150:920.e1-920.e9

Electrocardiography, ambulatory

Is ambulatory monitoring for "community-acquired" syncope economically attractive? A cost-effectiveness analysis of a randomized trial of external loop recorders versus Holter monitoring (Rockx et al). 2005;150:1065.e1-1065.e5

Electrodes

Randomized comparison of anterolateral versus anteroposterior electrode position for biphasic external cardioversion of atrial fibrillation (Siaplaouras et al). 2005;150:150-2

Electron beam tomography; see Tomography, x-ray computed

Embolism

Distal embolization during primary angioplasty: histopathologic features and predictability (Limbruno et al). 2005;150:102-8

Percutaneous coronary intervention-induced emboli during primary PCI for STEMI: too little, too much, or too late? (Kuntz et al). 2005;150:4-6 (Editorial)

Emergency medical services

To the Editor (Turner). 2005;150(4):e1-e2 (Letter)

Trends in prehospital delay time and use of emergency medical services for acute myocardial infarction: experience in 4 US communities from 1987-2000 (McGinn et al). 2005;150:392-400

Enalapril

Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril (Wagner et al). 2005;150:985.e1-985.e8

Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study (Solomon et al). 2005;150:257-62

Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction (Onodera et al). 2005;150:689.e11-689.e16

Endocarditis, bacterial

Analysis of mortality and risk factors associated with native valve endocarditis in drug users: the importance of vegetation size (Martín-Dávila et al). 2005;150:1099-1106

The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort (Wang et al). 2005;150:1086-91

Use of surgery in patients with native valve infective endocarditis: results from the International Collaboration on Endocarditis Merged Database (Cabeil et al). 2005;150:1092-8

Endocardium

A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy (Ardehali et al). 2005;150:459-63

Endothelial cells

Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease (Marroquin et al). 2005;150:109-15

Endothelins

Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation (Inai et al). 2005;150:588-94

Endothelium, vascular

Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation (Lee et al). 2005;150:756-66

Indinavir impairs endothelial function in healthy HIV-negative men (Shankar et al). 2005;150:933.e1-933.e7

The vulnerable endothelium—priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Becker). 2005;150:189-92 (Editorial)

Enoxaparin

Design and rationale of the Michelangelo Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes (Michelangelo OASIS 5 Steering Committee). 2005;150:1107-14 (Trial design)

Exoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the exoxaparin versus tinzaparin (EVE) trial at 6 months (Katsouras et al). 2005;150:385-91

The vulnerable endothelium—priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Becker). 2005;150:189-92 (Editorial)

Eotaxin

A randomized trial in patients undergoing percutaneous coronary angioplasty: roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against *Chlamydia pneumoniae* (Kaehler et al). 2005;150:987-93

Eplerenone

Effects of eplerenone versus losartan in patients with low-renin hypertension (Weinberger et al). 2005;150:426-33

Eptifibatide

Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADDressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial (ADVANCE MI Investigators). 2005;150:116-22

Erectile dysfunction; see Impotence

Estrogen

Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial (Lakoski et al). 2005;150:907-11

Estrogens

Long-term hormone replacement therapy does not cause increased platelet activation (Williams et al). 2005;150:434-8

Ethnic groups

Depressed autonomic nervous system function in African Americans and individuals of lower social class: a potential mechanism of race- and class-related disparities in health outcomes (Lampert et al). 2005;150:153-60

Diabetes status and racial differences in post-myocardial infarction mortality (Kamlesh et al). 2005;150:912-19

Racial differences in outcome and treatment effect in congestive heart failure (Mathew et al). 2005;150:968-76

Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000 (Brown et al). 2005;150:448-54

Evidence-based medicine

Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction (Spencer et al). 2005;150:838-44

Exercise

Independent elevations of N-terminal pro-brain natriuretic peptide and cardiac troponins in endurance athletes after prolonged strenuous exercise (Scharhag et al). 2005;150:1128-34

Exercise (continued)

Oxygen pulse during exercise is related to resting systolic and diastolic left ventricular function in older persons with mild hypertension (Lim et al). 2005;150:941-6

Protective effect of high diastolic blood pressure during exercise against exercise-induced myocardial ischemia (Yamagishi et al). 2005;150:790-5

Exercise test

Burst bicycle exercise facilitates diagnosis of latent long QT syndrome (Walker et al). 2005;150:1059-63

Can we reliably predict long-term mortality after exercise testing? An external validation (Hesse et al). 2005;150:307-14

Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy: A 12-month study (Patrianakos et al). 2005;150:985.e9-985.e18

Correlation of exercise capacity with high-sensitive C-reactive protein in patients with stable coronary artery disease (Rahimi et al). 2005;150:1282-9

Monitoring clinical changes in patients with heart failure: a comparison of methods (Spertus et al). 2005;150:707-15

Percent change in B-type natriuretic peptide levels during treadmill exercise as a screening test for exercise-induced myocardial ischemia (Win et al). 2005;150:695-700

Prognostic value of the Duke Treadmill Score in diabetic patients (Lakkireddy et al). 2005;150:516-21

Relationships among exercise capacity, hypertrophy, and left ventricular diastolic function in nonobstructive hypertrophic cardiomyopathy (Matsumoto et al). 2005;150:1449

Screening for coronary artery disease in patients with diabetes: a Bayesian strategy of clinical risk evaluation and exercise echocardiography (Rakhit et al). 2005;150:1074-80

Exercise therapy

Predictors of a sustained response to exercise training in patients with chronic heart failure: a telemonitoring study (Smart et al). 2005;150:1240-7

Exercise tolerance

Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation (Inai et al). 2005;150:588-94

Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity (Harris et al). 2005;150:1106.e1-1106.e6

F**Factor XA inhibitor**

Design and rationale of the Michelangelo Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor XA inhibitor, in patients with non-ST-segment elevation acute coronary syndromes (Michelangelo OASIS 5 Steering Committee). 2005;150:1107-14 (Trial design)

Femoral artery

Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction—the RADIAL-AMI pilot randomized trial (Cantor et al). 2005;150:543-9

Fetal heart

Reference charts of gestation-specific tissue Doppler imaging indices of systolic and diastolic functions in the normal fetal heart (Chan et al). 2005;150:750-5

Fibrin D dimer; see Fibrin fibrinogen degradation products**Fibrin fibrinogen degradation products**

Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation (Lee et al). 2005;150:756-66

Fibrinogen

Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation (Lee et al). 2005;150:756-66

Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study (McDermott et al). 2005;150:276-81

Flecainide

Targeted pharmacological reversal of electric remodeling after cardioversion—rationale and design of the Flecainide Short-Long (Flec-SL) trial (Kirchhof et al). 2005;150:899.e1-899.e6 (Trial design)

Fondaparinux

Design and rationale of the Michelangelo Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor XA inhibitor, in patients with non-ST-segment elevation acute coronary syndromes (Michelangelo OASIS 5 Steering Committee). 2005;150:1107-14 (Trial design)

Fontan procedure

Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation (Inai et al). 2005;150:588-94

Fractional flow reserve

Effect of lesion length on fractional flow reserve in intermediate coronary lesions (Brosh et al). 2005;150:338-43

G**Gelatinase A**

Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure (George et al). 2005;150:484-7

Gelatinase B

Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure (George et al). 2005;150:484-7

Genetics

Angiotensin I-converting enzyme insertion/insertion genotype as a genetic risk factor for cardiovascular disease (Ogimoto et al) (Letter); (Chou et al) (Reply). 2005;150(1):e1, e3

Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease (Whiting et al). 2005;150:243-50

Creation of large-scale genetic data bank for cardiovascular association studies (Agah et al). 2005;150:500-6

Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis (Satterthwaite et al). 2005;150:488-99

Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response (Cenarro et al). 2005;150:1154-62

Genetics (continued)

Identification of a novel 5-base pair deletion in calcineurin B (PPP3R1) promoter region and its association with left ventricular hypertrophy (Tang et al). 2005;150:845-51

Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction (Nakatani et al). 2005;150:652-8

Treating depression after myocardial infarction: can selecting patients on the basis of genetic susceptibility improve psychiatric and medical outcomes? (Williams). 2005;150:617-19 (Editorial)

Genotype

Angiotensin I-converting enzyme insertion/insertion genotype as a genetic risk factor for cardiovascular disease (Ogimoto et al) (Letter); (Chou et al) (Reply). 2005;150(1):e1, e3

Gestation; *see* Pregnancy

GFR; *see* Glomerular filtration rate

Glomerular filtration rate

The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention (Fathi et al). 2005;150:1190-7

Glucose

Admission glucose concentrations independently predict early and late mortality in patients with acute myocardial infarction treated by primary or rescue percutaneous coronary intervention (Straumann et al). 2005;150:1000-6

Glucose intolerance

Left ventricular diastolic function in normotensive subjects 2 months after acute myocardial infarction is related to glucose intolerance (Salmasi et al). 2005;150:168-74

Glycoprotein IIb/IIIa inhibitors; *see* Platelet aggregation inhibitors

Graft survival

The Project of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics (Alexander et al). 2005;150:643-9 (Trial design)

Granulocyte colony-stimulating factor

Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction (Kuethe et al). 2005;150:115.e1-115.e7

H

Health care costs

The impact of acute coronary syndrome on clinical, economic, and cardiac-specific health status after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: 1-year results from the stent or surgery (SoS) trial (Zhang et al). 2005;150:175-81

Health care quality, access, and evaluation

Enhancing quality of heart failure care in managed Medicare and Medicaid in North Carolina: results of the North Carolina Achieving Cardiac Excellence (NC ACE) Project (Goff Jr et al). 2005;150:717-24

Health knowledge, attitudes, practice

A simplified education program improves knowledge, self-care behavior, and disease severity in heart failure patients in rural setting (Caldwell et al). 2005;150:983.e7-983.e12

Health status

The impact of acute coronary syndrome on clinical, economic, and cardiac-specific health status after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: 1-year results from the stent or surgery (SoS) trial (Zhang et al). 2005;150:175-81

Heart

The relationship between electrical axis by 12-lead electrocardiogram and anatomical axis of the heart by cardiac magnetic resonance in healthy subjects (Engblom et al). 2005;150:507-12

Heart catheterization

To the Editor (Lim et al). 2005;150(1):e13 (Letter)

A simple prediction rule for significant renal artery stenosis in patients undergoing cardiac catheterization (Cohen et al). 2005;150:1204-11

Heart defects, congenital

Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy (Schulze-Nickl et al). 2005;150:716.e7-716.e12

Biopsychosocial experiences of adults with congenital heart disease: review of the literature (Kovacs et al). 2005;150:193-201 (Curriculum cardiol.)

Heart failure, congestive

Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved (Parkash et al). 2005;150:701-6

Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study (James et al). 2005;150:984.e1-984.e6

Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure (Rumsfeld et al). 2005;150:961-7

Depressive symptoms and inflammation among heart failure patients (Ferketich et al). 2005;150:132-6

Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study (Solomon et al). 2005;150:257-62

Enhancing quality of heart failure care in managed Medicare and Medicaid in North Carolina: results of the North Carolina Achieving Cardiac Excellence (NC ACE) Project (Goff Jr et al). 2005;150:717-24

Impact of implantable cardioverter defibrillators on survival and recurrent hospitalization in advanced heart failure (Nazarian et al). 2005;150:955-60

Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy (Warraich et al). 2005;150:263-9

Monitoring clinical changes in patients with heart failure: a comparison of methods (Spertus et al). 2005;150:707-15

Pilot study to determine the impact of a multidisciplinary educational intervention in patients hospitalized with heart failure (Gwadry-Sridhar et al). 2005;150:982.e1-982.e9

Predictors of a sustained response to exercise training in patients with chronic heart failure: a telemonitoring study (Smart et al). 2005;150:1240-7

Racial differences in outcome and treatment effect in congestive heart failure (Mathew et al). 2005;150:968-76

Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000 (Brown et al). 2005;150:448-54

Heart failure, congestive (continued)

A randomized clinical trial of hospital-based, comprehensive cardiac rehabilitation versus usual care for patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease (the DANREHAB trial)—design, intervention, and population (Zwisler et al). 2005;150:899.e7-899.e16 (Trial design)

Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure (Ralli et al). 2005;150:1220-7

A simplified education program improves knowledge, self-care behavior, and disease severity in heart failure patients in rural setting (Caldwell et al). 2005;150:983.e7-983.e12

Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRAIN Natriuretic Peptide Versus the Clinical Congestive Score (STARBRITE) trial (Shah et al). 2005;150:893-8

Vulnerabilities of patients recovering from an exacerbation of chronic heart failure (Moser et al). 2005;150:984.e7-984.e13

Heart failure, congestive, drug therapy

Association of β-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS) (Chan et al). 2005;150:464-70

Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II) (Konstam et al). 2005;150:123-31

Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril (Wagner et al). 2005;150:985.e1-985.e8

Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure (Fitzgerald et al). 2005;150:471-7

Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending dose trial (Mitrovic et al). 2005;150:1239.e1-1239.e8

Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS) (Teerlink et al). 2005;150:46-53 (Trial design)

Heart failure, congestive, prognosis

Assessing prognosis in heart failure: is hepatocyte growth factor the next B-type natriuretic peptide? (Katz and Drazner). 2005;150:1-3 (Editorial)

Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure (George et al). 2005;150:484-7

How do different indicators of cardiac pump function impact upon the long-term prognosis of patients with chronic failure? (Williams et al). 2005;150:983.e1-983.e6

Incidence, risk factors, and prognosis of inhospital heart failure after percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) (Aboufakher et al). 2005;150:455-8

Obesity as a prognostic factor in chronic symptomatic heart failure (Bozkurt and Deswal). 2005;150:1233-9

Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure (Lambin et al). 2005;150:137-43

Heart failure, congestive, therapy

Education by a dietitian in patients with heart failure results in improved adherence with a sodium-restricted diet: a randomized trial (Arcand et al). 2005;150:716.e1-716.e5

Incidence, risk factors, and prognosis of inhospital heart failure after percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) (Aboufakher et al). 2005;150:455-8

Heart rate

Depressed autonomic nervous system function in African Americans and individuals of lower social class: a potential mechanism of race- and class-related disparities in health outcomes (Lampert et al). 2005;150(5):153-60

A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy (Gentleski et al). 2005;150:478-83

Sotalol and amiodarone versus digoxin for conversion of recent onset atrial fibrillation (Veloso and de Paola) (Letter); (Thomas et al) (Reply). 2005;150:e1, e3

Heart septal defects, atrial

Regional myocardial velocities and isovolumic contraction acceleration before and after device closure of atrial septal defects: a color tissue Doppler study (Paukiks et al). 2005;150:294-301

Heart septum

Evaluation of left ventricular outflow tract area after septal reduction in obstructive hypertrophic cardiomyopathy: a real-time 3-dimensional echocardiographic study (Sitges et al). 2005;150:852-8

Heart valve diseases

The prevalence of bicuspid aortic valve in newborns by echocardiographic screening (Tutar et al). 2005;150:513-5

Heart valve prosthesis

The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients (Seshadri et al). 2005;150:27-34 (Curriculum cardiol.)

The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort (Wang et al). 2005;150:1086-91

Heart ventricles

Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity (Harris et al). 2005;150:1106.e1-1106.e6

Hemodynamics

Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study (James et al). 2005;150:984.e1-984.e6

Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation (Inai et al). 2005;150:588-94

Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction (De Luca et al). 2005;150:563-8

The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use (Krasuski et al). 2005;150:725-8

Hemorrhage

Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries (Segev et al). 2005;150:690-4

Heparin

The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients (Seshadri et al). 2005;150:27-34
(Curriculum cardiol.)

Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream Tirofiban, in cath Lab Downstream Abciximab (CLOTILDA) study (Leoncini et al). 2005;150:401.e9-401.e14

An internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation (Mehran et al). 2005;150:1171-6

The vulnerable endothelium—priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Becker). 2005;150:189-92 (Editorial)

Hepatocyte growth factor

Assessing prognosis in heart failure: is hepatocyte growth factor the next B-type natriuretic peptide? (Katz and Drazner). 2005;150:1-3 (Editorial)

Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure (Lamblin et al). 2005;150:137-43

Hispanic Americans

Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000 (Brown et al). 2005;150:448-54

HIV

Indinavir impairs endothelial function in healthy HIV-negative men (Shankar et al). 2005;150:933.e1-933.e7

HIV infections

Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P²C² HIV multicenter study (Fisher et al). 2005;150:439-47

Hormone replacement therapy

Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial (Lakoski et al). 2005;150:907-11

Long-term hormone replacement therapy does not cause increased platelet activation (Williams et al). 2005;150:434-8

Hospital mortality; see Mortality

Hospitalization

Association between lipid testing and statin therapy in acute myocardial infarction patients (Ko et al). 2005;150:419-25

Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure (Rumsfeld et al). 2005;150:961-7

Impact of implantable cardioverter defibrillators on survival and recurrent hospitalization in advanced heart failure (Nazarian et al). 2005;150:955-60

Incidence, risk factors, and prognosis of inhospital heart failure after percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) (Aboufakher et al). 2005;150:455-8

Obesity as a prognostic factor in chronic symptomatic heart failure (Bozkurt and Deswal). 2005;150:1233-9

Hospitalization (continued)

Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000 (Brown et al). 2005;150:448-54

Trends in prehospital delay time and use of emergency medical services for acute myocardial infarction: experience in 4 US communities from 1987-2000 (McGinn et al). 2005;150:392-400

Vulnerabilities of patients recovering from an exacerbation of chronic heart failure (Moser et al). 2005;150:984.e7-984.e13

Humoral immunity; see Antibody formation

Hydrocortisone

To the Editor (Daniell). 2005;150:(6)e1 (Letter)

Hydroxymethylglutaryl-CoA reductase inhibitors

Association between lipid testing and statin therapy in acute myocardial infarction patients (Ko et al). 2005;150:419-25

Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry (Danchin et al). 2005;150:1147-53

Is it time to prescribe statins to patients with calcified aortic stenosis? (Rashidi et al). 2005;150:41-5 (Curriculum cardiol.)

Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study (Yokoyama et al). 2005;150:287.e1-287.e7

Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event? (Goyal and Blazing). 2005;150:650-1

Hyperglycemia

Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era (Ishihara et al). 2005;150:814-20

Hyperlipidemia

Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey (Klingman et al). 2005;150:595-601

Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response (Cenarro et al). 2005;150:1154-62

Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance (Carmena). 2005;150:859-70 (Progress cardiol.)

Hypertension

Effects of eplerenone versus losartan in patients with low-renin hypertension (Weinberger et al). 2005;150:426-33

Oxygen pulse during exercise is related to resting systolic and diastolic left ventricular function in older persons with mild hypertension (Lim et al). 2005;150:941-6

Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials (Frazier et al). 2005;150:1260-7

Protective effect of high diastolic blood pressure during exercise against exercise-induced myocardial ischemia (Yamagishi et al). 2005;150:790-5

Sex differences in left ventricular function in older persons with mild hypertension (Lim et al). 2005;150:934-40

Hypertension, pulmonary

Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy (Schulze-Neick et al). 2005;150:716.e7-716.e12

Hypertension, pulmonary (continued)

The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use (Krasuski et al). 2005;150:725-8

Hypertriglyceridemia

Alterations of high-density lipoprotein subclasses in endogenous hypertriglyceridemia (Gou et al). 2005;150:1039-45

Hypertrophic cardiomyopathy; see Cardiomyopathy, hypertrophic**Hypertrophy, left ventricular**

Angiotensin-converting enzyme inhibitors as a new therapy for atrial fibrillation? Controversy (Zaman and Kearney). 2005;150(1):e5 (Letter)

Identification of a novel 5-base pair deletion in calcineurin B (PPP3R1) promoter region and its association with left ventricular hypertrophy (Tang et al). 2005;150:845-51

Prognostic value of electrocardiographic criteria for left ventricular hypertrophy (Hsieh et al). 2005;150:161-7

Relationships among exercise capacity, hypertrophy, and left ventricular diastolic function in nonobstructive hypertrophic cardiomyopathy (Matsumoto et al). 2005;150:144-9

Hypothermia

A pilot study: The Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (The NICAMI Study) (Ly et al). 2005;150:933.e9-933.e13

I

Imaging, three-dimensional

Coronary venous imaging with electron beam computed tomographic angiography: three-dimensional mapping and relationship with coronary arteries (Mao et al). 2005;150:315-22

Magnetic resonance angiography of coronary arteries with a 3-dimensional magnetization-prepared true fast imaging with steady-state precession sequence compared with conventional coronary angiography (So et al). 2005;150:530-5

Immunoabsorption

Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoabsorption (Staudt et al). 2005;150:729-36

Immunoglobulin G

Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoabsorption (Staudt et al). 2005;150:729-36

Immunoglobulins

Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy (Warrack et al). 2005;150:263-9

Immunohistochemistry

Chlamydia pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology (Liu et al). 2005;150:681-8

Implantable cardioverter defibrillator; see Defibrillators, implantable**Impotence**

Erectile dysfunction: the need to be evaluated, the right to be treated (Solomon et al). 2005;150:620-6 (Curriculum cardiol.)

Incidence

Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril (Wagner et al). 2005;150:985.e1-985.e8

Incidence, risk factors, and prognosis of in-hospital heart failure after percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) (Aboufakher et al). 2005;150:455-8

Incidence and predictors of restenosis after sirolimus-eluting stent implantation in high-risk patients (Berenguer et al). 2005;150:536-42

Indinavir

Indinavir impairs endothelial function in healthy HIV-negative men (Shankar et al). 2005;150:933.e1-933.e7

Infant, newborn

The prevalence of bicuspid aortic valve in newborns by echocardiographic screening (Tutar et al). 2005;150:513-5

Inflammation

Anti-inflammatory effect of alcohol and cigarette smoking (Mascitelli and Pezzetta) (Letter); (Ikonomidis) (Reply). 2005;150(6):e5, e7

Azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome (Gabrielli et al) (Letter); (Hillis) (Reply). 2005;150(1):e9, e11

Depressive symptoms and inflammation among heart failure patients (Ferketich et al). 2005;150:132-6

Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis (Satterthwaite et al). 2005;150:488-99

Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study (Kip et al). 2005;150:900-6

Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease (Marroquin et al). 2005;150:109-15

Inflammation and coronary artery disease (Tiong and Briege). 2005;150:11-18 (Progress cardiol.)

Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting (Dibra et al). 2005;150:344-50

The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention (Fathi et al). 2005;150:1190-7

Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study (McDermott et al). 2005;150:276-81

Intercellular adhesion molecule-1

Azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome (Gabrielli et al) (Letter); (Hillis) (Reply). 2005;150(1):e9, e11

Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial (Tahir et al). 2005;150:302-6

Interleukin-1

Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis (Satterthwaite et al). 2005;150:488-99

Interleukin-1 beta

Depressive symptoms and inflammation among heart failure patients (Ferketich et al). 2005;150:132-6

Interleukin-6

Depressive symptoms and inflammation among heart failure patients (Ferketich et al). 2005;150:132-6

Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial (Lakoski et al). 2005;150:907-11

Patterns of inflammation associated with peripheral arterial disease: the InCHANTI study (McDermott et al). 2005;150:276-81

Interleukin-8

Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis (Satterthwaite et al). 2005;150:488-99

Interleukin-10

A randomized trial in patients undergoing percutaneous coronary angioplasty: roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against *Clostridium pneumoniae* (Kaeberle et al). 2005;150:987-93

Internet

An internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation (Mehran et al). 2005;150:1171-6

Intra-aortic balloon pumping

The preoperative intraaortic balloon pump in coronary bypass surgery: a lack of evidence of effectiveness (Baskett et al). 2005;150:1122-7

Ischemic heart disease; see Myocardial ischemia

Isosorbide mononitrate

Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy (Kasama et al). 2005;150:477.e1-477.e8

Italy

The Italian registry for hypertrophic cardiomyopathy: a nationwide survey (Cecchi et al). 2005;150:947-54

J

Japan

A large-scale prospective cohort study on the current status of therapeutic modalities for acute myocardial infarction in Japan: rationale and initial results of the HIJAMI Registry (Kasanuki et al). 2005;150:411-8

K

Kansas City Cardiomyopathy Questionnaire

Monitoring clinical changes in patients with heart failure: a comparison of methods (Sperutis et al). 2005;150:707-15

Kawasaki disease; see Mucocutaneous lymph node syndrome

KCCQ; see Kansas City Cardiomyopathy Questionnaire

Kidney diseases

Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction (Goldberg et al). 2005;150:330-7

The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention (Fathi et al). 2005;150:1190-7

Kidney diseases (continued)

Outcomes in patients with chronic kidney disease undergoing cardiac rehabilitation (Venkataraman et al). 2005;150:1140-6

Kidney failure

Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial (Halkin et al). 2005;150:1163-70

Outcomes in patients admitted for chest pain with renal failure and troponin I elevations (Kontos et al). 2005;150:674-80

Predictive power of ejection fraction and renal failure in patients admitted for chest pain without ST elevation in the troponin era (Kontos et al). 2005;150:666-73

L

Latin America

Latin American randomized trial of balloon angioplasty versus coronary stenting in diabetic patients with small vessel reference size (Latin American Small Vessel [LASMAL II] Trial): immediate and long-term results (Rodriguez et al). 2005;150:188.e1-188.e7

Left ventricular dysfunction; see Ventricular dysfunction, left

Left ventricular function; see Ventricular function, left

Left ventricular hypertrophy; see Hypertrophy, left ventricular

Letters to the Editor

Angiotensin-converting enzyme inhibitors as a new therapy for atrial fibrillation? Controversy (Zaman and Kearney). 2005;150(1):e5

Angiotensin I-converting enzyme insertion/insertion genotype as a genetic risk factor for cardiovascular disease (Ogimoto et al) (Letter); (Chou et al) (Reply). 2005;150(1):e1, e3

Anti-inflammatory effect of alcohol and cigarette smoking (Mascitelli and Pezzetta) (Letter); (Ikonomidis) (Reply). 2005;150(6):e5, e7

Azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome (Gabrielli et al) (Letter); (Hillis) (Reply). 2005;150(1):e9, e11

To the Editor (Daniell). 2005;150(6):e1

To the Editor (Gross et al). 2005;150(6):e3

To the Editor (Lim et al). 2005;150(1):e13

To the Editor (Turner). 2005;150(4):e1-e2

Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Milionis and Elisa). 2005;150(1):e7

Sotalol and amiodarone versus digoxin for conversion of recent onset atrial fibrillation (Veloso and de Paola) (Letter); (Thomas et al) (Reply). 2005;150(5):e1, e3

Levosimendan

Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction (De Luca et al). 2005;150:563-8

Lipase

Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response (Cenarro et al). 2005;150:1154-62

Lipids and lipoproteins; see also Hyperlipidemia

Alterations of high-density lipoprotein subclasses in endogenous hypertriglyceridemia (Gou et al). 2005;150:1039-45

Association between lipid testing and statin therapy in acute myocardial infarction patients (Ko et al). 2005;150:419-25

Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease (Whiting et al). 2005;150:243-50

Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey (Klingman et al). 2005;150:595-601

Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response (Cenarro et al). 2005;150:1154-62

Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting (Braun et al). 2005;150:550-6

A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy (Gentleski et al). 2005;150:478-83

Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina (Segev et al). 2005;150:1007-14

Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance (Carmena). 2005;150:859-70 (Progress cardiol.)

Lipoproteins, LDL

Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study (Yokoyama et al). 2005;150:287.e1-287.e7

Long QT syndrome

Burst bicycle exercise facilitates diagnosis of latent long QT syndrome (Walker et al). 2005;150:1059-63

Losartan

Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II) (Konstam et al). 2005;150:123-31

Effects of eplerenone versus losartan in patients with low-renin hypertension (Weinberger et al). 2005;150:426-33

Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction (Onodera et al). 2005;150:689.e11-689.e16

M**Magnetic resonance imaging**

Magnetic resonance angiography of coronary arteries with a 3-dimensional magnetization-prepared true fast imaging with steady-state precession sequence compared with conventional coronary angiography (So et al). 2005;150:530-5

The relationship between electrical axis by 12-lead electrocardiogram and anatomical axis of the heart by cardiac magnetic resonance in healthy subjects (Engblom et al). 2005;150:507-12

Size and transmural extent of first-time reperfused myocardial infarction assessed by cardiac magnetic resonance can be estimated by 12-lead electrocardiogram (Engblom et al). 2005;150:920.e1-920.e9

Magnetic resonance imaging (continued)

Visual estimation versus quantitative assessment of left ventricular ejection fraction: a comparison by cardiovascular magnetic resonance imaging (Sievers et al). 2005;150:737-42

Mass screening

The prevalence of bicuspid aortic valve in newborns by echocardiographic screening (Tutar et al). 2005;150:513-5

Matrix metalloproteinase-2; see Gelatinase A**Matrix metalloproteinase-3; see Stromelysin 1****Matrix metalloproteinase-9; see Gelatinase B****Matrix metalloproteinases; see also specific metalloproteinases**

Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure (George et al). 2005;150:484-7

Mediastinum

Diastolic dysfunction after mediastinal irradiation (Heidenreich et al). 2005;150:977-82

Medicaid

Enhancing quality of heart failure care in managed Medicare and Medicaid in North Carolina: results of the North Carolina Achieving Cardiac Excellence (NC ACE) Project (Goff Jr et al). 2005;150:717-24

Medical history taking

Symptoms and type of symptom onset in acute coronary syndrome in relation to ST elevation, sex, age, and a history of diabetes (Thuresson et al). 2005;150:234-42

Medicare

Enhancing quality of heart failure care in managed Medicare and Medicaid in North Carolina: results of the North Carolina Achieving Cardiac Excellence (NC ACE) Project (Goff Jr et al). 2005;150:717-24

Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000 (Brown et al). 2005;150:448-54

Medroxyprogesterone

Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial (Lakoski et al). 2005;150:907-11

Metabolic syndrome X

Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Milionis and Elisaf). 2005;150(1):e7 (Letter)

Mitral regurgitation; see Mitral valve insufficiency**Mitral valve**

Doppler tissue imaging: a reliable method for estimation of left ventricular filling pressure in patients with mitral regurgitation (Agricola et al). 2005;150:610-5

Mitral valve insufficiency

Doppler tissue imaging: a reliable method for estimation of left ventricular filling pressure in patients with mitral regurgitation (Agricola et al). 2005;150:610-5

Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity (Harris et al). 2005;150:1106.e1-1106.e6

Prognostic significance of echocardiographically defined mitral regurgitation early after acute myocardial infarction (Hillis et al). 2005;150:1268-75

Mitral valve prolapse

Angiotensin I-converting enzyme insertion/insertion genotype as a genetic risk factor for cardiovascular disease (Ogimoto et al) (Letter); (Chou et al) (Reply). 2005;150(1):e1, e3

Monitoring, ambulatory

Is ambulatory monitoring for "community-acquired" syncope economically attractive? A cost-effectiveness analysis of a randomized trial of external loop recorders versus Holter monitoring (Rocks et al). 2005;150:1065.e1-1065.e5

Monitoring, physiologic

Monitoring clinical changes in patients with heart failure: a comparison of methods (Spertus et al). 2005;150:707-15
Predictors of a sustained response to exercise training in patients with chronic heart failure: a telemonitoring study (Smart et al). 2005;150:1240-7

Morphine

To the Editor (Daniell). 2005;150(6):e1 (Letter)
To the Editor (Gross et al). 2005;150(6):e3 (Letter)

Mortality

Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era (Ishihara et al). 2005;150:814-20
Admission glucose concentrations independently predict early and late mortality in patients with acute myocardial infarction treated by primary or rescue percutaneous coronary intervention (Straumann et al). 2005;150:1000-6
Analysis of mortality and risk factors associated with native valve endocarditis in drug users: the importance of vegetation size (Martin-Dávila et al). 2005;150:1099-1106
Association of β -blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS) (Chan et al). 2005;150:464-70
The association between prior percutaneous coronary intervention and short-term outcomes after coronary artery bypass grafting (Hassan et al). 2005;150:1026-31
Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved (Parkash et al). 2005;150:701-6
Blood glucose: a strong risk factor for mortality in nondiabetic patients with cardiovascular disease (Port et al). 2005;150:209-14
Can we reliably predict long-term mortality after exercise testing? An external validation (Hesse et al). 2005;150:307-14
Circadian variation in myocardial perfusion and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty (De Luca et al). 2005;150:1185-9
Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure (George et al). 2005;150:484-7
Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure (Rumsfeld et al). 2005;150:961-7
Diabetes status and racial differences in post-myocardial infarction mortality (Kamlesh et al). 2005;150:912-19
Do stents reduce mortality compared with balloon angioplasty? a critical review of all the evidence (Al Suwaidi and Berger). 2005;150:7-10 (Editorial)
The Doppler myocardial performance index during low-dose dobutamine echocardiography predicts mortality and left ventricular dilation after a first acute myocardial infarction (Norager et al). 2005;150:522-9
To the Editor (Daniell). 2005;150(6):e1 (Letter)
Improved long-term survival associated with stent deployment during percutaneous coronary interventions: results from a registry of 3399 patients (Muhlestein et al). 2005;150:182-7

Mortality (continued)

Incidence, risk factors, and prognosis of inhospital heart failure after percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) (Aboufakher et al). 2005;150:455-8
Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction (Goldberg et al). 2005;150:330-7
The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention (Fathi et al). 2005;150:1190-7
A large-scale prospective cohort study on the current status of therapeutic modalities for acute myocardial infarction in Japan: rationale and initial results of the HIJAMI Registry (Kasanuki et al). 2005;150:411-8
Left ventricular ejection fraction to predict early mortality in patients with non-ST-segment elevation acute coronary syndromes (Bosch and Théroux). 2005;150:215-20
Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P²C² HIV multicenter study (Fisher et al). 2005;150:439-47
Obesity as a prognostic factor in chronic symptomatic heart failure (Bozkurt and Deswal). 2005;150:1233-9
Outcomes in patients admitted for chest pain with renal failure and troponin I elevations (Kontos et al). 2005;150:674-80
Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients (Rathore et al). 2005;150:402-10
Predictive power of ejection fraction and renal failure in patients admitted for chest pain without ST elevation in the troponin era (Kontos et al). 2005;150:666-73
Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries (Segev et al). 2005;150:690-4
The preoperative intraaortic balloon pump in coronary bypass surgery: a lack of evidence of effectiveness (Baskett et al). 2005;150:1122-7
Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure (Lamblin et al). 2005;150:137-43
Prognostic value of electrocardiographic criteria for left ventricular hypertrophy (Hsieh et al). 2005;150:161-7
Racial differences in outcome and treatment effect in congestive heart failure (Mathew et al). 2005;150:968-76
Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure (Ralli et al). 2005;150:1220-7
The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To Open Occluded arteries (GUSTO) V trial (Brener et al). 2005;150:89-93
Schizophrenia and increased risks of cardiovascular disease (Hennekens et al). 2005;150:1115-21 (Curriculum cardiol.)
Temporal variation in inhospital mortality with percutaneous coronary intervention: a report from the National Heart, Lung and Blood Institute Dynamic Registry (Laskey et al). 2005;150:569-76
The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort (Wang et al). 2005;150:1086-91

Motor activity

Walking may be related to less vascular stiffness in the Activity Counseling Trial (ACT) (Havlik et al). 2005;150:270-5

Mucocutaneous lymph node syndrome

Coronary artery calcifications in the long-term follow-up of Kawasaki disease (Dadlani et al). 2005;150:1016-e1-1016.e8

**Multidetector-row computed tomography;
see Tomography, x-ray computed****Myocardial contraction**

Regional myocardial velocities and isovolumic contraction acceleration before and after device closure of atrial septal defects: a color tissue Doppler study (Pauliks et al). 2005;150:294-301

Myocardial infarction

Applicability of clinical prediction models in acute myocardial infarction: a comparison of traditional and empirical Bayes adjustment methods (Steyerberg et al). 2005;150:920.e1-1-920.e17

Association between cardiac troponin T elevation and angiographic morphology of culprit lesion in patients with non-ST-segment elevation acute coronary syndrome (Ohtani et al). 2005;150:227-33

Can the wrong statistic be bad for health? Improving the reporting of door-to-needle time performance in acute myocardial infarction (Schull et al). 2005;150:583-7

C. pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology (Liu et al). 2005;150:681-8

Clinical profile and outcomes of diabetic and nondiabetic patients in cardiac rehabilitation (Hindman et al). 2005;150:1046-51

Delay in acute myocardial infarction: why don't they come to the hospital more quickly and what can we do to reduce delay? (Luepker). 2005;150:368-70 (Editorial)

Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure (Rumsfeld et al). 2005;150:961-7

Design and methodology of the Occluded Artery Trial (OAT) (OAT research group). 2005;150:627-42 (Trial design)

Diabetes status and racial differences in post-myocardial infarction mortality (Kamlesh et al). 2005;150:912-19

Door-to-needle time in myocardial infarction: is there an ideal benchmark? (Canto and Kiefe). 2005;150:365-7 (Editorial)

Dynamics in N-terminal pro-brain natriuretic peptide concentration in patients with non-ST-elevation acute coronary syndrome (Riezbos et al). 2005;150:1255-9

To the Editor (Turner). 2005;150(4):e1-e2 (Letter)

Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute inferior myocardial infarction (Di Pasquale et al). 2005;150:919.e1-919.e8

Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction (Nakatani et al). 2005;150:652-8

Left ventricular diastolic function in normotensive subjects 2 months after acute myocardial infarction is related to glucose intolerance (Salmasi et al). 2005;150:168-74

A pilot study: The Noninvasive Surface Cooling

Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (The NICAMI Study) (Ly et al). 2005;150:933.e9-933.e13

Myocardial infarction (continued)

Predictive power of ejection fraction and renal failure in patients admitted for chest pain without ST elevation in the troponin era (Kontos et al). 2005;150:666-73

Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries (Segev et al). 2005;150:690-4

Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials (Frazier et al). 2005;150:1260-7

Size and transmural extent of first-time reperfused myocardial infarction assessed by cardiac magnetic resonance can be estimated by 12-lead electrocardiogram (Engblom et al). 2005;150:920.e1-920.e9

Symptoms and type of symptom onset in acute coronary syndrome in relation to ST elevation, sex, age, and a history of diabetes (Thuresson et al). 2005;150:234-42

Treating depression after myocardial infarction: can selecting patients on the basis of genetic susceptibility improve psychiatric and medical outcomes? (Williams). 2005;150:617-19 (Editorial)

Trends in prehospital delay time and use of emergency medical services for acute myocardial infarction: experience in 4 US communities from 1987-2000 (McGinn et al). 2005;150:392-400

Myocardial infarction, drug therapy

Association between lipid testing and statin therapy in acute myocardial infarction patients (Ko et al). 2005;150:419-25

Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study (Lewis et al). 2005;150:1177-84

Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction (Spencer et al). 2005;150:838-44

Design and rationale of the Michelangelo Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, synthetic factor XA inhibitor, in patients with non-ST-segment elevation acute coronary syndromes (Michelangelo OASIS 5 Steering Committee). 2005;150:1107-14 (Trial design)

To the Editor (Daniell). 2005;150(6):e1 (Letter)

To the Editor (Gross et al). 2005;150(6):e3 (Letter)

Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream Tirofiban, in cath Lab Downstream Abciximab (CLOTILDA) study (Leoncini et al). 2005;150:401.e9-401.e14

Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction (Onodera et al). 2005;150:689.e11-689.e16

Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months (Katsouras et al). 2005;150:385-91

Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADDressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial (ADVANCE MI Investigators). 2005;150:116-22

Myocardial infarction, drug therapy (continued)

Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry (Danchin et al). 2005;150:1147-53

Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—the smoker's paradox revisited (Weisz et al). 2005;150:358-64

Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction (De Luca et al). 2005;150:563-8

Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction—the RADIAL-AMI pilot randomized trial (Cantor et al). 2005;150:543-9

A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy (Parodi et al). 2005;150:220.e1-220.e5

The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To Open Occluded arteries (GUSTO) V trial (Brener et al). 2005;150:89-93

Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT) (Reed et al). 2005;150:323-9

Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial (Ohman et al). 2005;150:79-88

Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction (Kuehne et al). 2005;150:115.e1-115.e7

Myocardial infarction, prognosis

Diastolic wall motion abnormality after myocardial infarction: relation to neurohormonal activation and prognostic implications (Husic et al). 2005;150:767-74

The Doppler myocardial performance index during low-dose dobutamine echocardiography predicts mortality and left ventricular dilation after a first acute myocardial infarction (Norager et al). 2005;150:522-9

Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction (Goldberg et al). 2005;150:330-7

Left ventricular ejection fraction to predict early mortality in patients with non-ST-segment elevation acute coronary syndromes (Bosch and Théroux). 2005;150:215-20

Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients (Rathore et al). 2005;150:402-10

Prognostic significance of echocardiographically defined mitral regurgitation early after acute myocardial infarction (Hillis et al). 2005;150:1268-75

Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction (De Luca et al). 2005;150:1248-54

Prognostic use of echocardiography 1 year after a myocardial infarction (Skali et al). 2005;150:743-9

To score or not to score? (Roger). 2005;150:371-2

Myocardial infarction, therapy

Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era (Ishihara et al). 2005;150:814-20

Admission glucose concentrations independently predict early and late mortality in patients with acute myocardial infarction treated by primary or rescue percutaneous coronary intervention (Straumann et al). 2005;150:1000-6

Circadian variation in myocardial perfusion and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty (De Luca et al). 2005;150:1185-9

Design of a standardized system for transfer of patients with ST-elevation myocardial infarction for percutaneous coronary intervention (Henry et al). 2005;150:373-84 (Trial design)

Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial (Barbagelata et al). 2005;150:659-65

Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial (ADVANCE MI Investigators). 2005;150:116-22

The impact of acute coronary syndrome on clinical, economic, and cardiac-specific health status after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: 1-year results from the stent or surgery (SOS) trial (Zhang et al). 2005;150:175-81

Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—the smoker's paradox revisited (Weisz et al). 2005;150:358-64

A large-scale prospective cohort study on the current status of therapeutic modalities for acute myocardial infarction in Japan: rationale and initial results of the HIJAMI Registry (Kasanuki et al). 2005;150:411-8

Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction (De Luca et al). 2005;150:563-8

Percutaneous coronary intervention-induced emboli during primary PCI for STEMI: too little, too much, or too late? (Kuntz et al). 2005;150:446 (Editorial)

Preprocedural Thrombolysis in Myocardial Infarction (TIMI) flow significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute anterior myocardial infarction treated by primary angioplasty (De Luca et al). 2005;150:827-31

Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction (De Luca et al). 2005;150:1248-54

Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction—the RADIAL-AMI pilot randomized trial (Cantor et al). 2005;150:543-9

A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy (Parodi et al). 2005;150:220.e1-220.e5

Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty (De Luca et al). 2005;150:557-62

Myocardial ischemia

Antidepressant therapy in patients with ischemic heart disease (Jiang and Davidson). 2005;150:871-81 (Curriculum cardiol.)

Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy (Kasama et al.). 2005;150:477.e1-477.e8

Depression and ischemic heart disease: what have we learned so far and what must we do in the future? (Jiang et al.). 2005;150:54-78 (Meetings)

Design and rationale of the Michelangelo Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor XA inhibitor, in patients with non-ST-segment elevation acute coronary syndromes (Michelangelo OASIS 5 Steering Committee). 2005;150:1107-14 (Trial design)

Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis (Satterthwaite et al.). 2005;150:488-99

Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study (Kip et al.). 2005;150:900-6

Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy (Blatt et al.). 2005;150:986.e1-986.e7

Percent change in B-type natriuretic peptide levels during treadmill exercise as a screening test for exercise-induced myocardial ischemia (Win et al.). 2005;150:695-700

Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries (Segev et al.). 2005;150:690-4

Protective effect of high diastolic blood pressure during exercise against exercise-induced myocardial ischemia (Yamagishi et al.). 2005;150:790-5

A randomized clinical trial of hospital-based, comprehensive cardiac rehabilitation versus usual care for patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease (the DANREHAB trial)—design, intervention, and population (Zwisler et al.). 2005;150:899.e7-899.e16 (Trial design)

Myocardial perfusion

Circadian variation in myocardial perfusion and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty (De Luca et al.). 2005;150:1185-9

Myocardial reperfusion

Design of a standardized system for transfer of patients with ST-elevation myocardial infarction for percutaneous coronary intervention (Henry et al.). 2005;150:373-84 (Trial design)

Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial (Barbagelata et al.). 2005;150:659-65

Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—the smoker's paradox revisited (Weisz et al.). 2005;150:358-64

A large-scale prospective cohort study on the current status of therapeutic modalities for acute myocardial infarction in Japan: rationale and initial results of the HIJAMI Registry (Kasanuki et al.). 2005;150:411-8

Myocardial reperfusion (continued)

Preprocedural Thrombolysis in Myocardial Infarction (TIMI) flow significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute anterior myocardial infarction treated by primary angioplasty (De Luca et al.). 2005;150:827-31

Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction (De Luca et al.). 2005;150:1248-54

A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy (Parodi et al.). 2005;150:220.e1-220.e5

Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty (De Luca et al.). 2005;150:557-62

Myocardial revascularization

The association between prior percutaneous coronary intervention and short-term outcomes after coronary artery bypass grafting (Hassan et al.). 2005;150:1026-31

Clinical profile and outcomes of diabetic and nondiabetic patients in cardiac rehabilitation (Hindman et al.). 2005;150:1046-51

Temporal variation in inhospital mortality with percutaneous coronary intervention: a report from the National Heart, Lung and Blood Institute Dynamic Registry (Laskey et al.). 2005;150:569-76

Myocardial velocity

Regional myocardial velocities and isovolumic contraction acceleration before and after device closure of atrial septal defects: a color tissue Doppler study (Pauliks et al.). 2005;150:294-301

Myocardium

A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy (Ardehali et al.). 2005;150:459-63

N**Narcotics**

To the Editor (Daniell). 2005;150(6):e1 (Letter)

To the Editor (Gross et al.). 2005;150(6):e3 (Letter)

Natriuretic peptide, brain

Assessing prognosis in heart failure: is hepatocyte growth factor the next B-type natriuretic peptide? (Katz and Drazner). 2005;150:1-3 (Editorial)

Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study (James et al.). 2005;150:984.e1-984.e6

Can pro-brain natriuretic peptide be used as a noninvasive predictor of elevated left ventricular diastolic pressures in patients with normal systolic function? (Joung et al.). 2005;150:1213-19

Dynamics in N-terminal pro-brain natriuretic peptide concentration in patients with non-ST-elevation acute coronary syndrome (Riezbeek et al.). 2005;150:1255-9

Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure (Fitzgerald et al.). 2005;150:471-7

Independent elevations of N-terminal pro-brain natriuretic peptide and cardiac troponins in endurance athletes after prolonged strenuous exercise (Scharhag et al.). 2005;150:1128-34

Natriuretic peptide, brain (continued)

Percent change in B-type natriuretic peptide levels during treadmill exercise as a screening test for exercise-induced myocardial ischemia (Win et al). 2005;150:695-700

Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy (Arteaga et al). 2005;150:1228-32

Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure (Ralli et al). 2005;150:1220-7

Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain Natriuretic Peptide Versus the Clinical CongesTion Score (STARBRITE) trial (Shah et al). 2005;150:893-8 (Trial design)

Natriuretic peptides

Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending dose trial (Mitrovic et al). 2005;150:1239.e1-1239.e18

Nebivolol

Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study (Patrianakos et al). 2005;150:985.e9-985.e18

Necrosis

Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream Tirofiban, in cath Lab Downstream Abciximab (CLOTILDA) study (Leoncini et al). 2005;150:401.e9-401.e14

Nesiritide

Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure (Fitzgerald et al). 2005;150:471-7

Neurohormones; see Neurotransmitter agents

Neurotransmitter agents

Diastolic wall motion abnormality after myocardial infarction: relation to neurohormonal activation and prognostic implications (Husic et al). 2005;150:767-74

New York Heart Association

Monitoring clinical changes in patients with heart failure: a comparison of methods (Spertus et al). 2005;150:707-15

Niacin

Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Milionis and Elisaf). 2005;150(1):e7 (Letter)

Nicorandil

Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy (Kasama et al). 2005;150:477.e1-477.e8

Determinants of coronary events in patients with stable angina: results from the Impact of Nicorandil in Angina study (IONA study group). 2005;150:689.e1-689.e9

Nitrates

Reproducibility of nitrate-stimulated tilt testing in patients with suspected vasovagal syncope and a healthy control group (Aerts et al). 2005;150:251-6

Nitric oxide

The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use (Krasuski et al). 2005;150:725-8

Nitroglycerin

To the Editor (Gross et al). 2005;150(6):e3 (Letter)

Norepinephrine

Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation (Inai et al). 2005;150:588-94

Nutrition surveys

Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey (Klingman et al). 2005;150:595-601

NYHA; see New York Heart Association

O

Obesity

Obesity and clinical restenosis after coronary stent placement (Rana et al). 2005;150:821-6

Obesity as a prognostic factor in chronic symptomatic heart failure (Bozkurt and Deswal). 2005;150:1233-9

Women in cardiac rehabilitation: outcomes and identifying risk for dropout (Sanderson and Bittner). 2005;150:1052-8

Omapatrilat

Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study (Solomon et al). 2005;150:257-62

Opioids; see Narcotics

Outcome assessment

Depressed autonomic nervous system function in African Americans and individuals of lower social class: a potential mechanism of race- and class-related disparities in health outcomes (Lampert et al). 2005;150:153-60

Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting (Braun et al). 2005;150:550-6

Outcomes in patients with chronic kidney disease undergoing cardiac rehabilitation (Venkataraman et al). 2005;150:1140-6

Oxygen consumption

Walking may be related to less vascular stiffness in the Activity Counseling Trial (ACT) (Havlik et al). 2005;150:270-5

Oxygen pulse

Oxygen pulse during exercise is related to resting systolic and diastolic left ventricular function in older persons with mild hypertension (Lim et al). 2005;150:941-6

P

P-selectin

Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial (Tahir et al). 2005;150:302-6

Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation (Lee et al). 2005;150:756-66

Paclitaxel

"Full metal jacker" (stented length ≥ 64 mm) using drug-eluting stents for de novo coronary artery lesions (Aoki et al). 2005;150:994-9

Paclitaxel (continued)

Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial (Halkin et al). 2005;150:1163-70

Pakistan

Heart disease epidemic in Pakistan: women and men at equal risk (Jafar et al). 2005;150:221-6

Patient compliance

Education by a dietitian in patients with heart failure results in improved adherence with a sodium-restricted diet: a randomized trial (Arcand et al). 2005;150:716.e1-716.e5

Noncompliance in cardiovascular clinical trials (Serebruany et al). 2005;150:882-6 (Curriculum cardiol.)

Pilot study to determine the impact of a multidisciplinary educational intervention in patients hospitalized with heart failure (Gwadry-Sridhar et al). 2005;150:982.e1-982.e9

Predictors of a sustained response to exercise training in patients with chronic heart failure: a telemonitoring study (Smart et al). 2005;150:1240-7

Patient discharge

Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction (Spencer et al). 2005;150:838-44

Patient dropouts

Women in cardiac rehabilitation: outcomes and identifying risk for dropout (Sanderson and Bittner). 2005;150:1052-8

Patient education

Education by a dietitian in patients with heart failure results in improved adherence with a sodium-restricted diet: a randomized trial (Arcand et al). 2005;150:716.e1-716.e5

Effects of a psychosocial skills training workshop on psychophysiological and psychosocial risk in patients undergoing coronary artery bypass grafting (Bishop et al). 2005;150:602-9

Pilot study to determine the impact of a multidisciplinary educational intervention in patients hospitalized with heart failure (Gwadry-Sridhar et al). 2005;150:982.e1-982.e9

A simplified education program improves knowledge, self-care behavior, and disease severity in heart failure patients in rural setting (Caldwell et al). 2005;150:983.e7-983.e12

Patient transfer

Design of a standardized system for transfer of patients with ST-elevation myocardial infarction for percutaneous coronary intervention (Henry et al). 2005;150:373-84 (Trial design)

Peptidyl-dipeptidase A

Angiotensin I-converting enzyme insertion/insertion genotype as a genetic risk factor for cardiovascular disease (Ogimoto et al) (Letter); (Chou et al) (Reply). 2005;150(1):e1, e3

Percutaneous coronary intervention; see Angioplasty; Stents**Periodontal diseases**

Tooth loss is independently associated with the risk of acquired aortic valve sclerosis (Völzke et al). 2005;150:1198-1203

Peripheral vascular disease

Management of risk in peripheral artery disease: recent therapeutic advances (Hackam et al). 2005;150:35-40 (Curriculum cardiol.)

Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study (McDermott et al). 2005;150:276-81

Physical activity; see Motor activity**Physical endurance**

Independent elevations of N-terminal pro-brain natriuretic peptide and cardiac troponins in endurance athletes after prolonged strenuous exercise (Scharhag et al). 2005;150:1128-34

Platelet activation

Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation (Lee et al). 2005;150:756-66

Long-term hormone replacement therapy does not cause increased platelet activation (Williams et al). 2005;150:434-8

Platelet aggregation

Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study (Campbell et al). 2005;150:796-9

Long-term hormone replacement therapy does not cause increased platelet activation (Williams et al). 2005;150:434-8

Platelet aggregation inhibitors

Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry (Danchin et al). 2005;150:1147-53

Improved long-term survival associated with stent deployment during percutaneous coronary interventions: results from a registry of 3399 patients (Muhlestein et al). 2005;150:182-7

Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction—the RADIAL-AMI pilot randomized trial (Cantor et al). 2005;150:543-9

The vulnerable endothelium—priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Becker). 2005;150:189-92 (Editorial)

Postmenopause

Cereal fiber and whole-grain intake are associated with reduced progression of coronary-artery atherosclerosis in postmenopausal women with coronary artery disease (Eriksson et al). 2005;150:94-101

Effect of raloxifene on aortic elasticity in healthy postmenopausal women (Tritos et al). 2005;150:1212.e1-1212.e6

Pregnancy

The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients (Seshadri et al). 2005;150:27-34 (Curriculum cardiol.)

Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy (Warrach et al). 2005;150:263-9

Reference charts of gestation-specific tissue Doppler imaging indices of systolic and diastolic functions in the normal fetal heart (Chan et al). 2005;150:750-5

Prevalence

Heart disease epidemic in Pakistan: women and men at equal risk (Jafar et al). 2005;150:221-6

The prevalence of bicuspid aortic valve in newborns by echocardiographic screening (Tutar et al). 2005;150:513-5

Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary syndromes (SYMPHONY) randomized clinical trials (Frazier et al). 2005;150:1260-7

Prevalence (continued)

Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis (Michos et al). 2005;150:1276-81

Progestins

Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial (Lakoski et al). 2005;150:907-11

Prognosis

Assessing prognosis in heart failure: is hepatocyte growth factor the next B-type natriuretic peptide? (Katz and Drazner). 2005;150:1-3 (Editorial)

Blood glucose: a strong risk factor for mortality in nondiabetic patients with cardiovascular disease (Port et al). 2005;150:209-14

Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation (Inai et al). 2005;150:588-94

A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy (Ardehali et al). 2005;150:459-63

Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure (Lamblin et al). 2005;150:137-43

Prognostic value of the Duke Treadmill Score in diabetic patients (Lakkireddy et al). 2005;150:516-21

Prognostic value of electrocardiographic criteria for left ventricular hypertrophy (Hsieh et al). 2005;150:161-7

Prosthesis and Implants

Regional myocardial velocities and isovolumic contraction acceleration before and after device closure of atrial septal defects: a color tissue Doppler study (Pauliks et al). 2005;150:294-301

Prosthesis-related infections

The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort (Wang et al). 2005;150:1086-91

Protein A

Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoabsorption (Staudt et al). 2005;150:729-36

Psychosocial factors

Biopsychosocial experiences of adults with congenital heart disease: review of the literature (Kovacs et al). 2005;150:193-201 (Curriculum cardiol.)

Effects of a psychosocial skills training workshop on psychophysiological and psychosocial risk in patients undergoing coronary artery bypass grafting (Bishop et al). 2005;150:602-9

Pulmonary arterial hypertension; see Hypertension, pulmonary

Q

Quality of health care; see Health care quality, access, and evaluation

Quality of life

Biopsychosocial experiences of adults with congenital heart disease: review of the literature (Kovacs et al). 2005;150:193-201 (Curriculum cardiol.)

Quality of life (continued)

Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT) (Reed et al). 2005;150:323-9

R

Race; see Ethnic groups

Radial artery

Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction—the RADIAL-AMI pilot randomized trial (Cantor et al). 2005;150:543-9

Radio waves

Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study (Yokoyama et al). 2005;150:287.e1-287.e7

Radionuclide imaging

Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy (Kasama et al). 2005;150:477.e1-477.e8

Radiotherapy

Comparison of angiographic and clinical outcomes between rotational atherectomy and cutting balloon angioplasty followed by radiation therapy with a rhodium 106-mercaptoproacetyltriglycine-filled balloon in the treatment of diffuse in-stent restenosis (Lee et al). 2005;150:577-82

Diastolic dysfunction after mediastinal irradiation (Heidenreich et al). 2005;150:977-82

Raloxifene

Effect of raloxifene on aortic elasticity in healthy postmenopausal women (Tritos et al). 2005;150:1212.e1-1212.e6

Ramipril

Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity (Harris et al). 2005;150:1106.e1-1106.e6

Receptors, interleukin-1

Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study (McDermott et al). 2005;150:276-81

Reurrence

Randomized comparison of anterolateral versus anteroposterior electrode position for biphasic external cardioversion of atrial fibrillation (Siaplouras et al). 2005;150:150.e1

Renal artery obstruction

A simple prediction rule for significant renal artery stenosis in patients undergoing cardiac catheterization (Cohen et al). 2005;150:1204-11

Renal artery stenosis; see Renal artery obstruction

Renal failure; see Kidney failure

Renal insufficiency; see Kidney failure

Renin

Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation (Inai et al). 2005;150:588-94

Effects of eplerenone versus losartan in patients with low-renin hypertension (Weinberger et al). 2005;150:426-33

Reperfusion, myocardial; see Myocardial reperfusion

Reproducibility of results

Reproducibility of nitrate-stimulated tilt testing in patients with suspected vasovagal syncope and a healthy control group (Aerts et al). 2005;150:251-6

Resource use

Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT) (Reed et al). 2005;150:323-9

Revascularization, myocardial; see Myocardial revascularization**Rhenium-mercaptoacetyltriglycine**

Comparison of angiographic and clinical outcomes between rotational atherectomy and cutting balloon angioplasty followed by radiation therapy with a rhenium 88-mercaptoacetyltriglycine-filled balloon in the treatment of diffuse in-stent restenosis (Lee et al). 2005;150:577-82

Risk assessment

Analysis of mortality and risk factors associated with native valve endocarditis in drug users: the importance of vegetation size (Martín-Dávila et al). 2005;150:1099-1106

Assessing prognosis in heart failure: is hepatocyte growth factor the next B-type natriuretic peptide? (Katz and Drazner). 2005;150:1-3 (Editorial)

Association of β -blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS) (Chan et al). 2005;150:464-70

Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved (Parkash et al). 2005;150:701-6

Blood glucose: a strong risk factor for mortality in nondiabetic patients with cardiovascular disease (Port et al). 2005;150:209-14

Determinants of coronary events in patients with stable angina: results from the Impact of Nicorandil in Angina study (IONA study group). 2005;150:689.e1-689.e9

A global view of atherosclerosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial (Bhatt et al). 2005;150:401.e1-401.e7

Heart disease epidemic in Pakistan: women and men at equal risk (Jafar et al). 2005;150:221-6

Incidence, risk factors, and prognosis of inhospital heart failure after percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) (Aboufakher et al). 2005;150:455-8

Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction (Nakatani et al). 2005;150:652-8

Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients (Rathore et al). 2005;150:402-10

Schizophrenia and increased risks of cardiovascular disease (Hennekens et al). 2005;150:1115-21 (Curriculum cardiol.)

To score or not to score? (Roger). 2005;150:371-2

Screening for coronary artery disease in patients with diabetes: a Bayesian strategy of clinical risk evaluation and exercise echocardiography (Rakhit et al). 2005;150:1074-80

Tooth loss is independently associated with the risk of acquired aortic valve sclerosis (Völzke et al). 2005;150:1198-1203

Vulnerabilities of patients recovering from an exacerbation of chronic heart failure (Moser et al). 2005;150:984.e7-984.e13

Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis (Michos et al). 2005;150:1276-81

Risk factors

Angiotensin I-converting enzyme insertion/insertion genotype as a genetic risk factor for cardiovascular disease (Ogimoto et al) (Letter); (Chou et al) (Reply). 2005;150(1):e1, e3

To the Editor (Lim et al). 2005;150:e13 (Letter)

Risk management

Management of risk in peripheral artery disease: recent therapeutic advances (Hackam et al). 2005;150(1):35-40 (Curriculum cardiol.)

Risk reduction

Effects of a psychosocial skills training workshop on psychophysiological and psychosocial risk in patients undergoing coronary artery bypass grafting (Bishop et al). 2005;150:602-9

Roxithromycin

A randomized trial in patients undergoing percutaneous coronary angioplasty: roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against *Clostridium pneumoniae* (Kachler et al). 2005;150:987-93

Rural population

A simplified education program improves knowledge, self-care behavior, and disease severity in heart failure patients in rural setting (Caldwell et al). 2005;150:983.e7-983.e12

S**Sarcoidosis**

A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy (Ardehali et al). 2005;150:459-63

Schizophrenia

Schizophrenia and increased risks of cardiovascular disease (Hennekens et al). 2005;150:1115-21 (Curriculum cardiol.)

Scintigraphy; see Radionuclide imaging**Self care**

A simplified education program improves knowledge, self-care behavior, and disease severity in heart failure patients in rural setting (Caldwell et al). 2005;150:983.e7-983.e12

Serologic tests

Azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome (Gabrielli et al) (Letter); (Hillis) (Reply). 2005;150(1):e9, e11

Serology

Clostridium pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology (Liu et al). 2005;150:681-8

Serotonin plasma membrane transport proteins

Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction (Nakatani et al). 2005;150:652-8

Serotonin transporter; see Serotonin plasma membrane transport proteins**Sex factors**

Heart disease epidemic in Pakistan: women and men at equal risk (Jafar et al). 2005;150:221-6

Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials (Frazier et al). 2005;150:1260-7

Sex differences in depression after coronary artery bypass graft surgery (Mitchell et al). 2005;150:1017-25

Sex factors (continued)

Sex differences in left ventricular function in older persons with mild hypertension (Lim et al). 2005;150:934-40
Symptoms and type of symptom onset in acute coronary syndrome in relation to ST elevation, sex, age, and a history of diabetes (Thuresson et al). 2005;150:234-42

Simvastatin

Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Milionis and Elisaf). 2005;150(1):e7 (Letter)
A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy (Gentleski et al). 2005;150:478-83

Single-photon emission computerized tomography (SPECT); see Tomography, emission-computed, single-photon

Sirolimus

"Full metal jacket" (stented length ≥64 mm) using drug-eluting stents for de novo coronary artery lesions (Aoki et al). 2005;150:994-9
Incidence and predictors of restenosis after sirolimus-eluting stent implantation in high-risk patients (Berenguer et al). 2005;150:536-42
Sirolimus-eluting stent implantation and β-irradiation for the treatment of in-stent restenotic lesions: comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound (Schiele et al). 2005;150:351-7
Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease (Briguori et al). 2005;150:807-13

Skin

Skin cholesterol content identifies increased carotid intima-media thickness in asymptomatic adults (Tzou et al). 2005;150:1135-9

Smoking

Anti-inflammatory effect of alcohol and cigarette smoking (Mascitelli and Pezzetta) (Letter); (Ikonomidis) (Reply). 2005;150(6):e5, e7

Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—the smoker's paradox revisited (Weisz et al). 2005;150:358-64

Social class

Depressed autonomic nervous system function in African Americans and individuals of lower social class: a potential mechanism of race- and class-related disparities in health outcomes (Lampert et al). 2005;150:153-60

Sodium-restricted diet; see Diet, sodium-restricted

Sotalol

Sotalol and amiodarone versus digoxin for conversion of recent onset atrial fibrillation (Veloso and de Paola) (Letter); (Thomas et al) (Reply). 2005;150(5):e1, e3

STAT6; see Trans-activators

Statins; see Hydroxymethylglutaryl-CoA reductase inhibitors

Stents

Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era (Ishihara et al). 2005;150:814-20

Brachytherapy and bivalirudin evaluation study (Kuchukanti et al). 2005;150:832-7

Cilostazol improves long-term outcomes after coronary stent implantation (Han et al). 2005;150:568.e1-568.e5

Stents (continued)

Comparison of angiographic and clinical outcomes between rotational atherectomy and cutting balloon angioplasty followed by radiation therapy with a rhodium 106-mercaptopropyltriglyceride-filled balloon in the treatment of diffuse in-stent restenosis (Lee et al). 2005;150:577-82

Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era (Jacob et al). 2005;150:887-92 (Trial design)

Do stents reduce mortality compared with balloon angioplasty? a critical review of all the evidence (Al Suwaidi and Berger). 2005;150:7-10 (Editorial)

"Full metal jacket" (stented length ≥64 mm) using drug-eluting stents for de novo coronary artery lesions (Aoki et al). 2005;150:994-9

The impact of acute coronary syndrome on clinical, economic, and cardiac-specific health status after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: 1-year results from the stent or surgery (SoS) trial (Zhang et al). 2005;150:175-81

Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial (Halkin et al). 2005;150:1163-70

Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—the smoker's paradox revisited (Weisz et al). 2005;150:358-64

Improved long-term survival associated with stent deployment during percutaneous coronary interventions: results from a registry of 3399 patients (Muhlestein et al). 2005;150:182-7

Incidence and predictors of restenosis after sirolimus-eluting stent implantation in high-risk patients (Berenguer et al). 2005;150:536-42

Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting (Dibra et al). 2005;150:344-50

An internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation (Mehran et al). 2005;150:1171-6

Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting (Braun et al). 2005;150:550-6

Latin American randomized trial of balloon angioplasty versus coronary stenting in diabetic patients with small vessel reference size (Latin American Small Vessel [LASMAL II] Trial): immediate and long-term results (Rodriguez et al). 2005;150:188.e1-188.e7

Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction (De Luca et al). 2005;150:563-8

Obesity and clinical restenosis after coronary stent placement (Rana et al). 2005;150:821-6

Percutaneous coronary intervention-induced emboli during primary PCI for STEMI: too little, too much, or too late? (Kuntz et al). 2005;150:4-6 (Editorial)

Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction—the RADIAL-AMI pilot randomized trial (Cantor et al). 2005;150:543-9

Stents (continued)

A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy (Parodi et al). 2005;150:220.e1-220.e5

Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina (Segev et al). 2005;150:1007-14

Sirolimus-eluting stent implantation and β -irradiation for the treatment of in-stent restenotic lesions: comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound (Schiele et al). 2005;150:351-7

Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease (Briguori et al). 2005;150:807-13

Stress

A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy (Gentleski et al). 2005;150:478-83

Stress echocardiography; see Echocardiography, stress

Stroke; see Cerebrovascular accident

Stroke volume

Comprehensive assessment of patients after coronary artery bypass grafting by 16-detector-row computed tomography (Salm et al). 2005;150:775-81

Left ventricular ejection fraction to predict early mortality in patients with non-ST-segment elevation acute coronary syndromes (Bosch and Théroux). 2005;150:215-20

Predictive power of ejection fraction and renal failure in patients admitted for chest pain without ST elevation in the troponin era (Kontos et al). 2005;150:666-73

Visual estimation versus quantitative assessment of left ventricular ejection fraction: a comparison by cardiovascular magnetic resonance imaging (Sievers et al). 2005;150:737-42

Stromelysin 1

Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure (George et al). 2005;150:484-7

Substance abuse, intravenous

Analysis of mortality and risk factors associated with native valve endocarditis in drug users: the importance of vegetation size (Martin-Dávila et al). 2005;150:1099-1106

Survey; see Data collection**Survival analysis**

Association between completeness of percutaneous coronary revascularization and postprocedure outcomes (McLellan et al). 2005;150:800-6

Azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome (Gabrielli et al) (Letter); (Hillis) (Reply). 2005;150(1):e9, e11

Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry (Danchin et al). 2005;150:1147-53

Impact of implantable cardioverter defibrillators on survival and recurrent hospitalization in advanced heart failure (Nazarian et al). 2005;150:955-60

Sympathetic nervous system

Comparative effects of nifedipine with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy (Kasama et al). 2005;150:477.e1-477.e8

Sympathetic nervous system (continued)

A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy (Gentleski et al). 2005;150:478-83

Syncope

Is ambulatory monitoring for "community-acquired" syncope economically attractive? A cost-effectiveness analysis of a randomized trial of external loop recorders versus Holter monitoring (Rocks et al). 2005;150:1065.e1-1065.e5

Syncope, vasovagal

Reproducibility of nitrate-stimulated tilt testing in patients with suspected vasovagal syncope and a healthy control group (Aerts et al). 2005;150:251-6

Systole

Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved (Parkash et al). 2005;150:701-6

Can pro-brain natriuretic peptide be used as a noninvasive predictor of elevated left ventricular diastolic pressures in patients with normal systolic function? (Joung et al). 2005;150:1213-19

Effects of canrenone plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute inferior myocardial infarction (Di Pasquale et al). 2005;150:919.e1-919.e8

Oxygen pulse during exercise is related to resting systolic and diastolic left ventricular function in older persons with mild hypertension (Lim et al). 2005;150:941-6

Reference charts of gestation-specific tissue Doppler imaging indices of systolic and diastolic functions in the normal fetal heart (Chan et al). 2005;150:750-5

T**Telemedicine**

Predictors of a sustained response to exercise training in patients with chronic heart failure: a telemonitoring study (Smart et al). 2005;150:1240-7

Tenecteplase

Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial (Ohman et al). 2005;150:79-88

Tezosentan

Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS) (Teerlink et al). 2005;150:46-53 (Trial design)

Thoracic surgical procedures

The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort (Wang et al). 2005;150:1086-91

Use of surgery in patients with native valve infective endocarditis: results from the International Collaboration on Endocarditis Merged Database (Cabell et al). 2005;150:1092-8

Three-dimensional imaging; see Imaging, three-dimensional**Thrombolysis; see Thrombolytic therapy****Thrombolytic therapy**

Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial (Barbagelata et al). 2005;150:659-65

Thrombolytic therapy (continued)

Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients (Rathore et al). 2005;150:402-10

Preprocedural Thrombolysis in Myocardial Infarction (TIMI) flow significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute anterior myocardial infarction treated by primary angioplasty (De Luca et al). 2005;150:827-31

To score or not to score? (Roger). 2005;150:371-2

Thrombosis

Association between cardiac troponin T elevation and angiographic morphology of culprit lesion in patients with non-ST-segment elevation acute coronary syndrome (Ohtani et al). 2005;150:227-33

A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial (Bhatt et al). 2005;150:401.e1-401.e7

An internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation (Mehran et al). 2005;150:1171-6

The vulnerable endothelium—priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNergy) trial (Becker). 2005;150:189-92 (Editorial)

Ticlopidine

A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy (Parodi et al). 2005;150:220.e1-220.e5

Tilt table test

Reproducibility of nitrate-stimulated tilt testing in patients with suspected vasovagal syncope and a healthy control group (Aerts et al). 2005;150:251-6

Time factors

Temporal variation in inhospital mortality with percutaneous coronary intervention: a report from the National Heart, Lung and Blood Institute Dynamic Registry (Laskey et al). 2005;150:569-76

Tinzaparin

Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVE) trial at 6 months (Katsouras et al). 2005;150:385-91

Tirofiban

Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream Tirofiban, in cath Lab Downstream Abciximab (CLOTILDA) study (Leoncini et al). 2005;150:401.e9-401.e14

Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial (Ohman et al). 2005;150:79-88

Tissue Doppler imaging; see Echocardiography, Doppler

Tissue inhibitor of matrix metalloproteinase-1

Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure (George et al). 2005;150:484-7

Tomography, emission-computed, single-photon

Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial (Barbagelata et al). 2005;150:659-65

Tomography, x-ray computed

Comprehensive assessment of patients after coronary artery bypass grafting by 16-detector-row computed tomography (Salm et al). 2005;150:775-81

Coronary venous imaging with electron beam computed tomographic angiography: three-dimensional mapping and relationship with coronary arteries (Mao et al). 2005;150:315-22

Tooth loss

Tooth loss is independently associated with the risk of acquired aortic valve sclerosis (Völzke et al). 2005;150:1198-1203

Trans-activators

Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis (Satterthwaite et al). 2005;150:488-99

Transfection

The Project of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics (Alexander et al). 2005;150:643-9 (Trial design)

Transplantation, autologous

Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy (Blatt et al). 2005;150:986.e1-986.e7

Transportation of patients

To the Editor (Turner). 2005;150(4):e1-e2 (Letter)

Treadmill test; see Exercise test

Treatment failure

Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty (De Luca et al). 2005;150:557-62

Treatment outcome

The association between prior percutaneous coronary intervention and short-term outcomes after coronary artery bypass grafting (Hassan et al). 2005;150:1026-31

The benefit of cholesterol-lowering medications after coronary revascularization: a population study (Brophy et al). 2005;150:282-6

Cilostazol improves long-term outcomes after coronary stent implantation (Han et al). 2005;150:568.e1-568.e5

Clinical profile and outcomes of diabetic and nondiabetic patients in cardiac rehabilitation (Hindman et al). 2005;150:1046-51

Comparison of angiographic and clinical outcomes between rotational atherectomy and cutting balloon angioplasty followed by radiation therapy with a rhodium 88-mercaptoacetyltriglycine-filled balloon in the treatment of diffuse in-stent restenosis (Lee et al). 2005;150:577-82

Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II) (Konstam et al). 2005;150:123-31

Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending dose trial (Mitrovic et al). 2005;150:1239.e1-1239.e8

Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVE) trial at 6 months (Katsouras et al). 2005;150:385-91

Treatment outcome (continued)

"Full metal jacket" (stented length ≥ 64 mm) using drug-eluting stents for de novo coronary artery lesions (Aoki et al). 2005;150:994-9

The impact of acute coronary syndrome on clinical, economic, and cardiac-specific health status after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: 1-year results from the stent or surgery (SoS) trial (Zhang et al). 2005;150:175-81

Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—the smoker's paradox revisited (Weisz et al). 2005;150:358-64

Improved long-term survival associated with stent deployment during percutaneous coronary interventions: results from a registry of 3399 patients (Muhlestein et al). 2005;150:182-7

An internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation (Mehran et al). 2005;150:1171-6

Latin American randomized trial of balloon angioplasty versus coronary stenting in diabetic patients with small vessel reference size (Latin American Small Vessel [LASMAL II] Trial): immediate and long-term results (Rodriguez et al). 2005;150:188.e1-188.e7

Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke (Healey et al). 2005;150:288-93

Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine (Petrone et al). 2005;150:1015.e1-1015.e9

The preoperative intraaortic balloon pump in coronary bypass surgery: a lack of evidence of effectiveness (Baskett et al). 2005;150:1122-7

Tropomin

Independent elevations of N-terminal pro-brain natriuretic peptide and cardiac troponins in endurance athletes after prolonged strenuous exercise (Scharhag et al). 2005;150:1128-34

Predictive power of ejection fraction and renal failure in patients admitted for chest pain without ST elevation in the troponin era (Kontos et al). 2005;150:666-73

Tropomin I

Outcomes in patients admitted for chest pain with renal failure and troponin I elevations (Kontos et al). 2005;150:674-80

Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure (Ralli et al). 2005;150:1220-7

Tropomin T

Association between cardiac troponin T elevation and angiographic morphology of culprit lesion in patients with non-ST-segment elevation acute coronary syndrome (Ohtani et al). 2005;150:227-33

Tumor necrosis factor-alpha

Depressive symptoms and inflammation among heart failure patients (Ferketich et al). 2005;150:132-6

A randomized trial in patients undergoing percutaneous coronary angioplasty: roxithromycin does not reduce clinical restenosis but angioplasty increases antibody concentrations against *Clostridium penumonae* (Kaehler et al). 2005;150:987-93

Tunica intima

Skin cholesterol content identifies increased carotid intima-media thickness in asymptomatic adults (Tzou et al). 2005;150:1135-9

Tunica media

Skin cholesterol content identifies increased carotid intima-media thickness in asymptomatic adults (Tzou et al). 2005;150:1135-9

U**Ularitide**

Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending dose trial (Mitrovic et al). 2005;150:1239.e1-1239.e8

Ultrasoundography

Ultrasound-detected carotid plaque as a screening tool for advanced subclinical atherosclerosis (Wyman et al). 2005;150:1081-5

Ultrasoundography, interventional

Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study (Yokoyama et al). 2005;150:287.e1-287.e7

Sirolimus-eluting stent implantation and β -irradiation for the treatment of in-stent restenotic lesions: comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound (Scheile et al). 2005;150:351-7

Unstable angina; see Angina, unstable**Urodilatin**

Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending dose trial (Mitrovic et al). 2005;150:1239.e1-1239.e8

V**Valsartan**

Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT) (Reed et al). 2005;150:323-9

Vascular cell adhesion molecule-1

Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial (Tahir et al). 2005;150:302-6

Vascular endothelial growth factor

Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure (Lamblin et al). 2005;150:137-43

Vascular endothelium; see Endothelium, vascular**Vascular stiffness**

Walking may be related to less vascular stiffness in the Activity Counseling Trial (ACT) (Havlik et al). 2005;150:270-5

Vasodilator agents

The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use (Krasuski et al). 2005;150:725-8

Vasovagal syncope; see Syncope, vasovagal**Vein graft**

The Project of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics (Alexander et al). 2005;150:643-9 (Trial design)

Ventricular dysfunction, left

Doppler tissue imaging: a reliable method for estimation of left ventricular filling pressure in patients with mitral regurgitation (Agricola et al). 2005;150:610-5

Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction (De Luca et al). 2005;150:563-8

Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P²C² HIV multicenter study (Fisher et al). 2005;150:439-47

Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy (Arteaga et al). 2005;150:1228-32

Visual estimation versus quantitative assessment of left ventricular ejection fraction: a comparison by cardiovascular magnetic resonance imaging (Sievers et al). 2005;150:737-42

Ventricular ejection fraction; see Stroke volume

Ventricular function, left

Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved (Parkash et al). 2005;150:701-6

Can pro-brain natriuretic peptide be used as a noninvasive predictor of elevated left ventricular diastolic pressures in patients with normal systolic function? (Joung et al). 2005;150:1213-19

Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy (Kasama et al). 2005;150:477.e1-477.e18

Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study (Patrianakos et al). 2005;150:985.e9-985.e18

The Doppler myocardial performance index during low-dose dobutamine echocardiography predicts mortality and left ventricular dilation after a first acute myocardial infarction (Norager et al). 2005;150:522-9

Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study (Solomon et al). 2005;150:257-62

Enhancing quality of heart failure care in managed Medicare and Medicaid in North Carolina: results of the North Carolina Achieving Cardiac Excellence (NC ACE) Project (Goff Jr et al). 2005;150:717-24

Evaluation of left ventricular outflow tract area after septal reduction in obstructive hypertrophic cardiomyopathy: a real-time 3-dimensional echocardiographic study (Sitges et al). 2005;150:852-8

Left ventricular diastolic function in normotensive subjects 2 months after acute myocardial infarction is related to glucose intolerance (Salmasi et al). 2005;150:168-74

Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P²C² HIV multicenter study (Fisher et al). 2005;150:439-47

Oxygen pulse during exercise is related to resting systolic and diastolic left ventricular function in older persons with mild hypertension (Lim et al). 2005;150:941-6

Prognostic use of echocardiography 1 year after a myocardial infarction (Skali et al). 2005;150:743-9

Relationships among exercise capacity, hypertrophy, and left ventricular diastolic function in nonobstructive hypertrophic cardiomyopathy (Matsumoto et al). 2005;150:144-9

Sex differences in left ventricular function in older persons with mild hypertension (Lim et al). 2005;150:934-40

Ventricular function, right

Prognostic use of echocardiography 1 year after a myocardial infarction (Skali et al). 2005;150:743-9

Ventricular outflow obstruction

Evaluation of left ventricular outflow tract area after septal reduction in obstructive hypertrophic cardiomyopathy: a real-time 3-dimensional echocardiographic study (Sitges et al). 2005;150:852-8

Ventricular pressure

Doppler tissue imaging: a reliable method for estimation of left ventricular filling pressure in patients with mitral regurgitation (Agricola et al). 2005;150:610-5

Ventricular remodeling

Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study (Solomon et al). 2005;150:257-62

Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction (Onodera et al). 2005;150:689.e11-689.e16

Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine (Petronio et al). 2005;150:1015.e1-1015.e9

Vitamin C

Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial (Tahir et al). 2005;150:302-6

Vitamin E

Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial (Tahir et al). 2005;150:302-6

von Willebrand factor

Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation (Lee et al). 2005;150:756-66

W

Walking

Walking may be related to less vascular stiffness in the Activity Counseling Trial (ACT) (Havlik et al). 2005;150:270-5

Warfarin

A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era (Mohapatra et al). 2005;150:19-26 (Progress cardiol.)

Women

Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study (Kip et al). 2005;150:900-6

Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease (Marroquin et al). 2005;150:109-15

Women (continued)

Women in cardiac rehabilitation: outcomes and identifying risk for dropout (Sanderson and Bittner). 2005;150:1052-8

Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis (Michos et al). 2005;150:1276-81

Worsening renal function; see Kidney diseases

X

Ximelagatran

A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era (Mohapatra et al). 2005;150:19-26 (Progress cardiol.)

